

# CURRICULUM VITAE

## **Mohammad Jahanzeb, MD, FACP, FASCO**

Creative Precision Oncology, an OncAdvisor Practice  
951 NW 13th St #2A,  
Boca Raton, FL 33486  
Office: 561-247-0024  
Cell: 901-483-0486

**Citizenship** USA

**Current Positions:** Medical Oncologist (Lung and Breast Cancers) with OncAdvisor; Founder and President,  
Clinical Affiliate Professor, Department of Integrated Medicine  
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton

### **Positions Previously Held:**

- 08/22-04/23 Medical Oncologist (Lung and Breast Cancers) with Florida Cancer Specialists, at Delray Beach and Lake Worth
- 06/19-06/22 Founder and Managing Partner, Florida Precision Oncology Research and Consulting, LLC  
Medical Oncologist, Florida Precision Oncology a division of GenesisCare
- 06/19- 01/22 Chief Medical Oncology Scientific and Strategic Advisor, GenesisCare,
- 08/10- 06/19 Medical Director, USylvester Deerfield Beach and Professor of Clinical Medicine, University of Miami, Miller School of Medicine
- 04/10- 08/10 Volunteer Assistant Professor, USylvester Deerfield Beach
- 07/08 – 04/10 Medical Director, Lynn Comprehensive Cancer Center West, Boca Raton, Florida
- 08/02 – 06/08 Chief – Division of Hematology/Oncology, University of Tennessee College of Medicine Memphis, TN
- 09/05 – 06/08 Fellowship Program Director Hematology Oncology Division, University of Tennessee
- 12/02 – 06/08 Van Vleet Endowed Professor of Medical Oncology, University of Tennessee Health Science Center, Memphis, Tennessee

### **Undergraduate Education:**

- 4/74 – 9/79 Cadet College, Hasan Abdal, Punjab, Pakistan High School & Pre Med, F.Sc 9/79
- 10/79 – 5/80 Preparing for medical school

**Professional Education:**

06/80 – 06/86 Medical School: King Edward Medical College, University of Punjab Lahore, Pakistan, MBBS (MD) Completed 6/86

01/85 – 11/86 Rotating Internship & Clinical Clerkship, Mayo Hospital & University of Punjab, Lahore, Pakistan

11/86 – 06/87 Left for the United States in 11/86 and started applying for residencies; also prepared for FLEX taken in 6/87

**Post Graduate Training United States:**

07/87 – 06/88 Internship: New Britain General Hospital, University of CT, Department of Internal Medicine, New Britain, CT Internal Medicine, Completed 6/88

07/88 – 06/90 Residency: New Britain General Hospital, University of CT, Department of Internal Medicine, New Britain, CT Internal Medicine, Completed 6/90

07/90 – 06/93 Fellowship: Washington University, Barnes Jewish Hospital Dept. of Internal Medicine, Division of Hematology / Oncology, St. Louis, MO

07/92 – 06/93 Instructor/ Senior Fellow: Division of Hematology / Oncology, Washington University

**Honors / Awards:**

Castle Connolly Top Doctors in America 2010-2016  
Best Doctors in America 2007-2008, 2011  
Castle Connolly Medical Best Doctors in America 2006  
Gold Medal Award KEMCAANA 2006  
NCCN Board of Producers Award 2008  
Silver Medal in Final Professional M.B.B.S. (MD)  
National Talent Scholarship throughout medical school

**Leadership / Management Training:**

Wharton Executive Leadership Program, September 2006  
Alliance for Academic Internal Medicine (AAIM) Executive Leadership Program, July 2007

**American Board Certification:**

11/90 American Board of Internal Medicine (133053)  
11/93 American Board of Internal Medicine, subspecialty- Medical Oncology (133053)  
11/94 American Board of Internal Medicine, subspecialty - Hematology (133053)  
11/03 American Board of Internal Medicine, subspecialties of Hematology and Oncology – Recertification – Medical Oncology valid thru 2023; Hematology valid thru 2015

Licensure	Date Issued	Status	Expiration Date
Pennsylvania - # MD-041064-L	08/17/88	Inactive	12/31/90
Connecticut - #030101	07/07/89	Inactive	06/30/93
Missouri - #00607780	12/10/90	Inactive	01/31/16
Florida - #ME 68929	08/03/95	Active	01/31/22
Tennessee – MD0000036771	08/02/02	Inactive	06/30/08
Mississippi – 17856	11/18/02	Inactive	06/30/08
Arkansas – E-3595	02/07/03	Inactive	06/30/08

**Society Memberships:**

American Association for Professors of Medicine (AAPM)  
 American Society of Clinical Oncology (ASCO)  
 American College of International Physicians - Life Fellow  
 1997 American College of Physicians (ACP) – Fellow since April 1997  
 American Society of Internal Medicine (ASIM) - Fellow  
 American Association for Advancement of Science  
 International Association for the Study of Lung Cancer (IASLC)  
 Association of Pakistani Physicians of North America (APPNA) – Life Member  
 King Edward Medical College Alumni Association of North America (KEMCAANA) – Life Member, President Elect 2003, President 2004  
 Florida Society of Clinical Oncology (FLASCO)  
 Southwest Oncology Group (Institutional Principal Investigator) 2003-2008  
 Tennessee Medical Association (now lapsed)  
 Cancer and Leukemia Group B (now lapsed)  
 Hoosier Oncology Group (now lapsed)  
 Missouri Society of Clinical Oncology (now lapsed)  
 American Society of Hematology (ASH) (now lapsed)  
 American Medical Association (AMA) (now lapsed)  
 Palm Beach County Medical Society (now lapsed)  
 Broward County Medical Association (now lapsed)  
 American Association for Cancer Research (AACR) (now lapsed)

**University Appointments:**

08/19- Present Clinical Affiliate Professor, Department of Integrated Medicine  
 Charles E. Schmidt College of Medicine, Florida Atlantic University

08/10 – 06/19 Professor of Clinical Medicine, University of Miami Miller School of  
 Medicine, Department of Medicine, Division of Hematology/Oncology

Medical Director, University of Miami Miller School of Medicine  
 Sylvester Comprehensive Cancer Center, Deerfield Bch

Associate Director of Community Outreach, Sylvester Comprehensive Cancer Center  
 University of Miami Miller School of Medicine

07/08 – 07/10 Professor of Medicine, University of Tennessee

- 09/05 – 06/08 Fellowship Program Director, University of Tennessee, Hematology Oncology Division
- 08/02 – 06/08 Division Chief - Hematology/Oncology, University of Tennessee Hematology/Oncology Memphis, TN
- 12/02 – 06/08 Van Vleet Endowed Professor of Medical Oncology, University of Tennessee Health Science Center, Memphis, Tennessee
- 08/02 – 06/08 Associate Professor of Medicine, University of Tennessee College of Medicine
- 08/04 – 09/05 Interim Director, University of Tennessee Cancer Institute
- 08/02 – 2003 Planning Director, P-20 Grant (NCI Designation Planning Grant)
- 06/00 – 08/02 Assistant Professor, Biomedical Research, Florida Atlantic University, Boca Raton, Florida
- 07/93 – 09/95 Assistant Professor of Medicine, Division of Medical Oncology Washington University School of Medicine, St. Louis, Missouri
- 07/92 – 06/93 Clinical Instructor of Medicine, Division of Medical Oncology Washington University School of Medicine, St. Louis, MO

**Medical Student Teaching Experience:**

- 03/21- Present Hematology/Oncology Lectures, Aventura Medical Center, Miami, FL
- 04/14 – 2019 Lung Cancer Lecture, Miller School M2, Miami, FL
- 08/05 – 06/08 Pediatric Oncology Education (POE), St. Jude Children’s Research Hospital, Memphis, TN
- 09/05 – 06/08 Master Clinicians for DRS Course to M1 students, University of Tennessee Health Science Center, Memphis, TN
- 10/04 – 10/09 Molecular Basis of Disease to 2nd year student residents and fellows, University of Tennessee Health Science Center, Memphis, TN
- 11/03 – 06/08 CPC to 2nd year student residents and fellows, University of Tennessee Health Science Center, Memphis, TN
- 10/03 – 06/08 Internal Medicine Core Curriculum Lectures. Teaching to residents and medical students, University of Tennessee Health Science Center, Memphis, TN
- 08/02 – 02/05 Teaching hematology module to 2nd year student residents and fellows. Teaching in wards and clinic.
- 09/93 – 12/93 Taught "Introduction to Clinical Medicine" course to second-year medical students Washington University School of Medicine, St. Louis, MO

07/90 – 09/95 Participated in teaching Hematology Lab course to second year medical students at Washington University School of Medicine, St. Louis, MO

07/90 – 09/95 Hematology / Oncology Grand Rounds at Washington University - presented grand rounds on twenty different clinical topics over the course of 5 years

**Fellows Trained:**

- 01/15- 06/15 Sean Warsch, MD
- 07/07 \_ 06/08 Krishna Alluri, M.D.
- 07/07 – 06/08 Claudia Paba, M.D.
- 07/07 – 06/08 Andrew Schreiber, M.D.
- 08/06 – 06/08 Shehzad Azmi, M.D.
- 07/06 – 06/08 Saira Ahmed, M.D.
- 07/06 – 06/08 Josh McFarland, M.D.
- 01/06 – 06/08 Salil Goorha, M.D.
- 07/05 – 06/08 Jeffrey Allen, M.D.
- 07/05 – 06/08 Gregory Franz, M.D.
- 07/05 – 06/08 Arshad Husain, M.D.
- 07/04 – 06/07 Jasgit Sachdev, M.D.
- 07/04 – 06/07 Sarah Waheed, M.D.
- 07/03 – 06/06 Sal Vasireddy, M.D.
- 07/03 – 06/06 Naveed Aslam, M.D.
- 07/03 – 06/06 Brian McClune, M.D.
- 01/02 – 12/05 Sonia Benn, M.D.
- 08/02 – 06/05 Birendra Kumar, M.D.
- 08/02 – 06/04 James Peyton, M.D.
- 08/02 – 06/03 Arun Bhandari, M.D.
- 08/02 – 06/03 Sead Beganovic, M.D.
- 08/02 – 06/03 Khaleel Ashraf, M.D.

**Residents / Medical Students Mentored:**

•	2015	Jennifer M Schwenk
•	2015	Jason Heffley
•	2015	Anthony D'Andrea
•	2015	Jacquelyne Anthony
•	2014	Ali Khan
•	2014	Caitlin Hodge
•	2008	William Rogers
•	2008	Austin Mackens
•	2008	Ryan Dougherty
•	2008	Jason Booton
•	2008	Justin Marlar
•	2008	Annie Naik
•	2008	Andy Patrick
•	2007	Amna Khattak
•	2007	Muhammad Raza
•	2007	Nicholas Newsom
•	2007	Kevin Walls

•	2007	Allison Chesser
•	2007	Muhammad Mirza
•	2007	Stephen Snell
•	2007	Lee Sanders
•	2007	Stephanie Grissom
•	2007	Elizabeth Hinds
•	2006	Gautam Jha
•	2006	Aron Chary
•	2005	Jessica Snyder
•	2004	Stacy Jean Brown
•	2004	Erinn Michelle Myers
•	2004	Marion Lee Sanders

### **Research Mentorship with Fellows**

1. McFarlane J, "Contribution of positive renal vein margin to relapse risk in renal cell cancer".
2. Azmi S, "Hypersensitivity of Cetuximab: Is there an Association with Race, Region or both?"
3. Paba C, "Empiric dose reduction of Pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy."
4. Franz G, "Patterns of PET/CT scan use in patients with advanced Non-Small Cell Lung Cancer (NSCLC)."
5. Schreiber A, "Serial measurements of quality measures using the quality oncology practice initiative (QOPI) by oncology trainees (fellows) at a single institution."
6. Sachdev J, "A multicenter phase II trial of carboplatin, vinorelbine, and trastuzumab in previously untreated patients with HER2 positive metastatic breast cancer."
7. Waheed S, "Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy."
8. Peyton J, "Low utility of bone marrow biopsy and aspirate for ruling out malignancy as a cause for FUO in HIV patients."

### **Clinical Research Leadership Positions & Activities**

- 07/08 – 04/10 Institutional Principle Investigator, Southwest Oncology Group, Lynn Regional Cancer Center West, Boca Raton, FL
- 04/03 – 06/08 Institutional Principal Investigator, Southwest Oncology Group, University of Tennessee
- 08/02 – 06/08 Director of Research, University of Tennessee Cancer Institute  
Memphis, Tennessee
- 08/02 – 09/05 Planning Director, University of Tennessee Cancer Institute (submitted P-20 1/03)

04/97 – 08/02 Cancer Center Research Director, Comprehensive Cancer Center, Boca Raton, Florida

01/00 – 08/02 Medical Director, Eugene M. & Christine E. Lynn Clinical Research Center Boca Raton Regional, Boca Raton, Florida

10/95 – 08/02 Co-Chairman, Lung Committee, Salick Healthcare, Inc., Oversight of Clinical Research in Palm Beach County for CCRGI

**Institutional Principal Investigator Currently Open Trials at University of Miami:**

BO 28984: Randomized, Multicenter, Phase Iii, Open-Label Study Of Alectinib Versus Crizotinib In Treatment-Naïve Anaplastic Lymphoma Kinase-Positive Advanced Non- Small Cell Lung Cancer

C-1686-008: A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

9090-14: A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Adenocarcinoma

SO-BCA002: A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA-Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients with Metastatic Breast Cancer

ML 28257: SystHERS: An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive Metastatic Breast Cancer

SWOG 1400 1400A, 1400B, 1400C, 1400D, 1400E: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

**Institutional Principal Investigator Recent Trials in Boca Raton:**

E 5103: A Double Blind Phase III Trial of doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacuzumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

NR001-03: Registration Phase III Study of Lucanix™ (Belagenpumatulcel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy (PENDING OPENING)

OXC401-216: A Phase II Study to Assess the Safety and Efficacy of the Combination of Carboplatin, Paclitaxel and Bevacizumab ± CA4P in Subjects with Chemotherapy Naive Stage IIIB/IV Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC)

A7471017: A Phase 2, Open-Label Trial of PF-00299804 in Untreated Advanced Adenocarcinoma of the Lung in Never or Former Light Smokers (Pending Opening).

- S0429: A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemo radiation for Poor Risk Stage III Non-Small Cell Lung Cancer
- BRE 01-08: Neoadjuvant Weekly nap-paclitaxel (Abraxane®) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer

**Institutional Principal Investigator of Trials while in Tennessee:**

- CALGB 40302: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer
- NSABP B-40: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
- NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
- PACCT-1: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
- SWOG 0221: Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High- Risk Node Negative Breast Cancer
- SWOG 0226: Phase III Randomized Trial of Anastrozole versus Anastrozole and Fulvestrant as First Line Therapy for Post-Menopausal Women with Metastatic Breast Cancer
- SWOG 0307: Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
- AVF 3963g-Ribbon2: A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Treated Metastatic Breast Cancer
- AVF 3964g-Ribbon1: A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Untreated Metastatic Breast Cancer
- Pfizer 6171077: A Randomized Phase 2 Study of SU011248 versus Standard-of-care for Patients with Previously Treated, Advanced, Triple Receptor Negative (ER, PR, and HER2) Breast Cancer
- SWOG 0230: Phase III Trial of LHRH Analog Administration during Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer



Genentech AVF 4057g-SABRE: A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination with Bevacizumab and Paclitaxel in Previously Untreated Patients with Metastatic Breast Cancer

**Grants / External Support:**

12/07 – 07/08 National Comprehensive Cancer Network, “Neoadjuvant Weekly Nab-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bvacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer”, \$200,460.

10/07 – 2007 OSI730/SR06-941 Efficacy and Safety of Sorafenib in combination with topotinib in previously treated, advanced Non-Small Cell Lung Cancer Bayer grant \$143,000 OSI Grant \$102,500,

12/04 – 2007 Phase II Trial of Carboplatin/Navelbine/Herceptin in HER2+ Metastatic Breast Cancer; Genentech, \$150,000 (P.I.)

11/04 – 2007 REaCHIT; Research, Education and Collaborative Healthcare in Tennessee, \$482,000 (P.I.)

10/04 – 03/10 Enhancing Lives Via Information Systems (ELVIS): A Community Network to Reduce Cancer Health Disparities; \$3,450,670 (Co-Investigator)

12/02 – 08/04 Phase II Study of Docetaxel Consolidation After Chemo-Radiotherapy of Inoperable Stage III Non-Small Cell Lung Cancer; \$522,500; Aventis Pharmaceuticals (P.I.)

09/98 – 06/01 Multicenter Phase II Trial of Weekly Vinorelbine plus Herceptin in Chemo-naive Patients with HER-2/neu Positive Metastatic Breast Cancer; \$200,000; GlaxoSmithKline/Genentech (P.I.)

06/97 – 12/99 A Multicenter Phase II Trial of Carboplatin and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Carcinoma; \$75,000; Phone-Poulenc Rorer (P.I.)

01/97 – 12/98 Phase I Study of Doxil in Combination with Escalating Doses of Navelbine for the Treatment of Patients with Advanced Malignancies; \$30,000; Sequus (P.I.)

01/97 – 12/98 Phase I Study of Doxil in Combination with Escalating Doses of Taxotere for the Treatment of Patients with Advanced Malignancies; \$30,000; Sequus (P.I.)

09/96 – 12/98 Pegylated Liposomal Doxorubicin as Second Line Treatment of Advanced Non-Small Cell Carcinoma after Platinum Based Therapy: A Randomized Phase II Trial; \$100,000; Sequus (P.I.)

06/96 – 12/98 A Phase I Trial of Vinorelbine and Gemcitabine in Relatively Elderly Patients with Refractory Solid Tumors; \$135,000; GlaxoSmithKline, Eli Lilly, Amgen (P.I.)

**Completed Clinical Research:**

SWOG 0802: A Phase II Trial of AVE0005 (VEGF Trap; Aflibercept) in Patients with Platinum-Treated Extensive Small Cell Lung Cancer

NSABP B-38: A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC -> P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC -> PG)

BRE-25 A Phase III Study to Compare the Neoadjuvant Administration of Docetaxel and Vinorelbine or Docetaxel followed by Adriamycin and Cytoxan with all Chemotherapy Administered in a Dose-Dense Fashion to Women with Stage II and Stage III Breast Cancer

Roche: ML 18530 An open-label study of capecitabine (Xeloda®) and docetaxel (Taxotere®) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative breast cancer, plus trastuzumab (Herceptin®) for HER2-neu positive breast cancer

SWOG 0124 Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer

- Glaxo Smith Kline- KSP20007 A Phase II, Open-Label Study of SB-715992 in Subjects with Locally Advanced or Metastatic Platinum-Refractory or Platinum-Sensitive Relapsed Non-Small Cell Lung Cancer (NSCLC)
- H3074 A Multicenter, Open-Label, Single Arm, Phase II Trial Investigating the Efficacy and Tolerability of Vinorelbine, Carboplatin and Trastuzumab for the First-Line Treatment of Metastatic Breast Cancer in Women with HER2+Disease
- BRE-22 **NSABPB-33** - A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3 N0-1 M0 **Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy)**
- BRE-18 **GlaxoSmithKline** An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with **Advanced or Metastatic Breast Cancer** Who Have Progressed While Receiving Herceptin Containing Regimens
- BRE-19 **Wyeth 3066A1-204-WW** - A Phase 2 Randomized Open-Label Study of Letrozole in Combination with Two Dose Levels and Schedules of Oral CCI-779, or Letrozole Alone in **Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer**
- BRE-20 **SWOG NSABP B-34** – A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in **Early- Stage Breast Cancer** Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy
- BRE-21 **SWOG S9630** – A Randomized Comparison of Medroxyprogesterone Acetate (MPA) and Observation for Prevention of Endometrial Pathology in Postmenopausal Breast
- BRE-23 **SWOG NSABP B-30** – A Three-Arm Randomized Trial to Compare Adjuvant Adrimycin and Cyclophosphamide Followed by Taxotere (AC-T) Adrimycin and Taxotere (AT) and Adrimycin, Taxotere, and Cyclophosphamide (ATC) **in Breast Cancer Patients with Positive Axillary Lymph Nodes**
- BRE-24 **Pharmacia** – Phase II Randomized, Open-Label Study of 2 Schedules of Single-Agent Oral Irinotecan in Patients with Metastatic Breast Cancer Who Have Experienced Failure of Prior Therapy with an Anthracycline, a Taxane and Capecitabine
- BRE-26 **Genentech** – A Multicenter, Open-Label, Single Arm, Phase II Trial Investigating the Efficacy and Tolerability of Vinorelbine, Carboplatin and Trastuzumab for the First-Line Treatment of **Metastatic Breast Cancer in Women with HER2+ Disease**
- LUN-24 **OSI Pharmaceuticals** – A Phase III, Randomized, Double-Blind, Multicenter Study of the Efficacy of Taxotere® (Docetaxel) in Combination with Aptosyn™ (exisulind) verses Taxotere® (Docetaxel) and Placebo in **Non-Small Cell Lung Cancer** Patients after Failure of Prior Platinum Based Chemotherapy
- LUN-28 **SWOG S9900** – A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB, II and Selected IIIA **Non-Small Cell Lung Cancer**
- LUN-30 **SWOG S0023** – A phase III trial of cisplatin/etoposide/radiotherapy with consolidation docetaxel followed by maintenance therapy with ZD1839 or placebo in patients with inoperable locally advanced **stage III non-small cell lung cancer**
- LUN-31 (**NCIC CTG BR.19**): A phase III prospective randomized, double-blind placebo-controlled trial of the epidermal growth factor receptor antagonist, ZD1839 in completely resected primary stage IB, II and IIIA non-small cell lung cancer
- PRE-1 **SWOG S0002**: Smoking Cessation Intervention for Completely Resected Stage I and Stage II Non-Small Cell Lung Cancer Survivors Who Are Currently Smokers, Phase III
- SWOG 0802: A Phase II Trial of AVE0005 (VEGF Trap; Aflibercept) in Patients with Platinum-Treated Extensive Small Cell Lung Cancer

Participated in Pivotal Herceptin trials leading to its FDA approval (see appendix of “Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2”, NEJM, March 15, 2001, vol 344, no 11)

Started investigator initiated studies in metastatic breast cancer, during previous employment with Boca Raton Comprehensive Cancer Center Inc. Between 1996 -2002. (An asterisk denotes investigator initiated studies)  
Options for Breast Cancer Patients:

\*A Phase II Trial of Vinorelbine and Herceptin Given Weekly for Previously Untreated Metastatic HER/2 Neu Positive Breast Carcinoma ICRG B1, Proceedings of American Society of Clinical Oncology, May, 2001 (Abst #1986) Final publication *The Oncologist*, 11/2002

\*A Phase II Trial of Docetaxel plus Herceptin as First or Second Line Therapy for Metastatic, HER/2 Positive Breast Carcinoma ICRG B2 (Closed)

Options for Lung Cancer Patients:

Developed a new lung cancer research program within CCRGI offering multiple treatment options to lung cancer patients (see below) with research grants from pharmaceutical companies

First Line Treatment Options:

Paclitaxel/carboplatin with or without Tarceva (Closed to Accrual)

\*Taxotere + carboplatin (Published, Anticancer Research 2004, 24: 1239-1242)

Any Phase I Trials

\*Gemzar + Navelbine (Glaxo Wellcome/Lilly) (completed accrual, reported at ASCO, May 1999, Abst #897A)

\*Doxil + Taxotere (Sequus) (Completed accrual, reported at ASCO, May 1999, Abst. #820)

\*Doxil + Navelbine (Sequus) (Completed accrual, reported at ASCO, May 1999, Abst. #827)

Cisplatin VP16 vs cisplatin + tirapazamine (closed)

RPR 326 – A multicenter randomized trial comparing Taxotere/cisplatin vs. Taxotere/Carboplatin vs. cisplatin/vinorelbine (closed to accrual, reported at ASCO 2001)

Oral vs. IV Navelbine (closed)

Taxol + carboplatin ± Iressa (closed)

Aventis 203 – Taxotere/CPT-11 weekly x 4 with 2-week rest (Closed)

Post chemotherapy (within 60 days) for responders and stable patients

Tegretin (vit. A analog) Vs. Placebo, (Ligand) (closed)

Second Line Treatment Options (platinum failures):

Cell Pathways #208 – Weekly Taxotere ± Aptosyn (Closed)

\*Doxil Weekly or Q 4 weeks (Sequus)  
(completed accrual, reported at ASCO, May 1999, Abst. #2004)

AstraZeneca – Expanded Access IRESSA Program (closed)  
ZD0473 in Platinum Failures (Closed)

Patients with Stage IIIA or Selected IIIB Lung Cancer:

Minimal residual disease after treatment with any reasonable combination of chemotherapy, radiation and surgery:

Miramastat vs. Placebo, (Closed)

Patients with Stage I, II, or III Completely Resected Lung Cancer:

\*Paclitaxel/carboplatin/radiation followed by weekly or q3 weeks docetaxel consolidation  
International Adjuvant Lung Trial, The New England Journal of Medicine, Vol. 350, No. 4,  
January 22, 2004; 351-360.

Observation vs. cisplatin + vinorelbine (+XRT for N2 disease)

Resectable Stage III with mediastinoscopically proven N2 disease:

TAX 711 Neoadjuvant study, cisplatin/Taxotere x 3 cycles followed by surgery followed by  
radiation therapy (ASCO, June 2003, Abst. #2652) (Closed)

Small cell lung cancer (extensive stage after CR or PR to chemotherapy):

Bayer MMPI randomized placebo-controlled trial (closed to accrual)

ZD0473 in platinum failures (closed)

**Hospital Appointments:**

08/22 – Present Delray Medical Center, Delray Beach, FL  
07/08 – Present Boca Raton Regional Hospital, Boca Raton, FL  
12/20 – 09/22 Plantation General Hospital (Mercy Hospital), Miami FL  
06/16 - 12/16 Jackson Memorial Hospital, Miami, FL  
04/10 – 06/19 University of Miami Hospital and Clinics (Sylvester)  
08/02 – 07/08 Methodist Healthcare University Hospital, Memphis, TN  
08/02 – 07/08 Methodist Healthcare North, Memphis, TN  
08/02 – 07/08 Methodist Healthcare Germantown, Germantown, TN  
08/02 – 07/08 Methodist Healthcare Desoto, Southaven, MS  
08/02 – 07/08 Regional Medical Center at Memphis, TN

08/02 – 07/08 Veterans Affairs Medical Center, Memphis, TN  
08/02 – 07/08 Baptist Memorial Hospital East, Memphis, TN  
08/02 – 07/08 Baptist Women’s Hospital, Memphis, TN  
08/02 – 07/08 Baptist DeSoto Hospital, Southaven, MS  
08/02 – 07/08 St. Francis Hospital, Memphis, TN  
11/02 – 07/08 St. Francis Bartlett Hospital, Bartlett, TN  
07/07 – 07/08 St. Bernards Medical Center, Jonesboro, AR  
08/02 – 09/04 University of Tennessee Bowld Hospital, Memphis, TN  
01/00 – 06/08 Staff Physician and Medical Director, Eugene M. & Christine E. Lynn Clinical Research Center, Boca Raton Regional Hospital, Boca Raton, FL  
01/00 – 08/02 West Boca Medical Center, Boca Raton, FL  
01/00 – 08/02 Delray Medical Center, Delray Beach, FL  
01/00 – 08/02 JFK Medical Center, Lake Worth, FL  
01/00 – 08/02 Bethesda Memorial Hospital, Boynton Beach, FL  
10/95 – 08/02 Boca Raton Regional Hospital, Boca Raton, FL  
07/93 – 09/95 Staff Physician, John Cochran Veterans Administration Hospital, St. Louis, MO  
07/93 – 09/95 Attending Physician, Jewish Hospital, St. Louis, MO  
07/93 – 09/95 Attending Physician, Barnes Hospital, St. Louis, MO

**Editorial Appointments:**

2013 – Present Chief Editor for Journal of Cancer and Allied Specialties  
01/08 – Present Editorial Board for *Journal of Clinical Oncology*  
2011 – 2013 Chief Editor for *Managed Care in Oncology*  
01/99 – 06/05 Editorial Board for *Clinical Lung Cancer*  
01/02 – 2004 Editorial Board for *CURE*  
06/97 – 12/00 Editor-in-Chief for *Navelbine Update / Pipeline News* - A Quarterly Newsletter of Glaxo Welcome for Navelbine Investigators

**Ad-hoc Reviewer for Journals:**

*Clinical Cancer Investigation*  
*Journal of Clinical Oncology*  
*Lung Cancer* (Journal of International Association for the Study of Lung Cancer)  
*Cancer*  
*CA: A Cancer Journal for Clinicians*  
*Clinical Lung Cancer*  
*Clinical Breast Cancer*  
*Chemotherapy*  
*Cancer Investigation*  
*American Journal of Cancer*  
*Caring4Cancer*  
*Tumor*  
*Future Oncology*  
*Future Medicine*

**National Committee Memberships and Offices Held:**

ASCO Founder and Chair (2018-2021)  
ASCO International Quality Task Force (2017-2021)  
ASCO Quality of Care Committee (2009-2017)  
ASCO Breast Cancer Consensus Panel (2013-2017)

ASCO Women with Advanced HER2-. ER+/PR+ Breast Cancer (2012-2016)  
 ASCO Breast Cancer Guideline Advisory Group (2012-2014)  
 JCO Editorial Board (2011-2013)  
 QOPI Measures Working Group (2008-2011)  
 SystHERs Steering Committee- (2015)  
 FLASCO Board of Directors- (2015)  
 FLASCO Program Committee- Chairman (2015)  
 ASCO Quality of Care Committee (2014-2015)  
 ASCO Quality Oncology Practice Initiative (QOPI) Chair Elect- (2014 to 2015), Chair 2015- present  
 ASCO Breast Cancer Guidelines Panel for HR+ Patients (2012 to present)  
 ASCO Quality Oncology Practice Initiative (QOPI) Quality Measures Development Committee (2006-Present)  
 ASCO QOPI Alpha Group (2003 – 2011)  
 ASCO Venous Thromboembolism (2005-2012)  
 ASCO Breast Cancer Guidelines Panel (2012)  
 Adhoc Committee Information Technology (2012)  
 NCCN REMS Working Group (2010)  
 ICORE Advisory Board (2009 – 2012)  
 NCCN ARIES Lung Cancer Steering Committee (2007-Present)  
 Board of Directors, National Comprehensive Cancer Network (NCCN) (2003 – 2009)  
 Guidelines Steering Committee, NCCN (2002 – 2009)  
 CME Committee, NCCN (2007 – 2009)  
 Lung Cancer Expert Panel, NCCN (2003 – 2013)  
 Breast Cancer Expert Panel, NCCN (2003– 2009)  
 Research Investigators Steering Committee, NCCN (2004 –2009)  
 Venous Thromboembolism Panel, NCCN (2004 – 2008)  
 Lung Committee, Southwest Oncology Group (2003 – 2010)  
 Breast Committee, Southwest Oncology Group (2003 – 2010)  
 Adjuvant Panel, Breast Cancer, NCCN (2004 – 2009)  
 Elderly Breast Cancer Task Force, NCCN (2007)  
 HER2 Testing Task Force, NCCN (2006)  
 ASCO's Medical Oncology In-Training Examination Item Harvesting Committee (2007)  
 Venous Thromboembolism Panel, American Society of Clinical Oncology (ASCO) (2006)  
 Executive Committee Member, IACA (2007 – 2012)  
 Research and Education Committee, Association of Pakistani Physicians of North America (APPNA) (2006-Present); Chair for 2014  
 Resource Development Committee, APPNA (2002)  
 President, King Edward Medical College Alumni Association of North America (KEMCAANA) (2004)  
 President Elect, KEMCAANA (2003)  
 Secretary, KEMCAANA (2002)  
 Treasurer, KEMCAANA (2001)

**Local Committee/ Regional Memberships / Task Forces:**

CME Committee Boca Raton Regional Hospital (2008 – 2010)  
 Cancer Committee – Boca Raton Regional Hospital (2008 - Present)  
 Gilda's Club of South Florida (2008 - Present)  
 ACS Hope Lodge Foundation Committee (June 2006 – June 2008)  
 Central Biomedical District, Memphis, TN (March 2003 – June 2008)  
 Methodist Healthcare Foundation Board, Memphis, TN (March 2003 – June 2007)  
 Executive Committee, University of Tennessee Cancer Institute, Memphis, TN (Aug. 2002 – June 2004)  
 Clinical Committee, University of Tennessee Cancer Institute, Memphis, TN (Aug. 2002 – June 2004)

Transition Committee, University of Tennessee-Methodist Healthcare, Memphis, TN (2002 – 2003)  
Steering Committee, University of Tennessee Cancer Institute, Memphis, TN (2002 – 2003)  
Cancer Care Committee, Boca Raton Regional Hospital, Boca Raton, FL (1997 – 2002)  
Pharmacy and Therapeutics Committee, Boca Raton Regional Hospital, Boca Raton, FL (2000 – 2002)  
CME Committee, Boca Raton Regional Hospital, Boca Raton, FL (2000 – 2002, and 2008-2009)  
Cancer Care Committee, JFK Medical Center, Atlantis, FL (1995 - 2000)  
Advisory Board, Wellness Community, Boca Raton, FL (2000 – 2002)  
Cancer Care Committee, VA Hospital, St. Louis, MO (1993 - 1995)

### **University of Tennessee Committees**

Research Membership Committee for Internal Medicine Resident (July 2007 – June 2008)  
UTCi Planning Committee (2002-2005)  
UTCi Steering Committee (2002-2005)  
UTCi Focus Group (2002-2005)  
UTCi Cancer Center Director Search Committee (2002-2005)  
UTCi Membership Committee (2002-2005)  
UTCi Statewide Planning Committee (2002-2005)  
UTCi Community Advisory Board (2002-2005)

### **University of Miami Committees**

Quality and Value Committee, University of Miami- Sylvester Comprehensive Cancer Center (2010)  
Chair, Sylvester Research Acceleration Grant Committee (2012-present)  
UM Sylvester End of Life Task Force  
Breast Cancer SDG member  
Lung SDG Interim Chair 07/2012 - 07/2014  
UM Cancer service Line Governance Council (2008-2011)

### **Community Service:**

2018 – Dolphins Cycling Challenge, “DCC Heavy Hitter, All-Pro”  
2017 – Dolphins Cycling Challenge, “DCC Heavy Hitter, All-Pro”  
2016 – Dolphins Cycling Challenge, “DCC Heavy Hitter, All-Pro”  
2015 – Dolphins Cycling Challenge, “DCC Heavy Hitter”  
2013 – Dolphins Cycling Challenge, “DCC Heavy Hitter”  
2009 – Susan G Komen for the Cure South Florida “Knowledge is the Power of Pink” interactive panel  
2008 – Gilda’s Club – Professional Healthcare Council  
2007 – Methodist Hospice Fundraising Campaign Committee  
2007 – ACS Hope Lodge Capital Campaign Committee  
2007 – East Memphis Rotary Club, “Cancer and Its Treatment: Future is Here Now”  
2006 – Cancer Talk Live Forum, Peabody Hotel  
2004 – Collierville Rotary Club, “An Overview of UTCi”  
2004 – East Memphis Rotary Club, “An Overview of UTCi”  
2004 – Memphis Kwanis Club, “An Overview of UTCi”  
2004 – Medical Education and Research Institute, “The Value of a Multi-Disciplinary Breast Cancer Clinic”  
2003 – Memphis Rotary Club, “An Overview of UTCi”  
2003 – Chancellor’s Roundtable, “Rationale of a Statewide UTCi”  
2003 – University of Tennessee Board of Trustees, Rationale of a Statewide UTCi”  
2002 – Wellness Community of Boca Raton

### **Course Directorship of International, National and Regional CME Symposia**

Initiated, organized, and directed (including fundraising) the following CME symposia as Program Chair / Course

Director:

Annual Asia & Middle East Guidelines in Oncology Symposia:

- 04/09 2nd Annual Asia & Middle East Guidelines in Oncology Congress, Abu Dhabi, UAE
- 02/08 1st Annual Asia & Middle East Guidelines in Oncology Symposium, "Decision Making in Oncology: Evidence & Consensus", Al Ain, UAE

Annual Palm Beach Cancer Symposia:

- 04/11 12<sup>th</sup> Annual Palm Beach Cancer Symposium, "Personalizing Care in the Era of Genomic Tests and Targeted Therapies", 16 speakers, 2 days, Fort Lauderdale, FL
- 04/09 11th Annual Palm Beach Cancer Symposium, "Personalized Medicine in the Era of Targeted Therapy", 18 Speakers, 2 days, Hollywood, FL
- 04/08 10th Annual Palm Beach Cancer Symposium, "Practical Issues in Patient Care", Palm Beach, FL (Planning) 15 speakers, 2 days, Palm Beach, FL
- 04/07 9th Annual Palm Beach Cancer Symposium, "Tailoring Treatment with Targeted Therapies", 14 speakers, 2 days, Palm Beach, FL
- 04/06 8th Annual Palm Beach Cancer Symposium, "Shifting Paradigms of Treatment" 13 speakers, 2 days, Palm Beach, FL
- 04/05 7th Annual Palm Beach Cancer Symposium, "Combined Modality Therapy of Common Malignancies" 14 speakers, 2 days, Palm Beach, FL
- 04/04 6th Annual Palm Beach Cancer Symposium, "A Quickening Pace of Progress" – 12 speakers, 2 days, Palm Beach, FL
- 03/03 5th Annual Palm Beach Cancer Symposium, "Emerging Paradigms in Cancer Care" – 16 speakers, 2 days, Delray Beach, FL
- 03/02 4th Annual Palm Beach Cancer Symposium, "Moving Beyond the Ordinary" - 12 speakers, 2 days, Delray Beach, FL
- 03/01 3rd Annual Palm Beach Cancer Symposium, "Filling in the Gaps" - 14 speakers, 2 days, Delray Beach, FL
- 03/00 2nd Annual Palm Beach Cancer Symposium, "Cancer Care in the Community" - 13 speakers, 2 days, Pompano Beach, FL
- 02/99 1st Annual Palm Beach Cancer Symposium, "Multi-modality Management of Common Malignancies" - 18 speakers, 3 days, Boca Raton, FL

Annual Mid-South Cancer Symposia:

- 11/08 6th Annual Mid-South Cancer Symposium, "Multi Modality Therapies of Common Solid Tumors – Focus on Head & Neck Cancer
- 10/07 5th Annual Mid-South Cancer Symposium, "Focus on Thoracic Oncology", 11 speakers, 1 day, Memphis, TN
- 10/06 4th Annual Mid-South Cancer Symposium, "Evolving Paradigms in Oncology", 6 speakers, 1 day, Memphis, TN
- 10/05 3rd Annual Mid-South Cancer Symposium, 7 speakers, 1 day, Memphis, TN
- 10/04 2nd Annual Mid-South Cancer Symposium, 6 speakers, 1 day, Memphis, TN
- 10/03 1st Annual Mid-South Cancer Symposium, 5 speakers, 1 day, Memphis, TN



### Other Programs:

- 8/14 37<sup>th</sup> Association of Physician of Pakistan Descent of North America (APPNA), CME, National Harbor, Washington D.C.
- 06/04 Co-Director, CME Course, "Old Problems, New Solutions", APPNA Annual Convention, Washington, DC
- 11/97 "Lung Cancer in the New Millennium" - 6 speakers, 1 day, Boca Raton, FL 97 - 02  
Monthly CME accredited city-wide tumor board
- 08/95 CME meeting for Association of Pakistani Physicians of North America (APPNA), St. Louis, MO

### **Extracurricular Activities:**

- Writer of prose and poetry, publications in various magazines and broadcasts on Radio Pakistan, Lahore
- Contributed several pieces of prose and poetry to journals of APPNA and KEMCANNA
- World Travel
- Reading non-medical literature (History, Urdu poetry, Eastern philosophy, self-improvement, fiction etc.)
- Biking

### **International Lectures by Invitation:**

1. **Saudi Arabia (East)**, March 2024, Shaping HER Destiny
2. **Saudi Arabia (West)**, March 2024, Shaping HER Destiny
3. **Abu Dhabi, UA**, February 2024, Breast Cancer Updates SABCS Strategies in Treatment of Hormone Receptor- Positive
4. **Abu Dhabi, UA**, February 2024, HER2-Negative Breast Cancer
5. **Algiers, Algeria**, November 2023, NCCN Breast Cancer Guidelines v4.2023
6. **Algiers, Algeria**, November 2023, Navigating Emerging Developments in EGFR mutated Non-Small Cell Lung Cancer
7. **Madrid, Spain**, November 2022, 4<sup>th</sup> Oncology Quality Care Symposium
8. **Goias, Brazil**, May 2022, 11<sup>th</sup> Edition of the Brazilian Breast Cancer Symposium (BBCS), "What is the role of BRCA1/2 mutations in NON-triple-negative patients?"
9. **Virtual**, February 2022, "Canadian National Speaker Tour"
10. **Virtual Event in Madrid, Spain**, November 2021, 3rd Oncology Quality Care Symposium, "The real impact of COVID-19 in cancer patients"
11. **Lahore, Pakistan**, November 2021, Virtual 19<sup>th</sup> Shaukat Khanum Cancer Symposium, "Current recommendations for Breast Cancer, Brain Metastases and Leptomeningeal Disease"
12. **Virtual Event**, October 2021, MSD Mexico KN-355 Launch Symposium-Mexican Oncology Congress, "Actual and Future Approach in Triple Negative Breast Cancer"

13. **Goiania, Brazil**, May 2021, Virtual Brazilian Breast Cancer Symposium, “Targeting Triple Negative Breast Cancer with Immunotherapy. What Are the Current Available Drugs?”
14. **Goiania, Brazil**, May 2021, Virtual Brazilian Breast Cancer Symposium, “Recent Knowledge About HER2+Breast Cancer: Biology and Treatment in Specific Situations”
15. **Goiania, Brazil**, May 2021, Virtual Brazilian Breast Cancer Symposium, “Genetic Therapy, Do We Have Some Perspectives?”
16. **Karachi, Pakistan**, December 2020, Virtual Meeting “Kadcyla: Case Studies in the Neoadjuvant and the Adjuvant Setting”
17. **Madrid, Spain**, October 2020, Virtual Meeting “QOPI Update: The Next Generation Quality Cancer Care Delivery”
18. **Madrid, Spain**, October 2020, Virtual Meeting “ASCO’s Commitment to Quality: QOPI updates”
19. **Karachi, Pakistan**, July 2020, Virtual Meeting “Implications of recent data on the eBC treatment landscape and further development”
20. **Beirut, Lebanon**, February 2020, Webex “Evolving Overall Survival Data with the 3 CDK4/6 Inhibitors in HR+/HER2- ABC”
21. **Taipei, Taiwan**, December 2019, “Evolving ALK+NSCLC treatment Landscape-Key Data and Clinical Implication
22. **Taichung, Taiwan**, December 2019, “Evolving ALK+NSCLC treatment Landscape-Key Data and Clinical Implication
23. **Kaohsiung, Taiwan**, December 2019, “Evolving ALK+NSCLC treatment Landscape-Key Data and Clinical Implication
24. **Barcelona, Spain**, September 2019, ESMO “Real-World Treatment Patterns and Outcomes in ALK+ NSCLC Patients Receiving Immuno-Oncology Therapy in the United States”
25. **Hong Kong, China**, June 2019, “Overcoming Challenges in ALK+NSCLC”
26. **Brazil**, May 2019, “Systemic Therapy of Metastatic HER2+ Breast Cancer”
27. **Dubai, UAE**, April 2019, “Dual HER2+ blockade – What are our goals in eBC?”
28. **Dubai, UAE**, April 2019, “Optimizing Therapy decision- Continuation of PH post Neoadjuvant for Her2 + eBC patients”
29. **Singapore**, November 2018, “ALK + Metastatic Lung Cancer: Navigating Options in Second-Line”
30. **Campinas, Brazil**, October 2018, “Best of Breast Cancer from ESMO 2018”

31. **Budapest, Hungary**, October 2018, “Unmet need in ALK+NSCLC and the Alunbrig 2<sup>nd</sup> Line data”
32. **Amman, Jordan**, May 2018, Jordan Advanced Breast Cancer Advisory Board, “Current landscape of HR+/HER2- Metastatic Breast Cancer (MBC) management”
33. **Amman, Jordan**, May 2018, Jordan Advanced Breast Cancer Advisory Board “Moving from clinical data to clinical practice: How to optimize outcomes in HR+/HER2- MBC patients?”
34. **Beirut, Lebanon**, May 2018, Lebanon Advanced Breast Cancer Advisory Board, “Moving from clinical data to clinical practice: How to optimize outcomes in HR+/HER2- MBC patients?”
35. **Beirut, Lebanon**, May 2018, Lebanon Advanced Breast Cancer Advisory Board “Current landscape of HR+/HER2- Metastatic Breast Cancer (MBC) management”
36. **Goiania, Brazil**, May 2018, Brazilian Breast Cancer Symposium 2018 “An Overview on CD4/6 inhibitors: comparison on clinical benefits and safety for advanced breast cancer”
37. **Sao Paulo**, Brazil 2018, “Precision Oncology Lung Cancer: State of Art in 2018- MasterClass”
38. **Sao Paulo**, Brazil 2018, Hospital Sirio Libanes, Tumor Board cases discussions at Hospital Sírio Libanês
39. **Sao Paulo**, Brazil 2018, Lecture at Hospital Beneficiencia Portuguesa
40. **Singapore**, March 2018, “Evolving landscape of CDK 4/6 inhibition in metastatic HR+ Breast Cancer”
41. **Lima, Peru**, November 2017, “Clinical Application of Comprehensive Genomic Profiling in Lung Cancer”
42. **Amman, Jordan**, November 2017, “Addressing the unmet need in HR+/HER2- Advanced Breast Cancer
43. **Amman, Jordan**, November 2017, “Ibrance (Palbociclib) in HR+/HER2- abc: Reviewing the evidence”
44. **Amman, Jordan**, November 2017, Ibrance ad board
45. **Recife, Brazil**, October 2017, “Overcoming Hormone Therapy Resistance in HR+ Metastatic Breast Cancer”
46. **Recife, Brazil**, October 2017, “Neoadjuvant Systemic Therapy in Breast Cancer”
47. **Recife, Brazil**, October 2017, “Estimating Risk of Recurrence”
48. **Port-of-Spain, Trinidad and Tobago**, September 2017, “Quality Indicators in Cancer Management”
49. **Madrid, Spain**, September 2017, ESMO, “Clinical Application of Comprehensive Genomic Profiling in Lung Cancer”

50. **Madrid, Spain**, September 2017, ASCO Quality at ESMO, “Navigating the New Quality World: ASCO’s Map to International Quality Programs Expansion”
51. **São Paulo, Brazil**, August 2017, “Understanding the Impact of Anti PD-1/PDL-1 Therapies in Second-line Treatment, and Perspectives on Long Term Survival in Patients with NSCLC”
52. **Montevideo, Uruguay**, August 2017, “Clinical Application of Comprehensive Genomic Profiling in Lung Cancer”
53. **Santiago, Chile**, July 2017, “Genomic Profile and Precision Medicine in the Cancer Treatment”
54. **Buenos Aires, Argentina**, May 2017, “The Value of Comprehensive Genomic Profiling, including immunotherapy and liquid Biopsy Options”
55. **Buenos Aires, Argentina**, May 2017, “Clinical Utility of a Foundation One Test (Lung, Breast, and other tumors, some clinical cases of interest)
56. **Buenos Aires, Argentina**, May 2017, “Clinical Utility of a Foundation One Test in Breast Cancer”
57. **Buenos Aires, Argentina**, May 2017, “Clinical Utility of a Foundation One Test in CUP and Rare Tumors”
58. **Lahore, Pakistan, April 2017**, “How to Target Triple Negative Breast Cancer: What’s New”
59. **Lahore, Pakistan, April 2017**, “Overcoming Hormone Therapy Resistance in HR+ Metastatic Breast Cancer”
60. **Lahore, Pakistan, April 2017**, “Estimating Risk of Recurrence in Early-Stage Breast Cancer”
61. **Lahore, Pakistan, April 2017**, “Update on HER2+ Adjuvant Therapy”
62. **Sao Paulo, Brazil**, November 2016, GBOT Lung Cancer Symposium, “Clinical Applications of Comprehensive Genomic Profile in Lung Cancer” and “Immuno-Oncology: A Renaissance in the Treatment of NSCLC”
60. **Riyadh, Saudi Arabia**, October 2016, “Current Status of Immunotherapy in Lung Cancer”
61. **Dammam, Saudi Arabia**, October 2016, “Current Status of Immunotherapy in Lung Cancer”
62. **Jeddah, Saudi Arabia**, October 2016, “Current Status of Immunotherapy in Lung Cancer”
63. **Mecca, Saudi Arabia**, October 2016, “Current Status of Immunotherapy in Lung Cancer”
64. **Merida, Mexico**, September 2016, Current Trends in Immuno-oncology, “Emerging Immuno-Oncology Data in Other Solid Tumors”
65. **Merida, Mexico**, September 2016, “Current Status of Immunotherapy in Breast Cancer”

66. **Salvador, Brazil**, June 2016, "Discussant at Best of ASCO Breast Cancer 2016"
67. **Goiania, Brazil**, May 2016, Breast Cancer Symposium, "Bone protection after breast cancer treatment", "Developments in treatment of hormone receptor positive breast cancer".
68. **Lahore Pakistan**, April 2016, Pakistan Society, "Harnessing the Immune System as a Therapeutic Modality"
69. **Lahore Pakistan**, April 2016, Pakistan Society, "Lung Cancer: A General Introduction",
70. **Lahore Pakistan**, April 2016, Pakistan Society, "Targeted Therapy of Lung Cancer"
71. **Lahore, Pakistan**, December 2015, "APPNA Winter Meeting 2015, Genomic Medicine and Lung Cancer: A Revolution of Sorts"
72. **Foz do Iguacu, Parana, Brazil**, October 29- November 01, 2015, Brazilian Society on Clinical Oncology- SBOC "Locally advanced Disease: how to define the best multimodal strategy"
73. **Foz do Iguacu, Parana, Brazil**, October 29- November 01, 2015, "Lung Cancer clinical case discussion on advanced disease."
74. **Goiania, Brazil**, May 14- May 16, 2015, Breast Cancer Symposium, "Triple negative tumors: is there evidence for Platinum in adjuvant therapy"
75. **Goiania, Brazil**, May 14- May 16, 2015, "Advances in the early stage breast cancer adjuvant therapy"
76. **Goiania, Brazil**, May 14- May 16, 2015, Breast Cancer Symposium, "Breast cancer treatment advances of HER 2 (+) breast cancer".
77. **Goiania, Brazil**, May 23 – May 25, 2013, "Evaluation of Genomic Platforms in Invasive Breast Cancer: A Review of Clinical Validation Evidence and Two Head-to-Head Clinical Utility Studies"
78. **Goiania, Brazil**, May 23 – May 25, 2013, "Management of Bone Metastasis in Breast Cancer"
79. **Moscow, Russia**, December 19 – December 23, 2012, "Challenges in Adaptation and Adoption of the NCCN Guidelines"
80. **Lahore, Pakistan**, November 8 – November 12, 2012, "NCCN Guidelines: The Process of Guideline Development", "Towards More Personalized Therapy for Non-Small Lung Carcinoma", "Estimating Risk of Recurrence in Early-Stage Breast Cancer".
81. **Salvador, Brazil**, October 10 – October 13, 2012, "NCCN" Guidelines Process: International Adaptations", "Neoadjuvant Chemotherapy in Breast Cancer".
82. **Namibia, South Africa**, April 26 – 27, 2012, NCCN 1<sup>st</sup> Steering Committee Meeting for Sub-Saharan Africa, "NCCN Overview: Guidelines Development and Implementation in the United

States”, “NCCN International Initiatives:

83. **Doha, Qatar**, January 2012, MENA-NCCN Regional Meeting, “Challenges and Opportunities in the International Adaptation of the NCCN Guidelines”
84. **Gramado, Brazil**, October 2011, ASCO-SBOC Joint Symposium, XVII Brazilian Congress of Clinical Oncology, “Economic Implications of Cancer and Cancer Treatment” “Impact of Guidelines in Clinical Practice”
85. **Goiania, Brazil**, October 2011, Brazilian Congress Of Mastology, “Breast Conservation after Neoadjuvant Therapy” “Which Patient Should be Offered Neoadjuvant Therapy”
86. **Goiania, Brazil**, October 2011, Brazilian Congress of Mastology, “The State of the Art on the Treatment of HER2 Positive Breast Cancer Patients”
87. **Mexico City, Mexico**, August 2011, 1<sup>st</sup> Symposium Treatment with Care, “An Update in Supportive Care Therapies and Breast Cancer Treatments:
88. **Amsterdam, The Netherlands**, July 2011, 14<sup>th</sup> World Conference on Lung Cancer – IASLC – “Sarcoma of Lung”. Discussant for oral abstract session.
89. **Rio de Janeiro, Brazil**, July 2011, NCCN-GLICO Meeting, Personalized Medicine and Challenges in Clinical Research. “NCCN Global Initiatives”.
90. **Cape Town, South Africa**, May 2011, University of Stellenbosch Oncology “NCCN Guidelines in Early Breast Cancer”.
91. **Cape Town, South Africa**, May 2011, Cape Town Stadium “The Use of Avastin in Breast and Lung Cancer”.
92. **Durbin, South Africa**, May 2011, Moses Mabhid Stadium “NCCN Guidelines in Early Breast Cancer”.
93. **Pietermaritzburg, South Africa**, May 2011, “The Use of Avastin in Breast and Lung Cancer”.
94. **Johannesburg, South Africa**, May 2011, FNB Stadium “NCCN Guidelines in Early Breast Cancer” and “The Use of Avastin in Breast and Lung Cancer”.
95. **Cape Town, South Africa**, May 2011, University of Pretoria, “NCCN Guidelines in Early Breast Cancer”.
96. **Berlin, Germany**, January 2011, “Debate: It is time to switch to Denosumab in Breast Cancer Patients with Bone Mets”.
97. **Antalya, Turkey**, November 2010, “Using Gene Signatures in Assigning Adjuvant Therapy; Case Studies”
98. **Antalya, Turkey**, November 2010, “Clinical Endpoints in Metastatic Breast Cancer”
99. **Antalya, Turkey**, November 2010, “NCCN Guidelines”

100. **Riyadh, Saudi Arabia**, “Challenges of Disseminating NCCN Guidelines Worldwide
101. **Gramado, Brazil**, August 2010 “Antibody Therapy in Breast Cancer”
102. **Gramado, Brazil**, August 2010 “Genomic Tests in Clinical Practice”
103. **Cuernavaca, Mexico**, June 2010 “Progression-Free Survival vs. Overall Survival as Endpoints in Metastatic Breast Cancer”
104. **Kirenya, Cyprus**, May 2010 “Endpoints in Clinical Oncology Studies”
105. **Lima, Peru**, April 2010 “Clinical Guidelines, Present and Future in Latin America”
106. **Lahore, Pakistan, at Shaukat Khanum Cancer Research Hospital**, February 2010 “Recent treatment options in HER2 positive MBC”
107. **Lahore, Pakistan, at Shaukat Khanum Cancer Research Hospital**, February 2010 “Recent treatment options in HER2 positive MBC”
108. **Gujranwala Pakistan, at Inauguration of GINUM** (Institute of nuclear medicine) February 2010 “NCCN Guidelines in NSCLC”
109. **Kuwait City, Kuwait**, February 2010 “Breast Guideline Sessions”
110. **Vienna, Austria**, January 2010 “Case studies in Lung Cancer”
111. **Lahore, Pakistan**, November 2009 “Recent Treatment Options in HER2 Neu Metastatic Breast Cancer”
112. **Gramado, Brazil**, October 2009 “Evidence of Anticancer Properties of Bisphosphonates in the Treatment of Breast Cancer”
113. **Gramado, Brazil**, October 2009 “role of NCCN Guidelines in Cancer Care”
114. **Berlin, Germany**, September 2009 ECCO/ESMO “Safety of Bevacizumab (BV) Combined with Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Interim Results from the ARIES Lung Observational Cohort Study”
115. **Beirut, Lebanon**, May 2009 “Towards Tailored Therapies in Breast Cancer”
116. **Doha, Qatar**, May 2009 “Towards Tailored Therapies in Breast Cancer”
117. **Cairo, Egypt**, May 2009 “Guidelines in Treating ErbB2 Positive Breast Cancer”
118. **Cairo, Egypt**, May 2009 “NCCN Guidelines for Early Breast Cancer”
119. **Cairo, Egypt**, May 2009 “ST. Gallen Updates”

120. **Kuwait City, Kuwait**, April 2009 “Update on Targeted Therapy for ErbB2 positive breast cancer”
121. **Muscat, Oman**, April 2009 “Introducing Tykerb, A novel targeted therapy for ErbB2 breast cancer”
122. **Abu Dhabi, UAE**, April 2009 “Overview of NCCN Lung Cancer Guidelines”
123. **San Juan, PR**, February 2009, “Focus on the Host and Therapy-Related Toxicities”
124. **San Juan, PR**, February 2009, “Adjuvant HER-2 directed Therapy: Candidates and Practical Management.”
125. **Lahore, Pakistan**, February 2009, “Systemic Therapy for Node Positive Breast Cancer”
126. **Seville, Spain**, January 2009, “Identifying Patients iwth Aggressive Solid Tumors who would benefit from Bisphosphonate Therapy.”
127. **Riyadh, Saudi Arabia**, January 2009, “Prognosis, Prediction and Therapy in HR+ Breast Cancer: SABCS Review of Abstracts 53, 57 and 81”
128. **Riyadh, Saudi Arabia**, January 2009, “Tailoring Targeted Therapies in Breast Cancer”
129. **Madrid, Spain**, October 2008, “2008 Zenith Day: Focus on Breast Cancer”
130. **Sao Paulo, Brazil**, August 2008, “Emerging Strategies for Management of Endocrine Responsive Breast Cancer”
131. **Rio De Janeiro, Brazil**, August 2008, “NCCN Guidelines Discussion”
132. **Salvator, Brazil**, August 2008, “NCCN Guidelines Discussion”
133. **Curitiba, Brazil**, August 2008, “NCCN Guidelines Discussion”
134. **Dubai, UAE**, May, 2008, “Risk of Recurrence in Early Breast Cancer”
135. **Dubai, UAE**, May, 2008, “Decision Making in Endocrine Therapy for Early Breast Cancer”
136. **Beijing, China**, March, 2008, “Update on NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer”
137. **Shanghai, China**, March, 2008, “Update on NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer”
138. **Guangzhou, China**, March, 2008, “Update on NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer”
139. **Tokyo, Japan**, January, 2008, “Does ‘shifting gears’ toward recurrent breast cancer exist?”



140. **Seoul, South Korea**, November, 2007, "NCCN CRAC and Non-Small Cell Lung Cancer Guidelines"
141. **Barcelona, Spain**, September, 2007, "Non-Small Cell Lung Cancer: Improving Outcomes with Targeted Therapies"
142. **Islamabad, Pakistan**, April, 2007, "Role of Angiogenesis in Breast: Focus on Avastin"
143. **Islamabad, Pakistan**, April, 2007, "Adjuvant Herceptin Based Therapy"
144. **Lahore, Pakistan**, April, 2007, "Role of Angiogenesis in Breast: Focus on Avastin"
145. **Lahore, Pakistan**, April, 2007, "Adjuvant Herceptin Based Therapy"
146. **Karachi, Pakistan**, April, 2007, "Role of Angiogenesis in Breast: Focus on Avastin"
147. **Karachi, Pakistan**, April, 2007, "Adjuvant Herceptin Based Therapy"
148. **Tokyo, Japan**, March, 2007, "Navelbine I.V. in Breast Cancer: Efficacy and Preservation of Daily Activities"
149. **Dubrovnik, Croatia**, March, 2007, "Case Study: A 65-Year-Old Male with Hemoptysis"
150. **Dubrovnik, Croatia**, March, 2007, "Case Study: Newly Diagnosed Stage IV NSCLC in a Female Smoker"
151. **Zurich, Switzerland**, August, 2005, "Update in Biological Therapy of Breast Cancer: ASCO 2005".
152. **Zurich, Switzerland**, August, 2005, "Update in Biological Therapy of Non-Small Cell Lung Cancer".
153. **Lahore, Pakistan**, March, 2005, "Combined Modality Therapy in Non-Small Cell Lung Cancer", Seventh Shaukat Khanum Memorial Cancer Symposium.
154. **Lahore, Pakistan**, March, 2005, "How to Publish a Manuscript", Seventh Shaukat Khanum Memorial Cancer Symposium.
155. **Lahore, Pakistan**, March, 2005, "Targeted Therapy in the Management of Breast Cancer", Seventh Shaukat Khanum Memorial Cancer Symposium.
156. **Lahore, Pakistan**, December 2004, "Chemotherapy of Early Breast Cancer", 23rd Annual KEMCAANA Symposia.
157. **Rawalpindi, Pakistan**, December 2004, "Adjuvant Chemotherapy of Breast Cancer", Armed Forces Institute of Pathology.
158. **Peshawar, Pakistan**, December 2004, "Adjuvant Chemo of Breast Cancer", Golden Jubilee Celebration, Kayhee Medical College Pakistan, Plenary Session.

159. **Jaipur, India**, December 2002, NCCN “Lung Cancer Management Guidelines”, National Comprehensive Cancer Network for India.
160. **Multan, Pakistan**, December 2002, “Neo Adjuvant in Breast Cancer Chemotherapy”, Educational Symposium Golden Jubilee at Nishtar Medical College
161. **Lahore, Pakistan**, December, 2002, “Chemotherapy in Breast Cancer”, King Edward Medical College
162. **Buenos Aires, Argentina**, October 2001, “Present and Future Use of Herceptin in the Treatment of Breast Cancer,” XI Conference on Breast Cancer, Plenary Conference
163. **Buenos Aires, Argentina**, October, 2001, “Systemic Treatment of Breast Cancer in Situ,” XI Conference on Breast Cancer Symposium
164. **Lahore, Pakistan**, October, 2000, “Lung Cancer Management in the New Millennium,” Shaukat Khanum Research Hospital
165. **Tokyo, Japan**, September, 2000, “Carboplatin and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Carcinoma (NSCLC): a Multicenter Phase II Trial,” oral presentation of abstract, IASLC 9th World Conference on Lung Cancer
166. **Vancouver, Canada**, August, 2000, “Overview of Taxotere in Non-Small Cell Lung Cancer,” Taxotere Advisory Board Meeting
167. **Toronto, Canada**, July, 2000, “Overview of Taxotere in Breast Cancer,” Taxotere Advisory Board
168. **Rawalpindi, Pakistan**, December, 1999, “Neoadjuvant Treatment for Breast Cancer,” Armed Forces Postgraduate Medical Institute
169. **Lahore, Pakistan**, December, 1999, “Neoadjuvant Treatment for Breast Cancer,” Association of Family Physicians
170. **Lahore, Pakistan**, December, 1999, “Update in The Treatment of Non-Small Cell Lung Cancer,” King Edward Medical College Alumni Association of North America
171. **Lahore, Pakistan**, December, 1999, “Internet in Medicine,” King Edward Medical College Alumni Association of North America
172. **Lahore, Pakistan**, December, 1997, “Combined Modality Therapy in Non-Small Cell Lung Cancer,” King Edward Medical College Alumni Association of North America Annual Winter Symposium
173. **Rawalpindi, Pakistan**, December 1997, “Combined Modality Therapy in Non-Small Cell Lung Cancer,” Armed Forces Postgraduate Medical Institute
174. **Lahore, Pakistan**, December 1997, “Management of Locally Advanced Non-Small Cell Lung Cancer,” Shaukat Khanum Memorial Cancer Hospital and Research Center Annual Meeting of Pakistan Medical Research Society

175. **Singapore**, July 1997, “Advances in Treatment of Breast Cancer,” Singapore Society of Oncology
176. **Seoul, South Korea**, July 1997, “Role of Navelbine in Breast Cancer Treatment”
177. **Pusan, South Korea**, July 1997, “Role of Navelbine in Breast Cancer Treatment”
178. **Taegu, South Korea**, July 1997, “Role of Navelbine in Breast Cancer Treatment”
179. **Lahore, Pakistan**, February 1997, “Treatment Options for Women with Metastatic Breast Cancer,” Third annual symposium of Shaukat Khanum Memorial Cancer Hospital
180. **Rawalpindi, Pakistan**, December 1994, “Treatment of Early-Stage Breast Cancer,” CME conferences in Lahore, Pakistan and Armed Forces Institute of Medical Sciences
181. **Rawalpindi, Pakistan**, December 1992, “Role of Chemotherapy in Lung Cancer,” seminar on cancer therapy in Lahore, Pakistan and Armed Forces Institute of Medical Sciences

**CME Accredited Lectures as Invited Speaker within the US:**

1. **Hackensack, NJ**, February 2024, Immunotherapy for Early and Advanced Breast Cancer
2. **New Orleans, LA**, July 2022, Best of ASCO, “Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers”
3. **Hollywood, FL** May 2022, FLASCO 2<sup>ND</sup> Annual Lung Screening Summit, Moderator
4. **Orlando, FL**, May 2022 FLASCO Spring Session, “In patients with PDL-1 >50%”, Moderator
5. **San Antonio, TX**, December 2021, San Antonio Breast Cancer Conference Symposium
6. **Orlando, FL**, October 2021, FLASCO Fall Meeting
7. **Miami, FL**, October 2021, 2021 Updates in Cancer Therapy, An ASCO | ESMO Review, “New Developments in Therapeutics for Metastatic Breast Cancer”
8. **San Antonio, TX**, December 2020, San Antonio Breast Cancer Conference Symposium
9. **New Jersey**, February 2020, San Antonio Breast Cancer Review, “Immunotherapy in breast cancer-its role in neoadjuvant triple negative patients and metastatic triple negative patients”
10. **Phoenix, AZ**, October 2019, Highlights in Oncology- 2019 conference, “Highlights in Oncology”
11. **Fort Lauderdale, FL**, June 2019, Annual Oncology Update, “Updates on Breast Cancer- Regional”

12. **St. Louis, MO**, March 28<sup>th</sup>, 2019, “EMPOWER Breast Grand Rounds, “Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HR Positive, HER2- Negative Breast Cancer”
13. **Miami Beach, FL**, March 9, 2019, 36<sup>th</sup> Annual Miami Breast Cancer Conference, “Meeting Key Unmet Clinical Needs in HER2-Positive Breast Cancer: Aligning the Data With Strategy to Improve Patient Outcomes”
14. **Miami, FL**, March 31<sup>st</sup>, 2019, 16<sup>th</sup> Annual Miami Cancer Meeting, “TNBCa: What is Standard of Care and Potential Treatments in the Near Future?”
15. **Chicago, IL**, February 27<sup>th</sup>, EMPOWER Breast Grand Rounds, “Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HR Positive, HER2-Negative Breast Cancer”
16. **Hackensack, NJ**, February 22, 2019, 16<sup>th</sup> Annual Post SABCS Symposium, “Role of IMPASION-130 in Changing Therapy of Triple Negative Metastatic Breast Cancer”
17. **Miami, FL**, February 20<sup>th</sup>, EMPOWER Breast Grand Rounds, “Using Patient and Breast Cancer Disease Characteristics to Direct Combination Therapy in the Treatment of Metastatic HR Positive, HER2-Negative Breast Cancer”
18. **San Antonio, TX**, December 2018, San Antonio Breast Cancer Conference Symposium
19. **Philadelphia, PA**, September 2018, 3D Breast Cancer Grand Rounds, “The Multidisciplinary Team Approach: Optimizing Breast Cancer Therapy in the Targeted Treatment Era”
20. **Macon, GA**, August 2018, “Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer Action”
21. **Miami, FL**, July 2018, “Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer Action”
22. **Fort Lauderdale, FL**, June 2018, “Updates on Breast Cancer” ASCO Review
23. **White Plains, NY**, June 2018, “Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer Action”
24. **West Palm Beach**, April 2018, “A 3-D View of Novel Targeted Agents in Metastatic, Hormone-Receptor Positive, HER-2 Negative Breast Cancer”
25. **Miami FL**, October 2017, Core Curriculum Lecture, “Her-2 Overexpressing Breast Cancer”
26. **Miami, FL**, March 2017, 34<sup>th</sup> Annual Miami Breast Cancer Conference, “State-of-The-Art HER2 Therapy in Early-Stage Breast Cancer”

27. **Miami, FL**, March 2017, 34<sup>th</sup> Annual Miami Breast Cancer Conference, “SystHERs: Lessons From Real- World Patients With HER2+ Metastatic Breast Cancer”
28. **Miami, FL**, March 2017, 34<sup>th</sup> Annual Miami Breast Cancer Conference, “Evidence and Practical Strategies in Early-Stage Treatment Settings”
29. **Miami, FL**, July 2016, Grand Rounds lecture, “Evolution in the Hormonal Therapy of Metastatic Breast Cancer”
30. **Miami, FL**, May 2016, “Lung Cancer: Personalized Therapy”, APPNA Spring Meeting
31. **Pompano Beach, FL**, June 2016, North Broward Medical Center, “Advances in the Treatment of Metastatic Breast Cancer: Moving from Knowledge to Action”
32. **Las Vegas, NV**, March 2016, “Lung Cancer as a Model for Personalized Treatment”, Annual KEMCAANA Retreat
33. **New York**, November 2015, “Update on HER2 Adjuvant Therapy” *33rd Annual* Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow
34. **Miami, FL**, November 2015, ESMO, “Quality Improvement- Past, Present and Future”
35. **Tampa, FL**, November 2015, “New Developments in Lung Cancer”, FLASCO Fall Meeting
36. **Fort Lauderdale, FL**, September 2015, “Personalized Therapy of Non-Small Lung Cancer”, Holy Cross Hospital Lung Lecture
37. **Huntington Beach, CA**, July 2015, “Current and Emerging Strategies in the Management of Early HER2 + Breast Cancer”, “New Insights into HER2-Driven MBC Management”, 14<sup>th</sup> Annual International Congress on The Future of Breast Cancer
38. **Milwaukee, MI**, June 2015, 9<sup>th</sup> Annual KEMCAANA Retreat
39. **Orlando, FL**, January 31, 2015, “Management of HER2 Positive Breast Cancer”, Review and Interpretation of the 2014 San Antonio Breast Cancer Symposium
40. **Tampa, FL**, November 2014, FLASCO Fall Meeting
41. **Memphis, TN**, September 2014, The Inaugural Raza A. Dilawari Endowed Distinguished Visiting Professorship lecture.
42. **Tampa, FL**, November 2014, FLASCO Fall Meeting **Memphis, TN**, September 2014, The Inaugural Raza A. Dilawari Endowed Distinguished Visiting Professorship lecture.
43. **Oklahoma**, August 2014, OSCO/OU Stephenson Cancer Center ASCO Review

44. **Kansas City**, August 2014, The University of Kansas Medical Center, ASCO review
45. **New Orleans**, July 2014, 9<sup>th</sup> Annual New Orleans Summer Cancer Meeting
46. **Chicago, IL**, May 2014, American Society Clinical Oncology Conference
47. **Orlando, FL**, April 2014, FLASCO 2014 Spring Session and Annual Meeting
48. **Jacksonville, FL**, February 2014, Mayo Clinic Annual program “Targeted Therapy for Lung Cancer: A Case Based Presentation”
49. **Miami, FL**, January 2014, 10<sup>th</sup> Annual Miami Cancer Meeting, “Blockades and Barricades in the HER Family of Receptors”
50. **Miami, FL**, January 2013, 10<sup>th</sup> Annual Miami Cancer Meeting, “Blockades and Barricades in the HER Family of Receptors”
51. **San Antonio, TX**, December 2012, San Antonio Breast Cancer Conference Symposium
52. **Memphis, TN**, October 2012, “Consideration in Curative Systemic Therapy of Early Breast Cancer”, “Evolution of HER2 Directed Therapy in Breast Cancer”.
53. **Phoenix, AZ**, March 2012, “Options in the Treatment of Metastatic Breast Cancer”
54. **Jamaica, NY**, February 2012, “Updates in the Treatment of Metastatic Breast Cancer”
55. **San Francisco, CA**, January 2012 “Breast Cancer Academic Advisory Board”
56. **Dallas, TX**, December 2011 “Updates from San Antonio Breast Cancer Symposium”
57. **New York, NY**, August 2011 “17<sup>th</sup> Annual Perspectives in Breast Cancer”
58. **Chicago, IL**, May 2011 “American Society Clinical Oncology Conference”
59. **Hollywood, FL**, April 2011 “12<sup>th</sup> Annual Palm Beach Cancer Symposium”
60. **Hollywood, FL** March 2011, “NCCN Global Initiatives”, NCCN Annual Meeting, Industry Roundtable
61. **Dallas, TX**, April 2011 “NCCN Global Initiatives” at ASBD
62. **Tampa, FL**, November 2011, “FLASCO Fall Meeting”
63. **San Antonio, TX**, December 2010 “San Antonio Breast Cancer Conference”
64. **Chicago, IL**, October 2010 “Treatment of Breast Cancer in the Elderly Women”

65. **Key Biscayne, FL**, October 2010, "APPNA CME Fall Meeting"
66. **Grapevine, TX**, July 2010, "APPNA 33<sup>rd</sup> Annual Seminar Meeting"
67. **Dallas, TX**, July 2010, "Evolution of Therapy in Breast Cancer"
68. **Chicago, IL**, May 2010 "American Society of Clinical Oncology"
69. **Hollywood, FL**, March 2010, "Bone Complications in Cancer" at the annual NCCN conference for fellows
70. **Miami, FL**, November 2009, "NSCLC Roundtable at Miami Cancer Conference"
71. **Tupelo, MS**, October 2009, "Current Updates in the Management of Breast Cancer"
72. **San Francisco, CA**, October 2009, "Oncology Consultants Live: Practical Considerations in the Treatment of Breast Cancer"
73. **New York, NY** August 2009, 15th Annual Perspectives in Breast Cancer, "What therapy should be given pre-operatively for HER2 positive breast cancer?"
74. **New York, NY**, August 2009, 15th Annual Perspectives in Breast Cancer, "HER2 – positive metastatic disease and overcoming resistance to anti-HER2 therapy"
75. **Hilton Head, SC**, July 2009, "Role of VEGF and VEGFR Targeted Therapy on Breast Cancer"
76. **San Francisco, CA**, July 2009, NCCN Academy for Excellence and Leadership in Oncology, "Working Effectively with Key Decision Makers in the U.S. Cancer Care Delivery System"
77. **Philadelphia, PA**, March 2009, "Current Updates in the Treatment of Breast Cancer – 2009"
78. **Tampa, FL**, February 2009, "Optimizing treatment options for Non-Small Cell Lung Cancer in the Era of Targeted Therapies"
79. **Chicago, IL**, October 2008, 10th Annual Lynn Sage Breast Cancer Symposium "Improving Outcomes of Patients with Adjuvant Endocrine Therapy"
80. **Chicago, IL**, October 2008, "Breast Cancer Management: Updates, Advances and New Options"
81. **Miami, FL**, October 2008, "6th Annual Miami Cancer Meeting – Round Table Discussion Moderator"
82. **Brooklyn, NY**, September 2008, 14th Annual Perspectives in Breast Cancer "Current guidelines and new strategies for treating early HER2-Positive patients", "Screening for the high risk patient and "Overcoming resistance to Trastuzumab"
83. **Brooklyn, NY**, September 2008, "NCCN Innovative Diagnostics and Therapeutics in Cancer Care"

84. **Boston, MA**, August 2008, "Sanofi-Aventis Oncology Lecture Series Speaker Training Workshop"
85. **New York, NY**, March 2008, "Challenging Cases in Breast Cancer–Metastatic Breast Cancer ER(+)"
86. **Hollywood, FL**, Mar., 2008, "Sunday Brunch: Controversies in the Use of Imaging in the Management of Patients with Cancer"
87. **San Juan, PR**, Feb., 2008, "Novel Preoperative Therapy Strategies"
88. **Miami, FL**, Nov., 2007, "5th Annual Miami Gastrointestinal and Thoracic Oncology Meeting", Moderator and Panelist.
89. **Philadelphia, PA**, Sept., 2007, "Adjuvant Trastuzumab in the Older Adult", NCCN Breast Cancer in The Older Woman Task Force.
90. **Kohala Coast, HI**, July, 2007, "The Evolving Utility of Antimetabolites in Breast Cancer", Future of Breast Cancer Congress.
91. **Memphis, TN**, May, 2007, "Shifting Paradigms in Curative Management of Breast Cancer", 24th Annual Spring Update 2007, St. Francis Hospital.
92. **Hollywood, FL**, March, 2007, "Update: Non-Small Cell Lung Cancer", NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care.
93. **Hollywood, FL**, March, 2007, "Advances in the Treatment of Non-Small Cell Lung Cancer", NCCN 12<sup>th</sup> Annual Conference: Clinical Practice Guidelines & Quality Cancer Care
94. **Hollywood, FL**, March, 2007, "Management of Colon and Non-Small Cell Lung Cancer: Integrating Second-Line Therapies and Beyond", NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care.
95. **Philadelphia, PA**, February, 2007, "Integrating Novel Therapeutic Approaches into the Treatment of Breast Cancer", Educational Concepts Group.
96. **Denver, CO**, February, 2007, "Novel Pre-Operative Therapy Strategies", Current Trends in Breast Cancer Updates from 2006 SABCS.
97. **Boston, MA**, February, 2007, "Novel Pre-Operative Therapy Strategies", Current Trends in Breast Cancer, Updates from 2006 SABCS
98. **Washington, DC**, January, 2007, "Novel Preoperative Therapy Strategies", SABCS 2006 Review
99. **Hollywood, CA**, January, 2007, "Novel Preoperative Therapy Strategies", Update from SABCS 2006
100. **New York, NY**, November, 2006, "Biological Agents in Adjuvant Breast Cancer: State of the



Art Therapy and Current Challenges”, Annual Chemotherapy Foundation Meeting

101. **Las Vegas, NV**, October, 2006, “Great Debates in Breast Cancer: Are Taxanes Appropriate for ER+ Patients in the Adjuvant Setting?”
102. **Las Vegas, NV**, October, 2006, “Supportive Therapy for GI Complications of Chemotherapy”
103. **Kohala Coast, HI**, August, 2006, “Novel HER2 Targeted Antibody Combinations”, 5th Annual International Congress on the Future of Breast Cancer.
104. **Memphis, TN**, July, 2006, “Novel Strategies for Treatment of Lung Cancer”
105. **Chicago, IL**, July, 2006, “Advances in Antibody Therapy of Breast Cancer”, Annual APPNA Symposium
106. **Seattle, WA**, June, 2006, “Neoadjuvant Combined Modality Therapy for Potentially Resectable Stage III Non-Small Cell Lung Cancer”, NCCN Clinical Guidelines in Oncology Symposium
107. **Oakbrook, IL**, April, 2006, “Metastatic Breast Cancer: What is New?”
108. **Memphis, TN**, March, 2006, “Integrating Novel Therapeutic Approaches into the Treatment of Breast Cancer”
109. **Memphis, TN**, January, 2006, “Novel Strategies for the Treatment of Early-Stage Breast Cancer
110. **New York, Memorial Sloan Kettering Cancer Center**, NCCN Update in Non-Small Cell Lung Cancer, “Work-up, Prognosis and Markers in NSCLC”
111. **Lake Tahoe, NV**, October, 2005, “Great Debates in Breast Cancer: The Role of Targeted Adjuvant Therapy in breast Cancer”
112. **Durham, NC, Duke University**, October, 2005, NCCN Update in Non-Small Cell Lung Cancer, “Work-up, Prognosis and Markers in Non-Small Cell Lung Cancer”.
113. **Honolulu, HI**, August, 2005, “Does Dose Dense Make Sense?”
114. **San Jose, CA**, August, 2005, “Does Dose Dense Make Sense?”
115. **Sacramento, CA**, August, 2005, Tumor Board
116. **Redwood City, CA**, August, 2005, “Does Dose Dense Make Sense?”
117. **St. Louis, MO**, August, 2005, “The Evolving Role of HER2 – Targeted Therapies in Breast Cancer”
118. **Baltimore, MD**, April, 2005, The Sidney Kimmel Comprehensive Cancer Center at Johns

Hopkins, "Workup, Prognostic Factors, and Markers"

119. **Columbia, SC**, April, 2005, "Clinical Applications: Highlights from the 2004 San Antonio Breast Cancer Symposium"
120. **Hollywood, FL**, March, 2005, NCCN Annual Meeting, "Management of Deep Vein Thrombosis in Cancer Patients"
121. **Dallas, TX**, March, 2005, "Clinical Applications: Highlights from the 2004 San Antonio Breast Cancer Symposium"
122. **Honolulu, HI**, August, 2004, NCCN Clinical Practice Guidelines in Oncology Breast Cancer Regional Symposium, "Treatment for Advanced Breast Cancer: Chemotherapy, Immunotherapy, Hormonal Therapy, Bisphosphonates"
123. **San Diego, CA**, VA Medical Center, May, 2004, "New Advances in the Treatment of 1st Line NSCLC".
124. **Detroit, MI**, September, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
125. **Milwaukee, WI**, July, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
126. **Little Rock, AR**, May, 2003, "Metastatic Lung Cancer", University of Arkansas Medical School
127. **Las Vegas, NV**, February, 2003, Challenging Cases in Oncology Annual CME Meeting, NOCR
128. **New York, NY**, October, 2002, "Neoadjuvant Therapy in Breast Cancer," ION meeting

#### **Other Talks as Invited Speaker within the US:**

1. **Palm Beach Gardens, FL**, March 2024, (Long)Chemo Combo NSCLC Promotional Speaker Deck with Leadership Claims Update
2. **Trinity, FL**, March 2024, TRUQAP + fulvestrant: A Novel 2L Treatment Option for HR+/HER2- aBC or mBC With PIK3CA/AKT1/PTEN Alterations
3. **Abilene TX**, February 2024, Immunotherapy Early Stage Triple-Negative Cancer
4. **Rochester, MN**, January 2024, "A novel @L treatment option for HR+/HER2-aBC or mBC with PIK3CA/AKT/PTEN alterations"
5. **Minneapolis, MN**, January 2024, "A novel @L treatment option for HR+/HER2-aBC or mBC with PIK3CA/AKT/PTEN alterations"
6. **Austin, TX**, November 2023, ALUNBRIG (brigatinib) for the First-Line Treatment of ALK+ mNSCLC

7. **New York, NY**, November 2023, ALUNBRIG (brigatinib) for the first line Treatment of ALK+ mNSCLC
8. **San Juan, PR**, October 2023, An Overview of Clinical Data for ENHERTLU (fam-trastuzumab derixteca-nxki) in HER2-Expressing Metastatic Breast Cancer
9. **Philadelphia, PA**, September 2023, LUNG EXKIVITY (mobocertinib) The first and only oral therapy designed to target EGFR Exon20 insertion+ mNSCLC1,2
10. **Ashville, NC**, September 2023, ORSERDU (elacestrant) The first and only therapy indicated for ER+/HER2 - ESR1 - mutated mBC following progression on initial ET +/- a CDK4/6i
11. **Indianapolis, IN**, August 2023, LUNG EXKIVITY (mobocertinib) The first and only oral therapy designed to target EGFR Exon20 insertion mNSCLC1,2
12. **Delray Beach, FL**, July 2023, "LIBTAYO(R) (cemiplimab-rwlc)-NSCLC/ Chemo Combo NSCLC February 2023 Update".
13. **Boston, MA**, July 2023, IBC East Product Theatre: AstraZeneca, "A Treatment Option for Patients with Resectable NSCLC"
14. **New Orleans, June 2023**, Takeda Cardinal Health Summit, "ALUNBRIG® (brigatinib)for the First-Line Treatment of ALK+ mNSCLC".
15. **Virtual Event**, June 2023, LIBTAYO® (cemiplimab-rwlc) Speaker Bureau Training
16. **Wilson, North Carolina**, June 2023, Merck "Treatment Options for Patients With Certain Types of Triple-Negative Breast Cancer (TNBC) – LEC"
17. **Virtual Event**, May 2023, Takeda Oncology ALUNBRIG Virtual Speaker Training
18. **Stuart, FL**, May 2023, An Overview of Clinical Data for ENHERTU in HER2-Expressing Metastatic Breast Cancer
19. **Miami, FL**, April 2023, 19<sup>th</sup> Annual Miami Cancer Meeting
20. **Kissimmee, FL**, April 2023, FLASCO Foundation Gala
21. **Miami, FL**, April 2023, Gilead Live Speaker
22. **Virtual Event**, April 2023, Treatment Options for High-Risk Early-Stage TNBC and Certain Patient's With Advanced TNBC- LEC- KEYTRUDA
23. **Orlando, FL**, March 2023, NCCN 2023 State Oncology Society Forum
24. **Virtual Event**, March 2023, Mirati How Is The Treatment of Patient With KRAS G12C- Mutated Advanced NSCLC Evolving

25. **Delray Beach, FL**, March 2023, Bristol Myers Squibb- “A Treatment Option for Patients with Resectable Non- Small Cell Lung Cancer”
26. **Orlando, FL**, March 2023, AstraZeneca March 24 ION Advisory Board
27. **Houston, TX**, February 2023, Gilead Live Speaker
28. **Fort Meyers, FL**, February 2023, The Efficacy and Safety of ENHERTU in HER2-Expressing Metastatic Breast Cancer
29. **Virtual Event**, February 2023, Mirati Therapeutics Perspective On A New Treatment Option for Patients with KRAS G12C- Mutated Advanced NSCLC Progressing On First-Line Treatment
30. **Hollywood, FL**, February 2023, The Winter Lung
31. **Hollywood, FL**, January 2023, 2023 Early Lung Cancer Summit
32. **Virtual Event**, January 2023, Merck Case Study Discussion Patients With High-Risk Early-Stage Triple- Negative Breast Cancer (TNBC) - PDG
33. **San Antonio, Texas**, December 2022, Daiichi Sankyo
34. **Virtual Event**, December 2022, Takeda EXKIVITY
35. **San Juan, PR**, November 2022, Gilead Live Speaker Program Sanofi Speaker Resource Center IQVIA
36. **Virtual Event**, November 2022, Daiichi Sankyo Lung MSL
37. **Virtual Event**, November 2022, Dual Immunotherapy + Platinum Based Chemotherapy for the Treatment of NSCLC
38. **Madrid Spain**, November 2022, 4<sup>th</sup> Oncology Quality Care Symposium
39. **New Orleans, Charlotte, NC Charleston SC**, November 2022, Syneos Health
40. **Williston Park, NJ**, November 2022, Merck A Treatment Option for Patients with TNBC
41. **Orlando FL**, October 2022, FLASCO Board Meeting
42. **Coral Gables, FL**, October 2022, Daiichi Sankyo Speaking Engagement
43. **Sebring FL**, October 2022, Gilead Adding to the Tool Kit in Treating Metastatic Triple-Neg Breast Cancer
44. **Virtual Event**, October 2022, Merck Med on Perspectives on High-Risk Early Stage TNBC
45. **Webinar Event**, October 2022, Consider TRODELVY in 2L and Later m TNBC Speaker Program

46. **Brooklyn, NY**, October 2022, Takeda EXKIVITY Speaker Program
47. **Syracuse, NY**, October 2022, EXKIVITY (Mobocertinib) The first and only oral therapy designed to target EGFR EXON 20 insertion + m NSCLC
48. **Chicago, IL, October 2022**, Merck A Treatment Option for patients with High-Risk Early-Stage Triple Neg Breast Cancer (TNBC)-LEC
49. **Boca Raton, FL**, October 2022, Lynparza Offsite Evening Speaker Program
50. **Paterson, NJ**, September 2022, Merck High Risk Early-Stage Triple Neg Breast Cancer (TNBC)
51. **Memphis, TN**, September 2022, AstraZeneca HER2-Expressing Metastatic Breast Cancer
52. **Atlanta GA**, September 2022, Cardinal Health Summit
53. **Virtual Event**, September 2022, ENHERTU NSCLC Speaker
54. **Virtual Event**, September 2022, AstraZeneca Lynparza Targeted Adjuvant Therapy for patients with gBRCAm, HER2-Negative High-Risk Early Stage TNBC
55. **Virtual Event**, August 2022, Treating patients with EGFR Exon 20 Metastatic NSCLC
56. **Virtual Event**, September 2021, AstraZeneca and Daiichi Sankyo T-DXd HER2+ mBC Post ESMO Advisory Board
57. **Lawrence, KS**, July 2022, Merck, “Case Study Discussion Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)”
58. **Boca Raton, FL**, July 2022, Astrazeneca, “ENHERTU® (fam-trastuzumab deruxtecan-nxki): Establishing a New Standard of Care in 2L HER2+ mBC – ONC”
59. **The Villages, FL**, June 2022, Gilead program, Speaker Programs, “Consider TRODELVY in 2L and Later mTNBC”
60. **Charleston, SC**, June 2022, Gilead program, “Consider TRODELVY in 2L and Later mTNBC”
61. **New Orleans, LA**, June 2022, 17th Annual New Orleans Summer Cancer Meeting, “Endocrine Therapy for Early-Stage Breast Cancer: Who Needs more?”
62. **Miami, FL**, June 2022, LIBTAYO® (cemiplimab-rwlc) Webinar Speaker Training for the NSCLC Roundtable Speaker Program
63. **Youngstown, OH**, May 2022, AstraZeneca program, LYNPARZA® (olaparib): “A Targeted Adjuvant Therapy for Patients With gBRCAm, HER2-Negative, High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy”

64. **Mandeville, LA**, May 2022, Merck, “Case Study Discussion Patients With High-Risk Early-Stage Triple- Negative Breast Cancer (TNBC) – PDG”
65. **Miami, FL**, April 2022, MECC Miami Cancer Meeting, Takeda Exon20ins Branded Speaker Program
66. **Miami Beach, FL** March 2022, Astrazeneca 39<sup>th</sup> Annual Miami Breast Cancer Symposium Conference, Product Theatre, “Considerations for Second Line in HER2+ Metastatic Breast Cancer”
67. **Miami, FL**, February 2022, Regeneron, “Updated NSCLC Speaker Deck”
68. **Miami Beach, FL**, February 2022, 19th Annual Winter Lung Cancer Conference, Speaker Product Theatre: “Treatment Options for Patients With Lung Cancer”
69. **Miami Beach, FL**, February 2022, 19th Annual Winter Lung Cancer Conference, Dual Product Theatre: “Challenging Cases in Resectable NSCLC and ES-SCLC”.
70. **Virtual, May 2022**, Roundtable Daiichi Sankyo | ENHERTU Speaker Training
71. **San Antonio, TX**, December 2021, Daiichi Sankyo/AstraZeneca Product Theatre, “Considerations for Second Line in HER2+ Metastatic Breast Cancer”
72. **San Antonio, TX**, December 2021, Merck, “A Treatment Option for Patients With High-Risk Early-Stage Triple- Negative Breast Cancer (TNBC) -LEC”
73. **Miami Beach, FL**, November 2021, Daiichi Sankyo program, “ENHERTU: Extending HER2+ Expectations- MD”
74. **Greenville, SC**, November 2021, Gilead Sciences, “Abbreviated A Way in with TRODELVY”
75. **Virtual Event in Flint, MI**, November 2021, Gilead Sciences, “Abbreviated A Way in with TRODELVY”
76. **Coral Gables, FL**, September 2021, Daiichi Sankyo “ENHERTU: Extending HER2+ Expectations – MD”
77. **Pembroke Pines, FL**, Enhertu, “ENHERTU® (fam-trastuzumab deruxtecan-nxki): A HER2+ mBC Patient With Progression on 2L Therapy”
78. **Dallas, TX**, July 2021, Daiichi Sankyo, “ENHERTU: Extending HER2+ Expectations – MD”
79. **Kennesaw, GA**, May 2021, Daiichi Sankyo, “ENHERTU: Extending HER2+ Expectations – MD”
80. **Key Largo, FL**, May 2021, Daiichi Sankyo, “ENHERTU: Extending HER2+ Expectations – MD”
81. **Fort Lauderdale, FL**, May 2021, AstraZeneca Speaker Program, “Treatment Options for Patients with Lung Cancer”
82. **Rome, GA**, April 2021, Daiichi Sankyo program, “ENHERTU: Extending HER2+ Expectations – MD”

83. **San Antonio, TX**, December 2020, Virtual Meeting, San Antonio Breast Cancer Conference Symposium
84. **Boca Raton, FL**, December 2020, “Transforming the Treatment of NSCLC: Options for First-Line Treatment of Metastatic EGFR Mutation-Positive Disease and Immunotherapy for Stage III Unresectable Disease”
85. **Virtual Promotional Speaker**, November 2020, Immunomedics- Master Webcast, “Trodelvy: Triple Negative Breast Cancer”
86. **Virtual Promotional Speaker**, October 2020, Immunomedics- Master Webcast, “Trodelvy: Triple Negative Breast Cancer”
87. **Vero Beach, FL**, October 2020, Immunomedics “Trodelvy: Triple Negative Breast Cancer”
88. **Tamarac, FL** April 2020, Virtual Meeting, “Review of Treatment of ES-SCLC and Unresectable Stage III NSCLC”
89. **Coral Gables, FL**, February 2020, Daiichi Sankyo/Astrazeneca, “An ADC for the Treatment of HER2+ Metastatic Breast Cancer”
90. **Fort Lauderdale, FL**, February 2020, Astrazeneca, “Updates on the Treatment of Patients With Unresectable or Metastatic HER2+ Breast Cancer Who Previously Received Anti-HER2 Therapies”
91. **New Orleans, LA**, February 2020, Master Lecture Series: Evolving Treatments in Immunotherapy & Target Therapy, “Immunotherapy in Breast”
92. **Miami, FL**, January 2020, DS-8201 ENHERTU Speaker Training- East Coast Meeting
93. **San Francisco, CA**, October 2019, Xcenda “Challenging Cases in Oncology”
94. **Miami, FL**, January 26, 2019, 16<sup>th</sup> Annual Winter Lung Cancer Conference, “Pushing the Envelope: Expanding Real-World Eligibility for Immunotherapy”
95. **Washington D.C.**, October 2018, Breast Tumor Board, “The Multidisciplinary Team Approach, Optimizing Breast Cancer Therapy in the Targeted Treatment Era”
96. **Baltimore, MD**, October 2018, Breast Tumor Board, “The Multidisciplinary Team Approach, Optimizing Breast Cancer Therapy in the Targeted Treatment Era”
97. **Philadelphia, PA**, September 2018, “The Multidisciplinary Team Approach, Optimizing Breast Cancer Therapy in the Targeted Treatment Era”
98. **White Plains, NY**, June 2018, “Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer Action”
99. **Las Vegas, NV**, April 2018, EPIC: Breast Cancer in 2018 AND Beyond meeting

100. **Boston, MA**, November 2017, ALK+NSCLC, "Intro to Disease"
101. **Miami, FL**, November 2016, State of the Summit: Advanced Non-Small Cell Lung Cancer, "NSCLC: Treatment of Non-Driver Mutation Adenocarcinoma"
102. **West Palm Beach, FL**, Oncology Best Practice, "Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast Cancer"
103. **Dallas, TX**, October 2016, ARIAD Brigatinib Focus Group Oncology, "Brigatinib Phase 1/2, ALTA Data Review"
104. **Boston, MA**, September 2016, ARIAD Brigatinib, Discover The Difference "Alunbrig Clinical Update"
105. **Atlanta, GA**, September 2016, Aptitude Academy Meeting, "What's It Like to be a KOL and How is That Changing"
106. **Detroit MI**, May 2016, Comprehensive Genomic Profiling in the Age of Targeted Therapy
107. **Phoenix, AZ**, February 2016, ASCO Quality of Care Symposium
108. **Phoenix, AZ**, February 2016, IO-ICON Annual Meeting
109. **Miami, FL**, February 2016, The 13th Annual Winter Lung Cancer Conference
110. **Atlanta, GA**, October 2015, Xalkori POA2 2015 HCP Session
111. **Jacksonville, FL**, October 2015, "Adjuvant Therapy of HER2+ Breast Cancer"
112. **Las Vegas, NV**, April 2015, EPIC Metastatic Breast Cancer
113. **Orlando, FL**, February 2015, "SCOPE, Summit For Clinical Ops Executives"
114. **Miami, FL**, January 2015, 12<sup>th</sup> Annual Miami Cancer Meeting
115. **San Antonio, TX**, December 2014, San Antonio Breast Cancer Conference Symposium
116. **Oklahoma City, OK**, August 2014, OSCO/OU Stephenson Cancer Center ASCO Review
117. **New Orleans, LA**, July 2014 New Orleans Summer Cancer Meeting, "Treatment of Triple Negative Breast Cancer"
118. **Miami, FL**, October 2011, "Expert Forum on HER2+ Breast Cancer"
119. **Hollywood, FL** March 2011, "NCCN Global Initiatives", NCCN Annual Meeting, Industry Roundtable



120. **Port St. Lucie, FL** April 2011, "Systemic Treatment of HER2+ Breast Cancer"
121. **New York, NY** September 2010, "When is enough, enough? Panel discussion regarding multiple Chemotherapies, cost/benefit ratio"
122. **San Diego, CA**, May 2010, "Challenging Cases in Breast Cancer"
123. **Hollywood, FL** March 2010, "A Case-Based Discussion on the Treatment Options for HER2 Positive Metastatic Breast Cancer"
124. **McLean, VA** November 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
125. **Baltimore, MD** November 2009, "Molecular Basis of Cancer – Breast"
126. **Baltimore, MD** November 2009, "Avastin/Herceptin Breast – slides with 1 case study"
127. **Fort Worth, TX**, November 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
128. **Arlington, TX**, November 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
129. **Grapevine, TX**, November 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
130. **Chicago, IL**, October 2009, "Use of Avastin in Breast Cancer"
131. **Chicago, IL**, October 2009, "Avastin Breast/Herceptin Breast Journal Club and Case Studies"
132. **Chicago, IL**, October 2009, "Avastin/Herceptin Breast – slides with 1 case study"
133. **Memphis, TN**, October 2009, "Clinical Correlation: CA and Signal Transduction Inhibitors Molecular Basis of Disease" to first year medical students at UT Cancer
134. **Ventura, CA**, October 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
135. **Santa Barbara, CA**, October 2009, "Optimizing treatment options for Non-Small Cell Lung Cancer in the era of targeted therapies".
136. **Costa Mesa, CA**, September 2009, "Molecular Basis of Cancer – Breast"
137. **Los Angeles, CA**, September 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
138. **New York, NY**, August 2009, "Avastin / Herceptin Breast"

139. **Boca Raton, FL**, August 2009, "Avastin / Herceptin Breast"
140. **Atlanta, GA**, July 2009, "Avastin Breast / Herceptin Breast"
141. **Chicago, IL**, June 2009, P4 Healthcare Summit
142. **Roseville, CA**, June 2009, "Optimizing the Treatment for Non-Small Cell Lung Cancer"
143. **Sacramento, CA**, June 2009, "Optimizing the Treatment for Non-Small Cell Lung Cancer"
144. **Pleasant Hill, CA**, June 2009, "Optimizing the Treatment for Non-Small Cell Lung Cancer"
145. **Sioux Falls, SD**, May 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
146. **Grand Forks, ND**, May 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
147. **Fargo, ND**, May 2009, "The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer"
148. **Memphis, TN**, April 2009, "Avastin/Herceptin Breast"
149. **New Port Richey, FL**, February 2009, "Optimizing treatment options for Non-Small Cell Lung Cancer in the ERA of Targeted Therapies"
150. **Bradenton, FL**, February 2009, "Optimizing treatment options for Non-Small Cell Lung Cancer in the ERA of Targeted Therapies"
151. **Atlanta, GA**, February 2009, "ERBITUX (Cetuximab) in Non-Small Cell Lung Cancer"
152. **San Diego, CA**, December 2008 "the role of Taxotere (Docetaxel) Injection Concentrate in Breast Cancer"
153. **New York, NY**, November 2008 "Advanced Non-Small Cell Lung Cancer (NSCLC): Overview of Avastin and Tarceva"
154. **Tarrytown, NY**, November 2008 "Advanced Non-Small Cell Lung Cancer (NSCLC): Overview of Avastin and Tarceva"
155. **Norwalk, CT**, November 2008 "The role of Tarceva Tablets in the treatment of Advanced Solid Tumors"
156. **Tampa, FL**, October 2008, "Taxotere – Early-Stage Breast Cancer"
157. **Las Vegas, NV**, July, 2008, "Challenging Cases in Breast Cancer"

158. **San Francisco, CA**, July 2008, "Genomic Health Meeting – Speaker Training"
159. **Thorton, Colorado**, June 2008, "The Role of Taxotere (docetaxel): Injection Concentrate in Early Stage Breast Cancer"
160. **Colorado Springs, Colorado**, June 2008, "The Role of Taxotere (docetaxel): Injection Concentrate in Early-Stage Breast Cancer."
161. **Palm Beach Gardens, FL**, Apr. 2008, "Targeting HER-2 Positive Breast Cancer: Expanded Options for Herceptin (Trastuzumab) Therapy"
162. **San Diego, CA**, Jan. 2008, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
163. **Encinitas, CA**, Jan. 2008, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
164. **Port Charlotte, FL**, Dec. 2007, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
165. **West Cape Coral, FL**, Dec. 2007, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
166. **St. Petersburg, FL**, Dec. 2007, "Optimizing Treatment Options for NSCLC in the Era of Targeted Therapies: The Role of Taxotere (docetaxel) Injection Concentrate."
167. **Fort Myers, FL**, Dec. 2007, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
168. **Appleton, WI**, Oct., 2007, "An Update in the Treatment of HER2-positive Metastatic Breast Cancer"
169. **Green Bay, WI**, Oct., 2007, "An Update in the Treatment of HER2-positive Metastatic Breast Cancer"
170. **Long Beach, CA**, Oct., 2007, "Advances in the Treatment of Early Stage Breast Cancer"
171. **Orlando, FL**, Sept., 2007, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
172. **Cocoa, FL**, Sept., 2007, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
173. **Stuart, FL**, Sept., 2007, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"

174. **Boca Raton, FL**, Sept., 2007, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
175. **Jackson, TN**, Sept., 2007, "Advances in the Treatment of Early Stage Breast Cancer"
176. **La Jolla, CA**, August, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
177. **San Diego, CA**, August, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
178. **Chattanooga, TN**, July, 2007, An Update in the Treatment of Her2-Positive Metastatic Breast.
179. **Chicago, IL**, July, 2007, "The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer"
180. **New York, NY**, July, 2007, "Bevacizumab in Metastatic Breast Cancer: Clinical Data Discussion"
181. **New York, NY**, July, 2007, "Role of Bevacizumab in Metastatic Breast Cancer: Discussion"
182. **New York, NY**, July, 2007, "Practice Patterns in Metastatic Breast Cancer"
183. **New York, NY**, July, 2007, "Anti-VEGF activity in Breast Cancer Discussion"
184. **Boca Raton, FL**, July, 2007, "Herceptin (Trastuzumab) for the Adjuvant Treatment of HER2 Positive Node- Positive Breast Cancer"
185. **Lansdowne, VA**, June, 2007, "Locally advanced breast cancer: BINV-13, BINV-14 Inflammatory breast cancer guideline – separate guideline?"
186. **New Port Richey, FL**, May, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
187. **Bay Pines, FL**, May, 2007, "Combination Therapy with Taxotere (docetaxel) Injection Concentrate for Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer Patients"
188. **Ocala, FL**, May, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
189. **White Plains, CT**, March 2007, "The Role of Tarceva (erlotinib) Tablets in the Treatment of Solid Tumors: An Advance in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer"  
195.
190. **Greenwich, CT**, March, 2007, "The Role of Tarceva (erlotinib) Tablets in the Treatment of Solid Tumors: An Advance in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer"
191. **Hollywood, FL**, March, 2007, "Advances in the Treatment of Non-Small Cell Lung Cancer"
192. **Roseville, CA**, February, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
193. **Modesto, CA**, February, 2007, "Advances in the Treatment of Early Stage Breast Cancer"

194. **Sacramento, CA**, February, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
195. **Folsom, CA**, February, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
196. **Oakland, CA**, February, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
197. **Fremont, CA**, February, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
198. **Canton, OH**, February, 2007, "Avastin and Tarceva in Non-Small Cell Lung Cancer"
199. **Akron, OH**, February, 2007, Aultman Cancer Center, "Update on Chemotherapy and Targeted Therapies: San Antonio Breast Cancer Symposium Update"
200. **Chicago, IL**, January, 2007, "New Innovation in Cancer: Current and Imminent Application"
201. **Coral Springs, FL**, January, 2007, "Taxotere (docetaxel) for Injection Concentrate in Metastatic Breast Cancer"
202. **Orange, CA**, January, 2007, "Avastin and Tarceva in the Treatment of Lung Cancer"
203. **Riverside, CA**, January, 2007, "Chemotherapy with Taxotere (docetaxel) Injection Concentrate for Chemotherapy –Naive Advanced NSCLC Patients"
204. **Duarte, CA**, January, 2007, "Avastin and Tarceva in the Treatment of Non-Small Cell Lung Cancer"
205. **Mission Hills, CA**, January, 2007, "Avastin and Tarceva in the Treatment of Non-Small Cell Lung Cancer"
206. **Bradenton, FL**, January, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
207. **Dunedin, FL**, January, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
208. **Kissimmee, FL**, January, 2007, "Tarceva Tablets: An Advance in the Second-Line Treatment of Non-Small Cell Lung Cancer"
209. **Kissimmee, FL**, January, 2007, "Targeting VEGF in Non-Small Cell Lung Cancer: An Overview of Avastin"
210. **Brooksville, FL**, January, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
211. **Inverness, FL**, January, 2007, "Advances in the Treatment of Early Stage Breast Cancer"
212. **New York, NY**, December, 2006, "Phase II/III Trials of Bevacizumab in MBC: Discussion"
213. **Chicago, IL**, October, 2006, "New Innovations in Cancer Care: Current and Imminent"

Applications”, NCCN Case Management Study

214. **Miami, FL**, October, 2006, “Challenging Cases in Breast Cancer: Metastatic Breast Cancer Hepatic Mets After Adjuvant Therapy”
215. **Folsom, CA**, September, 2006 “Combination Therapy for Chemotherapy – Naive Advanced NSCLC Patients”
216. **Roseville, CA**, September, 2006 “Combination Therapy for Chemotherapy – Naive Advanced NSCLC Patients”
217. **Sacramento, CA**, September, 2006 “Combination Therapy for Chemotherapy – Naive Advanced NSCLC Patients”
218. **Stockton, CA**, September, 2006 “Combination Therapy for Chemotherapy – Naive Advanced NSCLC Patients”
219. **Lake Worth, FL**, September, 2006, “HER2 Targeted Therapy in the Treatment of Metastatic Breast Cancer
220. **Miami, FL**, September, 2006, Taxotere (docetaxel) for Injection Concentrate in Metastatic Breast Cancer”
221. **Lake Worth, FL**, August, 2006, “HER2 Targeted Therapy in the Treatment of Metastatic Breast Cancer”
222. **Orlando, FL**, August, 2006, “HER2 Targeted Therapy in the Treatment of Metastatic Breast Cancer.
223. **Los Angeles, CA**, August, 2006, “Combination Therapy with Taxotere (docetaxel) Injection Concentrate for Chemotherapy – Naive Advanced NSCLC Patients”
224. **San Diego, CA**, May, 2006, “Challenging Cases in Geriatric Oncology: Adjuvant Breast Cancer & Supportive Care Therapy”
225. **San Diego, CA**, May, 2006, “Challenging Cases in Geriatric Oncology: Metastatic Breast Cancer following Adjuvant Therapy”
226. **Wilmington, DE**, May, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
227. **Chevy Chase, MD**, May, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
228. **Baltimore, MD**, May, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
229. **Pikesville, MD**, May, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
230. **Sacramento, CA**, February, 2006, “Advances in the Treatment of Early Stage Breast Cancer”

231. **Fairfield, CA**, February, 2006, "Advances in the Treatment of Early Stage Breast Cancer"
232. **Roseville, Ca**, February, 2006, "Advances in the Treatment of Early Stage Breast Cancer"
233. **Sacramento, CA**, February, 2006, "Advance in the Treatment of Early Stage Breast Cancer"
234. **Memphis, TN**, January, 2006, "Novel Strategies for the Treatment of Early-Stage Breast Cancer (including adjuvant hormonal therapy trials, ongoing endocrine prevention trials, HER2-directed antibodies in adjuvant therapy, taxane combinations, and genomic tools for prediction of recurrence risks)"
235. **La Jolla, CA**, January, 2006, "Advances in the Treatment of Early Stage Breast Cancer"
236. **Dallas, TX**, November, 2005, "Taxotere in Breast Cancer Management"
237. **Miami, FL**, November, 2005, "Abraxane Development Program"
238. **Miami, FL**, November, 2005, "Abraxane Clinical Experience"
239. **Miami, FL**, November, 2005, "Review of Comparative Experience with Taxanes in Treatment of Metastatic Breast Cancer"
240. **Oklahoma City, OK**, October, 2005, "Advances for the 1st Line Treatment of Patients with HER2+ Metastatic Breast Cancer: The Role of Herceptin (Trastuzumab)"
241. **Miami, FL**, October, 2005, "Breast Cancer: Adjuvant Endocrine Therapy", Challenging Cases in Oncology
242. **Miami, FL**, October, 2005, "Breast Cancer: Adjuvant Chemotherapy", Challenging Cases in Oncology.
243. **Las Vegas, NV**, September, 2005, "Case Study of Neoadjuvant Hormonal Therapy – ER(+)"
244. **Las Vegas, NV**, September, 2005, "Case Study of Neoadjuvant Chemotherapy – HER2(+)"
245. **St. Louis, MO**, August, 2005, "The Role of Tarceva (erlotinib) in the Treatment of Locally Advanced or Metastatic NSCLC After Chemotherapy Failure"
246. **Kansas City, MO**, August, 2005, "The Role of Tarceva (erlotinib) in the Treatment of Locally Advanced or Metastatic NSCLC After Chemotherapy Failure"
247. **Kansas City, MO**, August, 2005 "The Role of Tarceva (erlotinib) in the Treatment of Locally Advanced or Metastatic NSCLC After Chemotherapy Failure"
248. **St. Louis, MO**, August, 2005 "The Evolving Role of HER2 – Targeted Therapies in Breast Cancer"

249. **Miami, FL**, June, 2005, "Role of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer"
250. **Memphis, TN**, June, 2005, St. Jude Children's Research Hospital, "Cancer and Cancer Care"
251. **Scottsdale, AZ**, June, 2005, "Metastatic Breast Cancer – Novel Taxanes, A Case Study."
252. **Scottsdale, AZ**, June, 2005, "Neoadjuvant Hormonal Therapy – ER(+), A Case Study."
253. **Huntington Beach, CA**, April, 2005, "Early Stage Breast Cancer Clinical Overview"
254. **Philadelphia, PA**, April, 2005, "The Role of Taxanes in the Metastatic Setting for Breast Cancer"
255. **Philadelphia, PA**, April, 2005, "Use of Taxanes in the Neoadjuvant and Adjuvant Settings"
256. **Baltimore, MD**, April, 2005, "The Evolving Role of HER2-Targeted Therapies in Breast Cancer"
257. **Stuart, FL**, March, 2005, "New Advances in the Treatment of NSCLC"
258. **Lake Worth, FL**, March, 2005, "New Advances in the Treatment of NSCLC"
259. **Dallas, TX**, March, 2005, "Recent Developments in Chemotherapy of NSCLC"
260. **Dallas, TX**, March, 2005, "New Advances in the Treatment of 1st Line NSCLC"
261. **Christiansburg, VA**, February, 2005, "New Advances in the Treatment of 1st Line NSCLC"
262. **Danville, VA**, February, 2005, "New Advances in the Treatment of 1st Line NSCLC"
263. **Bluefield, VA**, February, 2005, "New Advances in the Treatment of 1st Line NSCLC"
264. **Boca Raton, FL**, January, 2005, "Recent Developments in Chemotherapy of NSCLC"
265. **Boca Raton, FL**, January, 2005, "New Advances in the Treatment of 1st Line NSCLC"
266. **Ft. Lauderdale, FL**, November, 2004, "Breast Cancer: Choice of Therapy: A Case Study"
267. **Ft. Lauderdale, FL**, November, 2004, "Role of Taxanes and Their Progeny in Advanced Breast Cancer: A Case Study"
268. **Coral Springs, FL**, November, 2004, "New Advances in the Treatment of 1st Line NSCLC"
269. **New Orleans, LA**, October, 2004, "Adjuvant Therapy in Breast Cancer: A Case Study"
270. **New Orleans, LA**, October, 2004, "The Role of Taxanes in Metastatic Breast Cancer: A Case Study"



271. **Center Valley, PA**, October, 2004, "New Advances in the Treatment of 1st Line NSCLC"
272. **Darby, PA**, October, 2004, "New Advances in the treatment of 1st Line NSCLC"
273. **Philadelphia, PA**, October, 2004, "New Advances in the Treatment of 1st Line NSCLC"
274. **Cherry Hill, NJ**, October, 2004, "Advances in the Treatment of Metastatic Breast Cancer"
275. **Huntingdon Valley, PA**, October, 2004, "New Advances in the Treatment of 1st Line NSCLC"
276. **Irving, TX**, September, 2004, "A Review of Taxotere (docetaxel) in the Treatment of Early Stage Breast Cancer: Adjuvant Clinical Overview"
277. **Wauwatosa, WI**, September, 2004, "Early Stage Breast Cancer"
278. **Mequon, WI**, September, 2004, "Lung and Breast Cancer"
279. **Wauwatosa, WI**, September, 2004, "New Advances in the Treatment of Lung Cancer"
280. **Sheboygan, WI**, September, 2004, "Lung and Breast Cancer"
281. **Park City, UT**, August, 2004, NCCN Breast Cancer Panel, "Neoadjuvant Endocrine Therapy in Breast Cancer".
282. **Seattle, WA**, August, 2004, "Advances in the Treatment of Metastatic Breast Cancer"
283. **Renton, WA**, August, 2004, "Advances in the Treatment of Metastatic Breast Cancer"
284. **Edmonds, WA**, August, 2004, "Advances in the Treatment of Metastatic Breast Cancer"
285. **Maui, HI**, August, 2004, "New Advances in the Treatment of 1st Line NSCLC".
286. **Honolulu, HI**, August, 2004, "New Advances in the Treatment of 1st Line NSCLC"
287. **Dallas, TX**, Texas Oncology, June, 2004, "Advances in the Treatment of Metastatic Breast Cancer".
288. **Dallas, TX**, Center for Oncology Research and Treatment, June, 2004, "Advances in the Treatment of Metastatic Breast Cancer".
289. **Dallas, TX**, June, 2004, "Advances in the Treatment of Metastatic Breast Cancer".
290. **Austin, TX**, June, 2004, "Advances in the Treatment of Metastatic Breast Cancer".
291. **Irving, TX**, June, 2004, "Advances in the Treatment of Metastatic Breast Cancer".
292. **Placentia, CA**, May, 2004, "New Advances in the Treatment of 1st Line NSCLC".

293. **Orange, CA**, May, 2004, "New Advances in the Treatment of 1st Line NSCLC".
294. **Newport Beach, CA**, May, 2004, "New Advances in the Treatment of 1st Line NSCLC".
295. **Riverside, CA**, May, 2004, "New Advances in the Treatment of 1st Line NSCLC".
296. **San Diego, CA**, VA Medical Center, May, 2004, "New Advances in the Treatment of 1st Line NSCLC".
297. **Soquel, CA**, May, 2004, "Advances in the Treatment of Metastatic Breast Cancer".
298. **Oakland, CA**, May, 2004, "Advances in the Treatment of Metastatic Breast Cancer".
299. **Monterey, CA**, May, 2004, "Advances in the Treatment of Metastatic Breast Cancer".
300. **Scottsdale, AZ**, April, 2004, "What is the Current Standard for Adjuvant Therapy in Breast Cancer"?
301. **Phoenix, AZ**, April, 2004, "New Advances in the Treatment of 1st Line NSCLC"
302. **Paradise Valley, AZ**, April, 2004, "New Advances in the Treatment of 1st Line NSCLC"
303. **Hollywood, FL**, March, 2004, "Cancer Research: Implications for Oncology Pharmacy"
304. **Boca Raton, FL**, March, 2004, "New Advances in the Treatment of 1st Line NSCLC"
305. **Tampa, FL**, March, 2004, "New Advances in the Treatment of 1st Line NSCLC"
306. **Lakeland, FL**, March, 2004, "Advances in the Treatment of Metastatic Breast Cancer"
307. **Holmes Beach, FL**, March, 2004, "Advances in the Treatment of Metastatic Breast Cancer"
308. **Milwaukee, WI**, March, 2004, "Adjuvant and Neo-adjuvant Therapy of Early Breast Cancer"
309. **Staten Island, NY**, January, 2004, "Advances in the Treatment of Metastatic Breast Cancer"
310. **Staten Island, NY**, January, 2004, "Advances in Chemotherapy of Breast Cancer"
311. **Union, NJ**, January, 2004, "Advances in the Treatment of Metastatic Breast Cancer"
312. **St. James, NY**, October, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
313. **Brooklyn, NY**, October, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
314. **Annapolis, MD**, October, 2003, "Advances in the Treatment of Metastatic Breast Cancer"

315. **Berlin, MD**, October, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
316. **Lewes, DE**, October, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
317. **Denton, TX**, October, 2003, "New Advances in the Treatment of 1st Line NSCLC"
318. **Arlington, TX**, October, 2003, "New Advances in the Treatment of 1st Line NSCLC"
319. **Las Colinas, TX**, October, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
320. **Baltimore, MD**, September, 2003, "New Data and Ongoing Trials with Docetaxel in NSCLC"
321. **Rolla, MO**, September, 2003, "New Advances in the Treatment of 1st Line NSCLC"
322. **St. Louis, MO**, September, 2003, "New Advances in the Treatment of 1st Line NSCLC"
323. **Cape Girardeau, MO**, September, 2003, "New Advances in the Treatment of 1st Line NSCLC"
324. **New York, NY**, September, 2003, "Taxane Use in the Adjuvant Setting: Current Status and Future Directions."
325. **Great Falls, MT**, September, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
326. **Missoula, MT**, September, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
327. **Kalispell, MT**, September, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
328. **Billings, MT**, September, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
329. **Maui, HI**, August, 2003, "New Advances in the Treatment of 1st Line NSCLC"
330. **Honolulu, HI**, August, 2003, "Recent Developments in the Treatment of Early Stage Breast Cancer."
331. **Honolulu, HI**, August, 2003, "Early Stage Non-Small Cell Lung Cancer"
332. **Stockton, CA**, August, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
333. **Walnut Creek, CA**, August, 2003, Tumor Board, "New Advances in the Treatment of 1st Line NSCLC"
334. **Walnut Creek, CA**, August, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
335. **Orlando, FL**, July, 2003, "Adjuvant Treatment of Breast Cancer"
336. **Hales Corners, WI**, July, 2003, "What is the Current Standard for Adjuvant Therapy in Breast Cancer"

337. **Milwaukee, WI**, July, 2003, Medical College of Wisconsin, "Advances in the Treatment of Metastatic Breast Cancer"
338. **Monterey, CA**, July, 2003, "Advances in the Treatment of Adjuvant Breast Cancer"
339. **Santa Clara, CA**, July, 2003, "Advances in the Treatment of Adjuvant Breast Cancer"
340. **Oakland, CA**, July, 2003, "Advances in the Treatment of Adjuvant Breast Cancer"
341. **San Jose, CA**, July, 2003, "Advances in the Treatment of Adjuvant Breast Cancer"
342. **Philadelphia, PA**, June, 2003, "Advances in the Treatment of Front Line Lung Cancer"
343. **Philadelphia, PA**, June, 2003, "Advances in the Treatment of Non-Small Cell Lung Cancer"
344. **Cherry Hill, NJ**, June, 2003, "New Advances in the Treatment of Stage IIIb and Stage IV Non-Small Cell Lung Cancer"
345. **West Chester, PA**, June, 2003, "Post ASCO Update"
346. **Philadelphia, PA**, June, 2003, "Current Trends in Breast Cancer"
347. **Scranton, PA**, June, 2003, "Advances in the Treatment of Non-Small Cell Lung Cancer"
348. **Sacramento, CA**, June, 2003, "New Advances in the Treatment of 1<sup>st</sup> Line NSCLC"
349. **Roseville, CA**, June, 2003, "New Advances in the Treatment of 1<sup>st</sup> Line NSCLC"
350. **Long Beach, CA**, May, 2003, "New Advances in the Treatment of 1<sup>st</sup> Line NSCLC"
351. **Torrance, CA**, May 2003, "New Advances in the Treatment of 1<sup>st</sup> Line NSCLC"
352. **Seal Beach, CA**, May 2003, "New Advances in the Treatment of 1<sup>st</sup> Line NSCLC"
353. **Pasadena, CA**, May 2003, "New Advances in the Treatment of 1<sup>st</sup> Line NSCLC"
354. **Little Rock, AR**, May, 2003, "Metastatic Lung Cancer"
355. **Duxbury, MA**, April, 2003, "New Advances in the Treatment of 1<sup>st</sup> Line Non-Small Cell Lung Cancer"
356. **Pomona, CA**, March, 2003, "Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
357. **Colton, CA**, March, 2003, "Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"

358. **Mashpee, MA**, April, 2003, "New Advances in the Treatment of 1<sup>st</sup> Line Non-Small Cell Lung Cancer"
359. **Hemet, CA**, March, 2003, "Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
360. **Riverside, CA**, March, 2003, "Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
361. **New Orleans, LA**, February, 2003, San Antonio Breast Cancer Highlights Meeting
362. **Las Vegas, NV**, February, 2003, San Antonio Breast Cancer Highlights Meeting
363. **Lake Success, NY**, February, 2003, "Advances in the Treatment of Metastatic Breast Cancer"
364. **New York, NY**, February, 2003, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
365. **Merrick, NY**, February, 2003, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
366. **Brooklyn, NY**, Downstate Medical Center, February, 2003, "New Advances in the treatment of 1<sup>st</sup> Line Non- Small Cell Lung Cancer"
367. **Little Rock, AR**, February, 2003, "New Advances in the Treatment of 1<sup>st</sup> Line Non-Small Cell Lung Cancer"
368. **LaMesa, CA**, January, 2003, "Activated EFGR-TK is a Pivotal Signaling Pathway in Most Common Solid Tumors"
369. **Palm Desert, CA**, January, 2003, "Activated EFGR-TK is a Pivotal Signaling Pathway in Most Common Solid Tumors"
370. **San Antonio, TX**, December, 2002, "Chemotherapy and Targeted Therapies for Advanced Breast Cancer"
371. **Jackson, TN**, November, 2002, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
372. **New York, NY**, September, 2002, "Adjuvant Therapy – The Use of Taxotere in Early Stage Breast Cancer"
373. **Maui, HI**, August, 2002, "New Advances in the Treatment of 2<sup>nd</sup> Line NSCLC," Aventis Advisory Board Meeting
374. **New York, NY**, June, 2002, "Adjuvant Therapy – The Use of Taxotere in Early Stage Breast Cancer"
375. **Naples, FL**, June, 2002, "Adjuvant Therapy – The Use of Taxotere in Early Stage Breast

Cancer”

376. **Farmington, CT**, June, 2002, “Advances in the Treatment of Metastatic Breast Cancer”
377. **New York**, June, 2002, “The Evolving Role of Chemotherapy in the Treatment of Metastatic Breast Cancer: A Focus on Taxotere
378. **Modesto, CA**, June, 2002, “Advances in the Treatment of Metastatic Breast Cancer”
379. **New York**, April, 2002, “Advances in Neo-Adjuvant Therapy of Breast Cancer”
380. **Worcester, MA**, April, 2002, “Update in Chemotherapy in Breast Cancer”
381. **LeMesa, CA**, April, 2002, “New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer”
382. **Maui, HI**, March, 2002, “Taxotere and Xeloda in Breast Cancer,” Taxotere Speaker Training Workshop
383. **Maui, HI**, March, 2002, “Weekly Taxanes in Breast Cancer,” Taxotere Speaker Training Workshop
384. **Memphis, TN**, February, 2002, “Non-Small Cell Lung Cancer,” Lung Cancer Tumor Board
385. **Memphis, TN**, February, 2002, “Current Treatment of NSCLC”, Lung Cancer Tumor Board
386. **Memphis, TN**, February, 2002, “Non-Small Cell Lung Cancer,” St Francis Hospital
387. **New York, NY**, February, 2002, “2<sup>nd</sup> Line Therapy in Non-Small Cell Lung Cancer,” New York Lung Cancer Alliance
388. **Pomona, CA**, February, 2002 “Updates from the San Antonio Breast Cancer Symposium,” Pomona Valley Hospital
389. **Riverside, CA**, February, 2002, “Advances in the Treatment of Metastatic Breast Cancer”
390. **Los Angeles, CA**, February, 2002, “Updates from the San Antonio Breast Cancer Symposium”
391. **Los Angeles, CA**, February, 2002, “Advances in the Treatment of Metastatic Breast Cancer,” Cedars- Sinai Medical Center
392. **Ontario, CA**, February 2002, “Advances in the Adjuvant Therapy of Breast Cancer”
393. **Philadelphia, PA**, February, 2002, “Current Chemotherapy of Non-Small Cell Lung Cancer”
394. **Drexel Hill, PA**, February, 2002 “Advances in the Treatment of Non-Small Cell Lung Cancer”

395. **Allentown, PA**, February, 2002, "Update from San Antonio Breast Cancer Conference", Lehigh Valley Hospital
396. **New York, NY**, February, 2002, "Meeting Updates: SABCS2001," an NOCR review
397. **Los Angeles, CA**, January, 2002, "Meeting Updates: SABCS2001," an NOCR review
398. **Clearwater, FL**, January, 2002, "Advances in Adjuvant Therapy of Breast Cancer"
399. **Tampa, FL**, January 2002, "Updates from San Antonio Breast Cancer"
400. **San Antonio, TX**, December 2001, "A Phase II Trial of Navelbine Plus Herceptin in HER2 Positive Breast Cancer"
401. **Seattle, WA**, November 2001, "Update in Chemotherapy of Lung Cancer"
402. **Naples, FL**, December, 2001, "Current Data in the Treatment of Lung Cancer," Lung Cancer Regional Advisory Board
403. **St. Louis, MO**, November, 2001, "Current Treatment Modalities in Breast Cancer"
404. **Seattle, WA**, November, 2001, "Update in the Treatment of Metastatic Breast Cancer"
405. **Seattle, WA**, November, 2001, "Advances in the Treatment of Metastatic Breast Cancer"
406. **Carmel, CA**, October 2001, "Taxotere in the Treatment of Early Breast Cancer"
407. **Carmel, CA**, October, 2001, "Taxotere in Adjuvant Breast Cancer"
408. **Orlando, FL**, September, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
409. **Naples, FL**, September, 2001, "Taxotere in Adjuvant Breast Cancer," Taxotere Advisory Board Meeting
410. **Salt Lake City, UT**, August, 2001, "Advances in the Treatment of Lung Cancer"
411. **Salt Lake City, UT**, August, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
412. **Park City, UT**, August, 2001, "New Advances in the Treatment of Non-Small Cell Lung Cancer"
413. **Provo, UT**, August, 2001, "New Advances in the Treatment of Non-Small Cell Lung Cancer"
414. **Sacramento, CA**, August, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"

415. **Sacramento, CA**, August, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
416. **Walnut Creek, CA**, August, 2001, "New Advances in the Treatment of Metastatic Breast Cancer"
417. **Los Angeles, CA**, July, 2001, "New Advances in the Treatment of Lung Cancer," St. Vincent Medical Center
418. **Los Angeles, CA**, July, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
419. **Los Angeles, CA**, July, 2001, "New Advances in the Treatment of Non-Small Cell Lung Cancer"
420. **Los Angeles, CA**, July, 2001, "New Advances in Non-Small Cell Lung Cancer"
421. **Vail, CO**, June, 2001, "Taxotere in NSCLC," Regional Advisory Board
422. **Keystone, CO**, June, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
423. **Denver, CO**, June, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
424. **New Orleans, LA**, June, 2001, "Taxotere in Hormone Refractory Prostate Cancer," Advisory Board Meeting
425. **Philadelphia, PA**, June, 2001, Oncology Speakers Bureau
426. **St. Michael's, MD**, June, 2001, "Metastatic Breast Cancer: A Focus on Taxotere," Advisory Board Meeting
427. **St. Michael's, MD**, June, 2001, "Taxotere in Adjuvant Breast Cancer," Advisory Board Meeting
428. **Bryn Mawr, PA**, June, 2001, "Update in the Treatment of Non-Small Cell Lung Cancer"
429. **Denver, CO**, June, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
430. **New York, NY**, April, 2001, "Lung Cancer Overview," "Disease Progression and Clinical Decision Making", "Taxotere 2nd Line," Oncology Initial Sales Training Class
431. **Orlando, FL**, March, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
432. **New York, NY**, April, 2001 "Taxotere Combinations in Breast Cancer"
433. **Laguna Beach, CA**, March, 2001, "Taxotere Options in Breast Cancer"



434. **Modesto, CA**, March, 2001, "Taxotere Options for 2<sup>nd</sup> Line Non-Small Cell Lung Cancer Patients"
435. **Palo Alto, CA**, March, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
436. **Soquel, CA**, March, 2001, "Taxotere New Option for 2<sup>nd</sup> Line Non-Small Cell Lung Cancer Patients"
437. **Fontana, CA**, February, 2001, "Advances in the Treatment of Metastatic Breast Cancer," Kaiser Permanente Medical Center
438. **Los Angeles, CA**, February, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
439. **New York, NY**, February, 2001, "Lung Cancer Overview," "Disease Progression and Clinical Decision Making," "Taxotere 2<sup>nd</sup> Line," Oncology Initial Sales Training Class
440. **Los Angeles, CA**, February, 2001, "Advances in the Treatment of Metastatic Breast Cancer," Kaiser Permanente Medical Center
441. **Laguna Hills, CA**, February, 2001, "Recent Advances in the Treatment of Both Metastatic Breast Cancer and Non-Small Cell Lung Cancer," Saddleback Memorial Medical Center
442. **Pasadena, CA**, February, 2001, "Advances in the Treatment of Metastatic Breast Cancer"
443. **Burbank, CA**, February, 2001, "Advances in the Treatment of Non-Small Cell Lung Cancer," Providence St. Joseph Medical Center
444. **Lakeland, FL**, February, 2001, "New Advances in Non-Small Cell Lung Cancer," Lakeland Regional Medical Center
445. **Keystone, CO**, February, 2001, "Taxotere in NSCLC," Taxotere Advisory Board
446. **New Rochelle, NY**, January, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Sound Shore Cancer Center
447. **White Plains, NY**, January, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Dickstein Cancer Center
448. **Bronxville, NY**, January, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Montefiore Medical Center
449. **Garden City, NY**, January 18, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung 467.Cancer"

450. **New York, NY**, January, 17, 2001, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
451. **Las Vegas, NV**, December, 2000, "Taxane Therapy in the Treatment of Solid Tumors," American Society of Health System Pharmacists
452. **Atlanta, GA**, December, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Oncology Speakers Bureau
453. **Little Rock, AK**, December, 2000, "Overview of Taxotere in Metastatic Breast Cancer"
454. **Birmingham, AL**, November, 2000, "Taxotere in Metastatic Breast Cancer"
455. **Pomona, CA**, November, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Pomona Medical Center
456. **Ontario, CA**, November, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
457. **Victorville, CA**, November, 2000, "Advances in the Treatment of Non-Small Cell Lung Cancer," Victor Valley Community Hospital
458. **Colton, CA**, October, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Arrowhead Regional Medical Center
459. **Maui, HI**, October, 2000, "Taxotere in the Treatment of Breast Cancer"
460. **Maui, HI**, October, 2000, "Taxotere in the Treatment of Non-Small Cell Lung Cancer"
461. **Honolulu, HI**, October, 2000, "New Advances in Non-Small Cell Lung Cancer," St. Francis Medical Center
462. **Honolulu, HI**, October, 2000, "New Advances in Non-Small Cell Lung Cancer," Straub Hospital
463. **Boca Raton, FL**, October, 2000, "Non-Hodgkins Lymphoma Management," Informational Talk at Wellness Community
464. **Stuart, FL**, September, 2000, "Non-Small Cell Lung Cancer," Martin Memorial Hospital
465. **Memphis, TN**, August, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer" Boston Cancer Group
466. **Memphis, TN**, August, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
467. **Palm Beach, FL**, August, 2000, "New Therapies in the Treatment of Metastatic Breast Cancer" Palm Beach Area Oncology Nursing Society

468. **Asheville, NC**, September, 2000, "Overview of Taxotere in Breast Cancer"
469. **Washington, DC**, August, 2000, "Overview of Taxotere in Non-Small Cell Lung Cancer"
470. **Parsippany, NJ**, July, 2000, "Lung Cancer Overview"
471. **Parsippany, NJ**, July, 2000, "Disease Progression and Clinical Decision Making"
472. **Boca Raton, FL**, July, 2000, "Treatment of Lung Cancer," Wellness Community
473. **Atlanta, GA**, August, 2000, "Advances in the Treatment of Metastatic Breast Cancer"
474. **Braselton, GA**, July, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
475. **Absecon, NJ**, June, 2000, "Overview of Taxotere in Breast Cancer"
476. **Boca Raton, FL**, May, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
477. **Chicago, IL**, May, 2000, "Taxotere in the Treatment of Non-Small Cell Lung Cancer," Speaker Training Workshop
478. **Kohler, WI**, May, 2000, "An Overview of Taxotere in Breast Cancer," Regional Advisory Board Meeting
479. **Memphis, TN**, May, 2000 "Multimodality Treatment of Stage III NSCLC" and "Second Line Treatment of Advanced NSCLC"
480. **Washington, DC**, April, 2000, "Update in the Treatment of Lung Cancer, Regional Advisory Board Meeting
481. **Washington, DC**, April, 2000, "Update in the Treatment of Breast Cancer," Regional Advisory Board Meeting
482. **Chicago, IL**, March, 2000, "Taxotere in the Treatment of Non-Small Cell Lung Cancer," Regional Advisory Board Meeting
483. **Washington DC**, March, 2000, "A New Option for the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Washington University
484. **Washington DC**, March, 2000, "A New Option for the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Washington Cancer Institute
485. **Stuart, FL**, March, 2000, "Overview of Taxotere in the Treatment of NSCLC," Speaker Training Workshop

486. **Miami, FL**, February, 2000, "Update on Current Trends in the Management of Stage 3 & 4 Non-Small Cell Lung Cancer," Sylvester Cancer Center Grand Rounds
487. **Miami, FL**, "Monoclonal Antibodies in Breast Carcinoma," Florida Breast Cancer Coalition
488. **New York, NY**, February, 2000, "Overview of Taxotere in Breast Cancer," Advisory Board Meeting
489. **Knoxville, TN**, February, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer"
490. **Knoxville, TN**, February, 2000, "New Advances in the Treatment of 2<sup>nd</sup> Line Non-Small Cell Lung Cancer," Thompson Cancer Center
491. **Hilton Head, SC**, November, 1999, "Overview of Taxotere in Breast Cancer," Taxotere Advisory Board Meeting
492. **Boca Raton, FL**, November, 1999, "An Overview of Treatment Options in Non-Small Cell Lung Cancer," Wellness Community
493. **Salt Lake City, UT**, November, 1999, "Advances in the Treatment of Metastatic Breast Cancer"
494. **Sundance, UT**, November, 1999, "Overview of Taxotere in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)"
495. **Joliet, IL**, October, 1999, "Update in the Treatment of Non-Small Cell Lung Cancer"
496. **Westmont, IL**, October, 1999, "Update in the Treatment of Non-Small Cell Lung Cancer"
497. **Winchester, MA**, October, 1999, "Advances in the Treatment of Metastatic Breast Cancer"
498. **New Haven, CT**, October, 1999, "Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer," Taxotere Advisory Board Meeting
499. **Fort Lauderdale, FL**, September, 1999, "Update in the Treatment of Non-Small Cell Lung Cancer"
500. **Scottsdale, AZ**, September, 1999, "Single Agent Taxotere in 1<sup>st</sup> and 2<sup>nd</sup> Line Therapy for Non-Small Cell Lung Cancer"
501. **Boca Raton, FL**, September, 1999, "An Overview of Treatment Options in Non-Small Cell Lung Cancer," Wellness Community
502. **Atlanta, GA**, September, 1999, "Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer," Taxotere Advisory Board Meeting

503. **Pittsburgh, PA**, August, 1999, "Advances in the Treatment of Metastatic Breast Cancer"
504. **Phoenix, AZ**, August, 1999, "Advances in the Treatment of Metastatic Breast Cancer"
505. **Asheville, NC**, July, 1999, "Advances in the Treatment of Non-Small Cell Lung Cancer,"  
Regional Advisory Board Meeting
506. **Asheville, NC**, July, 1999, "New Therapies in the Treatment of Non-Small Cell Lung Cancer"
507. **Louisville, KY**, July, 1999, "Current Treatment of Non-Small Cell Lung Cancer," University of  
Louisville Tumor Board
508. **Savannah, GA**, July, 1999, "New Therapies in the Treatment of Non-Small Cell Lung Cancer"
509. **Lewisburg, PA**, July, 1999, "Update in the Treatment of Metastatic Breast Cancer," Divine  
Providence Hospital
510. **Allentown, PA**, July, 1999, "Update in the Treatment of Metastatic Breast Cancer"
511. **Boynton Beach, FL**, July, 1999, "Update in Lung Cancer Treatment," Bethesda Memorial  
Hospital Cancer Conference
512. **Lenox, MA**, June, 1999, "Overview of Taxotere in Breast Cancer," Taxotere Advisory Board  
Meeting
513. **Chicago, IL**, June, 1999, "Overview of Taxotere in NSCLC," Taxotere Advisory Board Meeting
514. **Hartford, CT**, June, 1999 "Overview of Taxotere in NSCLC"
515. **Augusta, GA**, May, 1999, "Recent Advances in the Treatment of NSCLC"
516. **Huntsville, AL**, April, 1999, "Management of NSCLC in Elderly Patients"
517. **Jacksonville, FL**, April, 1999, "Combined Modality Treatment in Non-Small Cell Lung Cancer,"  
Baptist Regional Cancer Institute
518. **Des Moines, IA**, April, 1999, "Recent Advances in The Treatment of Lung Cancer," McFarland  
Clinic Grand Rounds
519. **Waterloo, IA**, April, 1999, "Recent Advances in the Treatment of Lung Cancer"
520. **Sundance, UT**, February, 1999, "Overview of Taxotere in Locally Advanced or Metastatic  
Non-Small Cell Lung Cancer," Taxotere Advisory Board Meeting
521. **Columbus, OH**, February, 1999, "Update in Chemotherapy for Non-Small Cell Lung Cancer,"  
Central Society of Clinical Oncologists

522. **Ponte Vedre Beach, FL**, February, 1999, "Single Agent Taxotere in 1<sup>st</sup> and 2<sup>nd</sup> Line NSCLC," Taxotere Speakers Training Workshop
523. **Myrtle Beach, SC** February, 1999, "Use of Herceptin in the Treatment of Breast Cancer," Coastal Cancer Center
524. **Wilmington, NC**, February, 1999, "Use of Herceptin in the Treatment of Breast Cancer"
525. **Stuart, FL**, February, 1999, "Update in Lung Cancer"
526. **Columbia, SC**, January, 1999, "Use of Herceptin in the Treatment of Breast Cancer"
527. **Aiken, GA**, January, 1999, "Use of Herceptin in the Treatment of Breast Cancer," Aiken HCA
528. **Augusta, GA**, January, 1999, "Use of Monoclonal Antibodies in the Treatment of Breast Cancer," Augusta Hematology/Oncology Journal Club
529. **Minneapolis, MN**, December, 1998, "Chemotherapy in Non-Small Cell Lung Cancer," Antimetabolites in Lung Cancer Advisory Board
530. **Detroit, Michigan**, December, 1998, "Doxil in Breast Cancer," Michigan Society of Hematology/Oncology
531. **Asheville, NC**, November, 1998, "Lung Cancer Overview," Navelbine Advisory Panel
532. **Port Richey, FL**, November, 1998, "Update on Non-Small Cell Lung Cancer"
533. **Fort Lauderdale, FL**, November, 1998, "Advances in the Treatment of Lung Cancer"
534. **Miami, FL**, November, 1998, "Combinations of Chemotherapy in Lung Cancer," University of Miami Sylvester Comprehensive Cancer Center Symposium "Focus on Tumors: Lung and Thoracic"
535. **Tampa, FL**, October, 1998, "Advances in the Treatment of Breast Cancer"
536. **Chicago, IL**, October, 1998, "Advances in the Treatment of Breast Cancer," Sequus Speakers Education Program
537. **Cromwell, CT**, October, 1998, "Advances in the Treatment of Breast Cancer"
538. **Norwich CT**, October, 1998, "Advances in the Treatment of Breast Cancer"
539. **Pensacola, FL**, October, 1998, "Current Treatment of Non-Small Cell Lung Carcinoma"
540. **Washington, DC**, September, 1998, "Lung Cancer: New Treatments, Future Directions," "ALCASE Workshop"

541. **Charleston, SC**, September 1998, "Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer," Taxotere Advisory Board
542. **Madison, Wisconsin**, September, 1998, "Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer," Taxotere Advisory Board
543. **Greenville, SC**, September 1998, "Update in the Treatment of Lung Cancer," Greenville Memorial Hospital
544. **Baltimore, MD**, August, 1998, "Breast Cancer Training," Genentech Bio-Oncology Southern Crescent Regional Meeting
545. **Fort Lauderdale, FL**, July, 1998, "Multimodality Therapy in Non-Small Cell Lung Carcinoma," Cleveland Clinic, Florida
546. **Portland, OR**, June, 1998, "Fatigue in Lung Cancer Patients," ALCASE Distinguished Faculty Program
547. **St. Louis, MO**, June, 1998, Lung Cancer "Locally Advanced Disease – Potential for Curability," Cancer Management for Practitioners, Washington University School of Medicine
548. **Orlando, FL**, June, 1998, "Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer," Taxotere Advisory Board Meeting
549. **Coeur D'Alene, Idaho**, June, 1998, "Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer"
550. **Boston, MA**, June, 1998, "Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer," Taxotere Advisory Board Meeting
551. **San Francisco, CA**, June, 1998, "Lymphoma Diagnosis and Treatment Review," Genentech Oncology Training Session
552. **Boca Raton, FL**, June, 1998, "Advances in the Treatment of Anthracycline Resistant Metastatic Breast Cancer," RPR Oncology Speakers Bureau
553. **Los Angeles, CA**, May, 1998, "A Phase I Trial of Gemcitabine and Vinorelbine Employing Planned Half Doses on Day 8 in Patients With Refractory Solid Tumors," Poster Presentation, Glaxo Wellcome Investigator's Meeting
554. **Fogelsville, PA**, April, 1998, "Chemotherapy in Breast Cancer," Lehigh Valley Oncology Society Meeting
555. **Baltimore, MD**, February, 1998, "Update: A Review of New Clinical Data on Taxotere in Locally Advanced or Metastatic Breast Cancer," Taxotere Local Advisory Board Meetings
556. **Short Hills, NJ**, February, 1998, "Update: A Review of New Clinical Data on Taxotere in Locally

Advanced or Metastatic Breast Cancer," Taxotere Local Advisory Board Meeting

557. **Fort Lauderdale, FL**, December, 1997, "Recent Advances in the Treatment of Breast Cancer"
558. **Boca Raton, FL** November, 1997, "Lung Cancer: How to Answer the Unanswered Questions," CME Symposium
559. **Boca Raton, FL**, November, 1997, "Present and Future Role of Chemotherapy in Non-Small Cell Lung Carcinoma," CME Symposium
560. **Stuart, FL**, November, 1997, "Advances in the Treatment of Non-Small Cell Lung Cancer," Oncology Grand Rounds, Martin Memorial Hospital
561. **Little Rock, AK**, August, 1997, "Advances in Treatment of Breast Cancer," Breast Cancer Initiative Program
562. **La Jolla, CA**, June, 1997, "Taxotere in Breast Cancer: Have We Discovered The Most Active Drug?" Breast Cancer Initiative Dinner at UCSD Perlman Cancer Center
563. **Boston, MA**, June, 1997, "Taxotere in Breast Cancer," Area Advisory Board Meeting
564. **Richmond, VA**, July, 1997, "Taxotere in Breast Cancer," Area Advisory Board Meeting
565. **Boston, MA**, January, 1997, "Taxotere in Anthracycline Resistant Metastatic Breast Cancer"
566. **Boca Raton, FL**, February, 1997, "Non-Small Lung Cancer: How to Answer the Unanswered Questions"
567. **Hartford, CT**, January, 1997, "Taxotere in Anthracycline Resistant Metastatic Breast Cancer"
568. **San Antonio, TX**, December, 1996, "Navelbine in the Elderly Breast Cancer Patients," Glaxo Welcome seminar on "Navelbine: Emerging Data in Solid Tumors
569. **Birmingham, AL**, August, 1995, "Chemotherapy in Non-Small Cell Lung Carcinoma: Update 1995," Medical Grand Rounds, Carraway Medical Center,
570. **Tampa, Florida** and **Sarasota, Florida**, July, 1995, "Chemotherapy in Non-Small Cell Lung Carcinoma" in 199 at invitation dinner lectures on two consecutive evenings
571. **Champagne, IL**, June, 1995, "Navelbine for Non-Small Cell Lung Cancer," Carle Clinic
572. **Bethesda, MD**, 1995, "Newer Treatments in Non-Small Cell Lung Cancer," Naval Hospital Bethesda
573. **Paducah, KY**, February, 1995, "Navelbine in Non-Small Cell Lung Cancer" monthly meeting Kentucky Cancer Program



574. **Cedar Rapids, IA**, October, 1994, "Navelbine in Non-Small Cell Lung Cancer," at Fall Meeting of Iowa Oncology Society
575. **St. Louis, MO**, August, 1994, "Role of chemotherapy in non-small cell lung cancer," at weekly conference of Mallinckrodt Institute of Radiology, Division of Radiation Oncology
576. **St. Louis, MO**, August, 1994, "Role of chemotherapy in non-small cell lung cancer," Grand Rounds at the VA Hospital
577. **St. Louis, MO**, August, 1994, "Combined modality therapy in non-small cell lung cancer," Grand Rounds at the VA Hospital
578. **St. Louis, MO**, May, 1992, "Multimodality approach in lung cancer," Continuing Medical Education Conference at Washington University (an update in thoracic surgery)

**Cooperative Group/Experts Round Table/Speakers Bureau Meetings by Invitation:**

1. **Santa Monica, CA**, February 2024, Novocure NSCLC Commercial Strategic Council Meeting
2. **Dallas, TX**, October 2023, Novocure Advisory Board
3. **Virtual Event**, July 2023, Cardinal Health Summit: Post ASCO II
4. **Boston, MA**, July 2023, Novocure Lung Cancer Ad Board
5. **Philadelphia, PA**, June 2023, Roundtable Speaker Program, "Personalizing Treatment for Adult Patients with NSCLC with no EGFR or ALK Mutations".
6. **Virtual Event**, June 2023, AstraZeneca Post-ASCO Advisory Board: Therapeutic options in 2L HR+/HER2-Metastatic Breast Cancer
7. **Fort Lauderdale, FL**, May 2023, Advisory Board Meeting for the PROphet® NSCLC Test
8. **Virtual Meeting**, May 2023, PatientPoint Advisory Board Meeting
9. **Virtual Event**, July 2021, Pfizer Medical Oncologist Ad Board
10. **Virtual Event**, July 2021, NRG Oncology Summer 2021 Virtual Meeting
11. **Orlando, FL**, July 2021, APPNA 44<sup>th</sup> Annual Convention
12. **Delray Beach, FL**, June 2021, Daiichi Sankyo "Roundtable: A Therapeutic Approach for the Treatment of HER2+ mBC with ENHERTU"
13. **Virtual Event**, December 2020, Merck: "A Treatment Option for Patients with Certain Types of Advanced TNBC Webcast – eMF"
14. **Virtual Meeting**, April 2020, Seattle Genetics Virtual Regional Tucatinib Advisory Board
15. **New York, NY**, January 2020, NSCLC Biomarker Testing Think Tank Meeting

16. **San Antonio, TX**, December 2019, SABCS, Advanced HER2-Expressing Breast Cancer Workshop
17. **San Antonio, TX**, December 2019, SABCS Foundation Medicine- Cell Free DNA Testing Advisory Board
18. **San Antonio, TX**, December 2019, Ibrance: SABCS Advisory Board
19. **Orlando, FL**, November 2019, FLASCO Fall Session
20. **Chicago, IL**, October 2019, Post ESMO Advisory Board
21. **Philadelphia, PA**, October 2019, US Dosing/Formulary Expert Input Forum
22. **Salt Lake City, UT**, October 2019, ION Large Practice Program (LPP) Excel Meeting
23. **Salt Lake City, UT**, October 2019, Daiichi /Astra Zeneca Advisory board
24. **Barcelona, Spain**, September 2019, ESMO 2019, EPIC (*Emerging Paradigms in Care*) Metastatic Breast Cancer in 2019 and Beyond.
25. **Barcelona, Spain**, September 2019, International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer
26. **Dallas, TX**, August 2019, Brigatinib National Medical Advisory Board Meeting
27. **Miami, FL**, July 2019, Kisqali Regional Advisory Board Southeast Meeting
28. **Philadelphia, PA**, June 2019, US Breast Cancer Advisory Board
29. **Chicago, IL**, June 2019, ASCO Annual Meeting
30. **Las Vegas, NV**, April 5<sup>th</sup>, 2019, EPIC: Breast Cancer in 2019 and Beyond
31. **Miami, FL**, March 31<sup>st</sup>, 2019, 16<sup>th</sup> Annual Miami Cancer Meeting
32. **Orlando, FL**, March 21<sup>st</sup>, 2019, 2019 NCCN State Oncology Society Forum and Annual Conference
33. **Denver, CO**, March 14<sup>th</sup>, 2019, IO-ICON Steering Committee meeting
34. **Dallas, TX**, March 1, 2019, Takeda Oncology Brigatinib Advisory Board
35. **Miami, FL**, January 26, 2019, 16<sup>th</sup> Annual Winter Lung Cancer Conference
36. **Houston, TX**, January 25, 2019 Breast Cancer Advisory Board
37. **Hackensack, NJ**, January 22, 2019, HUMC Post SABCS 16<sup>th</sup> Annual Symposium
38. **Fort Lauderdale, FL**, December 2018, ANCERS-2 Investigators and Coordinators Meeting
39. **New York, NY**, November 2018, EPIC (*Emerging Paradigms in Care*): Lung Cancer in 2018 and Beyond
40. **Orlando, FL**, November 2018, FLASCO Fall Session
41. **Munich, Germany**, October 2018, ESMO 2018, EPIC (*Emerging Paradigms in Care*) Global Perspectives on Breast Cancer in 2018 and Beyond

42. **Phoenix, AZ**, September 2018, ASCO-ECO Collaborative Meeting: ASCO Quality of Care Symposium
43. **Toronto, Canada**, September 2018, International Association for the Study of Lung Cancer (IASLC) 19<sup>th</sup> World Conference on Lung Cancer
44. **Chicago, IL**, June 2018, ASCO Annual Meeting
45. **Tampa, FL**, May 2018, FLASCO 2018 Spring Session and Annual Meeting
46. **Herndon VA**, May 2018, OCM- Critical Elements in the Design of Future Alternative Payment Models Advisory Board
47. **Philadelphia, PA**, April 2018, Immunomedics TNBC Advisory Board
48. **Miami, FL**, March 2018, US Breast Cancer Advisory Board
49. **Dallas, TX**, February 2018, Takeda Oncology National Advisory Board
50. **Dallas, TX**, November 2017, Brigatinib National Advisory Board
51. **Dallas, TX**, November 2017, Amgen's Impact of New Payment Methods – Oncology Care Model and other APMs Advisory Board
52. **Chicago, IL**, October 2017, abbvie, Value-Based Care Delivery Advisory Board
53. **Yokohama, Japan 2017**, International Association for the Study of Lung Cancer (IASLC) 18<sup>th</sup> World Conference Lung Cancer 2017
54. **Alexandria, VA**, October 2017, American Society of Clinical Oncology, QOPI Steering Group and QCP Joint Task Force Meeting
55. **Denver, CO**, October 2017, IO-ICON Annual Fall Meeting
56. **Madrid, Spain**, September 2017, ESMO, Expert Roundtable, Emerging Paradigms in Care (EPIC) Metastatic Breast Cancer in 2017 and Beyond: Insight From the Experts
57. **Tampa, FL**, July 2017, FLASCO Board of Directors Retreat
58. **Chicago, IL**, June 2017, ASCO Annual Meeting
59. **Chicago, IL**, May 2017, Brigatinib Regional Advisory Board Meeting
60. **Dana Point, CA**, May 2017, Brigatinib National Sales Launch Meeting
61. **Orlando, FL**, May 2017, AstraZeneca's Lung Cancer Spring Regional Advisory Panel
62. **Marrakech, Morocco**, April 2017, Consult for The Evolution of the Oncology Center of Marrakech Healthcare City (MHCC)
63. **Las Vegas, NV**, April 2017, Expert Roundtable, EPIC: Breast Cancer in 2017 and Beyond
64. **New York, NY**, March 2017, Genentech-Roche IMpower010 Accrual Workshops
65. **Orlando, FL**, March 2017, FLASCO Board Meeting, the Business of Oncology Summit, Spring Session

66. **Manalapan, FL**, March 2017, R&D Leadership Summit
67. **Orlando, FL**, March 2017, ASCO Quality Care Symposium
68. **Santa Monica, CA**, February 2017, ARIAD's ALK/Brigatinib Expert Advisory Group Meeting
69. **Alexandria, VA**, February 2017, American Society of Clinical Oncology, QOPI Steering Group and QCP Oversight Council Joint Meeting
70. **Alexandria, VA**, January 2017, Medical Expert Panel discussion, Novartis National Meeting
71. **Miami, FL**, January 2017, Abbvie SCLC DLL3 Testing Advisory Board
72. **Vienna, Austria**, December 2016, IASLC- 17<sup>th</sup> World Conference on Lung Cancer, ARIAD Brigatinib Ad Board
73. **New York, New York**, October 2016, Celldex METRIC Accrual Workshop
74. **Cambridge, MA**, October 2016, Foundation Medicine- Comprehensive Genomic Profiling Educational Program
75. **Copenhagen, Denmark**, October 2016, Metastatic Breast Cancer in 2016 and Beyond: An Expert Roundtable
76. **Alexandria, VA**, September 2016, ASCO's Inaugural Advocacy Summit
77. **Jersey City, NJ**, September 2016, ALK/Brigatinib Expert Advisory Group
78. **Chicago, IL**, September 2016, 2016 IO-ICON Fall Meeting Advisory Lung Group
79. **Las Vegas, NV**, August 2016, Metastatic Breast Cancer in 2016 and Beyond: An Expert Roundtable
80. **Dallas, TX**, June 2016, BMS US IO Innovations Meeting – Franchise Ad Board
81. **Chicago, IL**, June 2016, ASCO Annual Meeting
82. **Orlando, FL**, May 2016, XALKORI POA1 2016 HCP Workshop
83. **Boston, MA**, April 2016, Brigatinib Regional Advisory Board
84. **San Diego, CA**, March 2016, Novartis: Zykadia Metastatic Advisory Board
85. **Phoenix, AZ**, February 2016, IO-ICON Annual Meeting
86. **Tampa, FL** November 2015, FLASCO Fall Meeting
87. **Austin, TX** October 2015, Lung NET Advisory Board
88. **Dallas, TX**, September 2015, IO ICON Mid-Year Meeting
89. **Denver, CO**, September 2015, 16<sup>th</sup> World Conference on Lung Cancer
90. **Denver, CO**, September 2015, Axess Oncology's Roundtable Discussion, "New Approaches in the Treatment of Non-Small Cell Lung Cancer"
91. **Miami, FL**, September 2015, Regional NSCLC Advisory Board

92. **Washington D.C.**, May 2015, APPNA Spring Meeting
93. **Chicago, IL** May 2015, ASCO Annual Meeting
94. **Las Vegas, NV**, April 2015, EPIC Metastatic Breast Cancer
95. **The Woodlands, TX**, February 2015, IO-ICON Annual Meeting
96. **Hollywood, FL**, January 2015, Quest Diagnostics Breast Cancer Advisory Board
97. **Atlanta, FL**, November 2014, U.S. Payor / Provider Advisory Board Oncology
98. **Tampa, FL**, November 2014, FLASCO Fall Meeting
99. **Chicago, IL**, October 2014, XALKORI Medical Advisory Board
100. **Washington D.C.**, August 2014, APPNA 37<sup>th</sup> Annual Convention
101. **Chicago, IL**, May 2014, ASCO Annual Meeting
102. **Orlando FL**, April 2014, FLASCO Business Oncology, Spring Session and Meeting
103. **Dallas TX**, March 2014, EPIC Metastatic Breast Cancer in 2014 and Beyond: An Expert Round Table
104. **Beverly Hills, CA**, March 2014, APPNA Spring Meeting
105. **Chicago, IL**, May 2013, ASCO Annual Meeting
106. **Baltimore, MD**, March 2013, Ventana Medical Systems, Breast Cancer Diagnostic Advisory Board Meeting
107. **Ft. Lauderdale, FL**, January 2013, Lilly JFCK ISST Meeting
108. **San Antonio, TX**, December 2012, Genentech Breast Cancer National Advisory Board
109. **Tampa, FL**, November 2012, FLASCO Business Oncology, Fall Session and Meeting
110. **Chicago, IL**, October 2012, Abbott Investigator Meeting
111. **Washington, DC**, July 2012, APPNA 35<sup>th</sup> Annual Summer Meeting
112. **Chicago, IL**, May 2012, ASCO Annual Meeting
113. **Chicago, IL**, May 2012, HER2 Registry Steering Committee Meeting,
114. **Ft. Lauderdale, FL**, May 2012 Xcenda “Challenging Cases in Breast and Lung Cancer”
115. **Durham, NC**, May 2012, Genentech Breast Cancer National Advisory Board
116. **Orlando, FL**, April 2012, FLASCO Business Oncology, Spring Session and Annual Meeting
117. **Miami, FL**, March 2012, Breast Cancer Regional Advisory Board
118. **San Antonio, TX**, December 2011, Genentech Breast Cancer National Advisory Board

119. **Tampa, FL**, November 2011, "FLASCO Fall Meeting"
120. **Hoboken, NJ**, November, Roche Global Advisory Board Meeting
121. **Mexico City, Mexico**, August, Roche 1<sup>st</sup> Symposium Treatment with Care
122. **Rio de Janeiro, Brazil**, July 2011, NCCN/GLICO Global Initiatives
123. **Philadelphia, PA**, June 2011, NCCN Non-Small Cell Lung Cancer Panel Meeting
124. **Johannesburg, SA**, April 2011, Roche Academic Presentations on Avastin for NSCLC and Breast Cancer
125. **Hollywood, FL**, March 2011, NCCN Annual Meeting
126. **San Antonio, TX**, December 2010, Genentech National Breast Cancer Advisory Board
127. **San Antonio, TX**, December 2010, Novartis: SABCS Advisory Board
128. **San Antonio, TX**, December 2010, Avastin Ribbon 2 Steering Committee
129. **San Francisco, CA**, October 2010, Zybrest Lung Advisory Panel
130. **Chicago, IL**, September 2010, ARIES Lung Steering Committee
131. **New York, NY**, July 2010, ICORE Advisory Board
132. **Philadelphia, PA**, July 2010, NCCN Academy, Panelist
133. **Miami, FL**, May 2010, CRIPTO/Light HER2 Breast Cancer Advisory Board
134. **Washington, DC**, May 2010, NCCN Academy Summit – Round Table Discussion
135. **Memphis, TN**, October 2009, Mid-South Cancer Symposium Moderator – Round Table Discussion Panel
136. **Chicago, IL**, October 2009, ARIES Lung Steering Committee
137. **Miami, FL**, October 2009, Miami Cancer Meeting, "Developments in Cancer Care in the 21st Century Lung Cancer Round Table"
138. **San Francisco, CA**, October 2009, Xeloda Breast Cancer Advisory Board
139. **San Francisco, CA**, September 2009, Abraxis Advisory Board
140. **Chicago, IL**, August 2009, Avastin Breast Cancer Center Regional Advisory Board
141. **Seattle, WA**, April 2009, Herceptin Advisory Board
142. **Chicago, IL**, April 2009, Avastin Sales and Marketing Meeting
143. **Chicago, IL**, October 2008, Southwest Oncology Group Meeting (SWOG)
144. **Miami, FL**, October 2008, Cetuximab in NSCLC Clinical Forum

145. **Boston, MA**, August 2008, Sanofi-Aventis Oncology Lecture Series Speaker Training
146. **Washington, DC**, May 2008, NCCN Bendamustine Scientific Review Committee Meeting
147. **Chicago, IL**, May 2008, Herceptin, Experts Round Table
148. **Chicago, IL**, May 2008, Mammaprint / Agenda Expert Round Table
149. **Atlanta, GA**, May 2008, Southwest Oncology Group Meeting (SWOG)
150. **New York, NY**, March 2008, NMCR Challenging Cases in Breast Cancer
151. **Miami, FL**, February 2008, Genentech Oncology Moderator Orientation Meeting
152. **Alexandria, VA**, January 2008, ASCO Quality Oncology Practice Initiative Meeting
153. **San Diego, CA**, January 2008, Breast Experts Tumor Board, Genentech National Sales Meeting
154. **Philadelphia, PA**, November 2007, NCCN Bendamustine Scientific Advisory Board
155. **Newport Beach, CA**, November 2007, Herceptin Nurse Advisory Board Meeting
156. **San Francisco, CA**, October 2007, Avastin Community Experts Breast Cancer Advisory Board
157. **Huntington Beach, CA**, October 2007, Southwest Oncology Group Meeting
158. **Philadelphia, PA**, September 2007, NCCN Breast Cancer in the Older Woman Task Force Meeting
159. **Chicago, IL**, August 2007, NCCN Oncology Research Program (ORP) Strategic Planning Meeting
160. **Washington, DC**, July 2007, NCCN Abraxane Scientific Advisory Board Meeting
161. **Lansdowne, VA**, June 2007, NCCN Breast Panel
162. **Chicago, IL**, May 2007, NCCN Non-Small Cell Lung Cancer Panel
163. **Chicago, IL**, May 2007, Southwest Oncology Group Meeting
164. **Chicago, IL**, October 2006, ASCO Item Writing Workshop
165. **Seattle, WA**, October 2006, Southwest Oncology Group Meeting
166. **New York, NY**, September 2006, Novacea Virtual Webcast of Top Tier Key Opinion Leaders
167. **New York, NY**, July 2006, Tarceva Speakers Bureau
168. **Chicago, IL**, July 2006, New Approaches to Lung Cancer: Translating Clinical Research into Clinical Practice Faculty Training Program,
169. **Salt Lake City, UT**, April 2006, Southwest Oncology Group Meeting
170. **Chicago, IL**, February 2006, NCCN HER2 Testing in Breast Cancer Task Force Meeting

171. **San Diego, CA** January 2006, Berlex Consultant Meeting
172. **San Antonio, TX**, December 2005, Avastin Regional Academic Breast Cancer Advisory Board Meeting
173. **San Antonio, TX** December 2005, Aventis Consultants Meeting
174. **San Antonio, TX** December 2005, VERN Metastatic Breast Cancer Curriculum Review Meeting
175. **New York, NY**, September 2005, Taxotere (docetaxel) KOL Meeting
176. **New Orleans, LA**, September 2005, Southwest Oncology Group Meeting
177. **Seattle, WA**, July 2015, Taxotere (docetaxel) Breast and Lung Cancer Consultant Program
178. **New Orleans, LA** 07/05, Taxotere (docetaxel) Breast and Lung Cancer Consultant Program
179. **Chicago, IL** 07/05, NCCN Breast Cancer Panel Meeting
180. **Chicago, IL** 07/05 VEGF Educational Resource Network Focus on Non-Small Cell Lung Cancer
181. **Chicago, IL** 06/05 NCCN Non-Small Cell Lung Cancer Panel Meeting
182. **Atlanta, GA**, July 2005, Taxotere (docetaxel) Breast Consultant Program
183. **Scottsdale, AZ**, July 2005, NOCR Challenging Cases in Breast Cancer
184. **Chicago, IL**, May 2005, NCCN Breast Adjuvant Task Force Meeting
185. **Beverly Hills, CA**, April 2005, Herceptin Advisory Board
186. **Denver, CO**, April 2005, Southwest Oncology Group Meeting
187. **Baltimore, MD**, April 2005, NCCN Non-Small Cell Lung Cancer Guidelines
188. **Bonita Springs, FL** March 2005, Taxotere (docetaxel) Speaker Summit
189. **New York, NY**, February 2005, Tarceva Regional Lung Advisory Board Meeting
190. **Alexandria, VA**, February 2005, QOPI Planning Meeting
191. **Phoenix, AR**, January 2005, Genomics in Breast Cancer Oncotype DX Summit
192. **Kansas City, MO**, October 2014, Southwest Oncology Group Meeting
193. **Salt Lake City, UT**, August 2014, NCCN Breast Cancer Panel Meeting
194. **New York, NY**, July 2004, Fragmin Oncology Guidelines Steering Committee
195. **Boston, MA**, November 2014, Genasense Scientific Exchange Meeting
196. **Huntington Beach, CA**, April 2004, Southwest Oncology Group Meeting
197. **New York, NY**, November 2003, Abraxane KOL Advisory Board



198. **Dallas, TX**, October 2003, EMD Pharmaceuticals Oncology Advisory Board
199. **Seattle, WA**, October 2003, Southwest Oncology Group Meeting
200. **Scottsdale, AZ**, July 2003, NCCN Breast Cancer Panel Meeting
201. **San Diego, CA**, April 2003, Southwest Oncology Group Meeting
202. **Naples, FL**, January 2003, EMD Pharmaceuticals Oncology Advisory Board
203. **Chicago, IL**, December 2002, NCCN Non-Small Cell Lung Cancer Panel
204. **Washington, DC**, October 2012, Access to Cancer Care and National Initiatives in Quality Cancer Care, NCCN Cancer Policy Summit
205. **New York, NY**, December 2012, The Year 2002 Process: An Evidenced Based Approach for the Treatment of Advanced Non-Small Cell Lung Cancer
206. **San Antonio, TX**, December 2012, Process of Care in Metastatic Breast Cancer, San Antonio Breast Cancer Symposium
207. **Tucson, AZ**, November 1996, Rationale of Studying Doxil in Advanced Breast Cancer

**National Audio / Web Conferences:**

- |              |   |
|--------------|---|
| 04/18/23     | JFK's 2023 Breast Cancer Conference, Multidisciplinary Breast Cancer Conference via WebEx   |
| 02/25/22     | The John Theurer Cancer presents the 2021 San Antonio Breast Cancer Review Virtual Webinar  |
| 11/25/20     | Bard, Advance- A Clinical Training & Educational Program "The Role of the Multidisciplinary Team in Port Management"  |
| 08/21/20     | China Webinar, "Use of Ports in Oncology Patients: An Oncologist's Perspective"   |
| 07/22/20     | "Alunbrig for Metastatic ALK+ Non-Small Cell Lung Carcinoma"  |
| 07/23/20     | "Alunbrig for Metastatic ALK+ Non-Small Cell Lung Carcinoma"  |
| 07/29/20     | "Alunbrig for Metastatic ALK+ Non-Small Cell Lung Carcinoma"  |
| 07/30/20     | "Alunbrig for Metastatic ALK+ Non-Small Cell Lung Carcinoma"  |
| 06/23/20     | PIQRAY On-Demand Roundtable Moderator-Led Discussion  |
| 06/16/20     | Live Webcast, Targeting HER2/3 in Advanced NSCLC: Where Are We and Where Are We Going, "Current Therapeutic Options for NSCLC Patients with HER2/3 Alterations" |
| 03/27/20     | Takeda Brigatinib Community Advisory Board WebEx Meeting  |
| 11/2015      | Prime Oncology Webinar, "Immunotherapy in NSCLC: A New Treatment Paradigm"  |
| 04/14- 04/15 | "ImmunoOncology in Melanoma and Lung Cancer"  |

- 08/07/09 “Avastin Breast / Herceptin Breast”
- 09/22/08 “Current Debates in the Treatment of HER 2+ Metastatic Breast Cancer”
- 08/07 – 12/07 “New Developments in the Management of Advanced Breast Cancer”, 3 programs
- 08/09/06 “Controversies Surrounding the Optimal Use of Chemotherapy in Breast Cancer”
- 11/02 – 03/03 “Off-label use of Herceptin within Managed Care Settings and Hospitals” 4 programs
- 10/02 – 11/02 “Targeted Therapies for Advanced Breast Cancer” 4 programs
- 07/02 – 09/02 “HER2 Testing in Breast Cancer: What is the Best Strategy” 4 programs
- 01/02 – 04/02 “Update in Chemotherapy of Metastatic Breast Cancer” 8 programs
- 06/01 – 09/01 “Advances in the Management of Metastatic Breast Cancer” 11 presentations
- 04/97 – 07/97 “Role of Doxil in the Treatment of Solid Tumors” 15 presentations, 1,352 participants, 192 sites.

## Publications:

### Original Publications:

1. **Jahanzeb M**, Lin HM, Wu Y, Zhang P, Gorritz M, McGuinness CB, Huang WT, Sun K, Chen CC, Camidge DR. *Oncologist*. 2022 Sep 2;27(9):790-798. doi: 10.1093/oncolo/oyac116. PMID: 35781589
2. Pierobon M, Robert NJ, Northfelt DW, **Jahanzeb M**, Wong S, Hodge KA, Baldelli E, Aldrich J, Craig DW, Liotta LA, Avramovic S, Wojtusiak J, Alemi F, Wulfkuhle JD, Bellos A, Gallagher RI, Arguello D, Conrad A, Kemkes A, Loesch DM, Vocila L, Dunetz B, Carpten JD, Petricoin EF, Anthony SP. *Mol Oncol*. 2022 Jan;16(1):104-115. doi: 10.1002/1878-0261.13091. Epub 2021 Sep 12. PMID: 34437759
3. M Pierobon, N.J. Robert, D.W. Northfelt, **M Jahanzeb**, S Wong, K. A. Hodge, E Baldelli, J Aldrich, D. W. Craig, L. A. Liotta, S Avramovic, J Wojtusiak, F Alemi, J. D. Wulfkuhle, A Bellos, R.I. Gallagher, D Arguello, A Conrad, A Kemkes, D. M. Loesch, L Vocila, B Dunetz, J. D. Carpten, E.F. Petricoin, S.P. Anthony, “Multi-omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial” 26 August 2021. *Mol Oncol*, 16: 104-115. <https://doi.org/10.1002/1878-0261.13091>
4. Kaufman PA, Hurvitz SA, O’Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, **Jahanzeb M**. “Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry”. *Breast Cancer Res Treat*. 2021 Jul;188(1):179-190. doi: 10.1007/s10549-021-06103-z. Epub 2021 Feb 28. PMID: 33641083.
5. Garcia Campelo MR, Lin HM, Zhu Y, Pérol M, **Jahanzeb M**, Popat S, Zhang P, Camidge DR. “Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive

- ALK + non-small cell lung cancer (ALTA-1L)". *Lung Cancer*. 2021 May; 155:68-77. doi: 10.1016/j.lungcan.2021.03.005. Epub 2021 Mar 9. PMID: 33744781
6. Mohammadi O, Haines K, **Jahanzeb M**. "Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report". *Cancer Treat Res Commun*. 2021;26:100291. doi: 10.1016/j.ctarc.2020.100291. Epub 2020 Dec 19. PMID: 33388727.
  7. Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, **Jahanzeb M**, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. "Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial". *J Thorac Oncol*. 2020 Dec;15(12):1907-1918. doi: 10.1016/j.jtho.2020.09.001. Epub 2020 Sep 9. PMID: 32916310.
  8. R Dawar, K Haines, **M Jahanzeb**, "Remarkable Role of Chemotherapy in Selected ALK Positive Non-Small Cell Lung Cancer Before or After Targeted Therapy: Two Case Reports"  
DOI:  
10.1200/PO.20.00191 *JCO Precision Oncology* no. 4 (2020) 1425-1428. Published online November 18, 2020.
  9. **Jahanzeb M**, Lin HM, Pan X, Yin Y, Wu Y, Nordstrom B, Socinski MA. "Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer". *Oncologist*. 2020 Oct;25(10):867-877. doi: 10.1634/theoncologist.2020-0011. Epub 2020 Jul 23. PMID: 32490560; PMCID: PMC7543352
  10. **Jahanzeb M**, Lin HM, Pan X, Yin Y, Baumann P, Langer CJ. "Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer". *Clin Lung Cancer*. 2021 Jan;22(1):49-57. doi: 10.1016/j.clc.2020.08.003. Epub 2020 Sep 18. PMID: 33250347.
  11. Wender IO, Haines K, **Jahanzeb M**. "Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review". *Oncol Ther*. 2020 Dec;8(2):351-358. doi: 10.1007/s40487-020-00126-0. Epub 2020 Sep 2. PMID: 32876928; PMCID: PMC7683665.
  12. Lin HM, Pan X, Hou P, Huang H, Wu Y, Ren K, **Jahanzeb M**. "Economic burden in patients with ALK + non- small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors". *J Med Econ*. 2020 Aug;23(8):894-901. doi: 10.1080/13696998.2020.1762620. Epub 2020 May 21. PMID: 32347754.
  13. Jazieh AR, Abdelhafiez N, Al Mutairi N, Hashem A, Alkaiyat M, Al Shami M, **Jahanzeb M**. "Improving Quality of Cancer Care by Participating in Quality Oncology Practice Initiative Certification Program". *JCO Glob Oncol*. 2020 Jul;6:1087-1092. doi: 10.1200/GO.20.00217.
  14. Blayney DW, Abdelhafiez N, Jazieh AR, Pinto CF, Udrea A, Roach A, Das D, Grubbs S, Hamm J, **Jahanzeb M**, Kamal AH, Kelly RJ, Martin SE, O'Mahony D, Birch W, Bowman R, Crist STS, Evers A, Gilmore T, Klein M, Siegel R. "International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification". *JCO Glob Oncol*. 2020 May;6:697-703. doi: 10.1200/GO.20.00048. PMID: 32374622; PMCID: PMC7268902.
  15. Hunter N, Dempsey N, Tbaishat F, **Jahanzeb M**, Al-Sukhun S, Gralow JR. "Resource-Stratified Guideline-

Based Cancer Care Should Be a Priority: Historical Context and Examples of Success". Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-10. doi: 10.1200/EDBK\_279693. PMID: 32223670.

16. M Cobleigh, D A Yardley, A Brufsky, H S Rugo, S M Swain, PA Kaufman, D Tripathy, S A. Hurvitz, Joyce O'Shaughnessy, G Mason, V Antao · H Li, L Chu, **M Jahanzeb**, "Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status From SystHERs" Clin Cancer Res. 2020 Mar 1;26(5):1105-1113
17. Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, Caramella C, Ferrara R, Agte S, Oh M, Mudad R, **Jahanzeb M**, Suzuki H, Besse B, Lopes G. "Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer". Br J Cancer. 2020 Feb;122(3):340-347. doi: 10.1038/s41416-019-0643-y. Epub 2019 Nov 25. PMID: 31761899; PMCID: PMC7000664.
18. Tripathy D, Brufsky A, Cobleigh M, **Jahanzeb M**, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. "De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry". Oncologist. 2020 Feb;25(2):e214-e222. doi: 10.1634/theoncologist.2019-0446. Epub 2019 Oct 14. PMID: 32043771; PMCID: PMC7011632.
19. SA. Hurvitz, J O'Shaughnessy, G Mason, D A. Yardley, **M Jahanzeb**, A Brufsky, HS. Rugo, SM. Swain, P A. Kaufman, D Tripathy, L Chu, H Li, V Antao and M Cobleigh "Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs" Clin Cancer Res 2019 Apr 28;25(8):2433-2441
20. J Mortimer, J Di Palma, K Schmid, Y Ye, **M Jahanzeb**, "Pattern of occurrence and implications of neratinib- associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial" Breast Cancer Res 2019 02 27;21(1):32
21. **M Jahanzeb**, R Mahtani, A C Sandoval, "Adjuvant Therapy", In press July 2018
22. S A Hurvitz, J O'Shaughnessy, G Mason, D A Yardley, **M Jahanzeb**, A Brufsky, H S. Rugo, S M Swain, P A Kaufman, D Tripathy, L Chu, H Li, V Antao, M Cobleigh, "Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERs" Submitted, June 2018
23. Zhang B, Lloyd W, **Jahanzeb M**, Hassett J.M, "Use of patient-reported outcome measures in Quality Oncology Practice Initiative registered practices: Results of a national survey", J Oncol Pract 2018 10 12;14(10):e602-e611
24. QJ Khan, LH Prochaska, J Mohammad, Y Yuan, A O'Dea, A Bardia, K Wisinski, M Hard, S Baccaray, I Makhoul, J Wagner, S Laura, C Ma and P Sharma "Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial" SABCS16-OT3-02-06 Published February 2017
25. W Park, DKwon, D Saravia, A Desai, F Vargas, MD, M El Dinali, J Warsch, R Elias, Y K Chae, D W Kim, S Warsch, A Ishkanian, C Ikpeazu, R Mudad, MD, G Lopes, **M Jahanzeb**, "Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab." Clin Lung Cancer. 2017 Dec 21. pii: S1525-7304(17)30346-7. doi: 10.1016/j.clcc.2017.12.007
26. Rocque G.B, Blayney D, **Jahanzeb M**, Kadlubek P, Knape A, Markham M.J Pham T, Evans T.L, "Choosing Wisely in Oncology: Are we ready for value-based care?" J Oncol Pract. 2017 Nov;13(11):e935-e943. doi: 10.1200/JOP.2016.019281. Epub 2017 Aug 7

27. Ernani V, Steuer CE, **Jahanzeb M**. "The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer". *Annu Rev Med*. 2017 Jan 14;68:153-168. doi: 10.1146/annurev-med-042915-102442. Epub 2016 Sep 7. PMID: 27618751.
28. J C. Sachdev, J N. Snider, J W. Allen, LS. Schwartzberg<sup>3</sup>, R R. Young, A Y. Javed<sup>5</sup>, M P. Smeltzer, F Yunus, C S. Verrier<sup>5</sup>, **Jahanzeb M**, "Neoadjuvant Weekly nab-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Operable Triple-Negative Invasive Breast Cancer", *J Can Allied Spec*. 2016;2(1):3
29. Balfe.L, Warsch S, **Jahanzeb M**, "Patient with a Typical Carcinoid Initially Diagnosed as High-Grade Neuroendocrine Carcinoma" November 2016, PS01.38, J.THO.2016.09.073
30. H S. Rugo, R. B Rumble, **Jahanzeb M**, et.al., "Endocrine therapy for hormone receptor positive metastatic breast cancer: American Society of Clinical Oncology Guideline." *J Clin Oncol*. 2016 Sep 1;34(25):3069-103
31. L Leon,<sup>1</sup> M Kosty,<sup>2</sup> **M Jahanzeb**,<sup>3</sup> D Spigel,<sup>4</sup> A J. Wozniak,<sup>5</sup> J Brahmer,<sup>6</sup> P Kumar,<sup>7</sup> S Fish,<sup>1</sup> E. D Flick,<sup>1</sup> S J.Hazard,<sup>1</sup> TJ Lynch, Jr<sup>8</sup>, "Effectiveness of Bevacizumab Exposure Beyond Disease Progression in Patients With Non-Small Cell Lung Cancer: Analyses of the ARIES Observational Cohort Study", *Pharmacoepidemiol Drug Saf*. 2016 May;25(5):569-77
32. Wozniak AJ, Kosty MP, **Jahanzeb M**, Brahmer JR, Spigel D, Leon L, Fish S, Flick ED, Hazard SJ, Lynch Jr TJ, "Clinical Outcomes in Elderly Patients with Advanced Non-Small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study" *Clinical Oncology*, Epub 2015 Apr;27(4):187-96
33. MP Kosty, A Wozniak, **M Jahanzeb**, L Leon, S. Fish, S. Hazard, TJ Lynch Jr, "Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small cell lung cancer: results from the ARIES observational cohort study" *Target Oncol*. 2015 Dec;10(4):509-16
34. Sachdev JC · Snider JN, Allen JW, Schwartzberg LS, Young RR, Javed AY, Smeltzer MP, Yunus F, Verrier CS, **Jahanzeb M**, "Neoadjuvant Weekly *nab*-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer" Submitted August 2014
35. Tripathy D, Rugo H, Kaufman PA, Swain S, O'Shaughnessy J, **Jahanzeb M**, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S, "The SystHERs registry: an observation cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer", *BMC Cancer* 2014 May 2;14:307
36. Allen J, Moon J, Redman M, Gadgeel S, Kelly K, Mack P, Saba H, Mohamed M, **Jahanzeb M**, and David R Gandara. "SWOG S0802: A Randomized Phase II Trial of Weekly Topotecan with and without Ziv-aflibercept in Patients with Platinum-Treated Small Cell Lung Cancer" *J Clin Oncol*. 2014 Aug 10;32(23):2463-70
37. Aapro M, Andre F, Blackwell K, Calvo E, **Jahanzeb M**, Papazisis K, Porta C, Pritchard K, Ravaud A, "Adverse Event Management in Patients With Advanced Cancer Receiving Oral Everolimus: Focus on Breast Cancer" *Ann Oncol*. 2014 Apr; 25(4):763-73
38. Lynch TJ Jr, Brahmer J, Fischbach N, Garst J, **Jahanzeb M**, Kumar, P, Robles R, Spigel DR, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Datal D, Hazard SJ, Kosty MP; "Safety and Effectiveness of Bevacizumab - Containing Treatment for Non-Small Cell Lung Cancer: Final Results of the ARIES

Observational Cohort Study” J Thorac Oncol. 2014 Sep

39. Ettinger DS, Akerley W, Borhhaei H, Chang AC, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan, R, Grannis, Jr. FW, Horn L, Jahan TM, **Jahanzeb M**, Kessinger, A, Komaki R, Kong KF, Krs, MG, Krug LM, Lennes IT, Loo, Jr. BW, Martins R, O’Malley J, Osarogiabon RU, Otterson GA, Patel JD, Pinder- Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood, DE, Yang SC, Hughes M, Gregory KM; “Non-Small Lung Cancer: “Clinical Practice Guidelines in Oncology”. J National Comprehensive Cancer Network 2012; 10:1236-1271
40. Ettinger DS, Akerley, **Jahanzeb M**, et.al. “Malignant Pleural Mesothelioma” J Natl Compr Canc Netw. 2012 Jan;10(1):26-41
41. Abulkhair O, Saghi L, Saadedin A, Elzahwary H, Siddiqui N, Al Saleh M, Geara F, Birido N, Al-Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S, Kandil A, Khatib S, El-Mistiri M, Salem D, Sayd ek SH, Jaloudi M, **Jahanzeb M**, Gradishar WI; MENA Breast Cancer Regional Guidelines Committee “Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North Africa Region”. J Natl Compr Canc Netw. 2010 Jul; 8 Suppl 3:S8-S15.
42. Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, Geara FB, Javaid M, Khader J, Omar W, Saadeddin A, Sabe HA, Shadmehr MB, El Sherif A, Uddin N, **Jahanzeb M**, Ettinger D; MENA Lung Cancer Regional Guidelines Committee “Modification and Implementation of NCCN Guidelines on Non-Small Cell Lung Cancer in the Middle East and North Africa Region. J Natl Compr Canc Netw. 2010 Jul; 8 Suppl 3:S16-21.
43. Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, **Jahanzeb M**, Johnson S, Mackler E, Rubino M, Sarokhan B, Marc Stewart F, Tyler T, Vose, JM, Weinstein S, Li EC, Demartino J; NCCN Oncology Risk Evaluation and Mitigation Strategies (REMS) Work Group. J Natl Compr Canc Netw. 2010 Sep 8.
44. Jazieh A, Azim H, McClure J, **Jahanzeb M** “The Abu Dhabi Declaration: Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region” Journal of the National. Comprehensive Cancer Network, 2010 Jul: Volume 8 Supplement 3.
45. Jazieh AR, Azim HA, McClure J, **Jahanzeb M**. “The process of NCCN Guidelines adaptation to the Middle East and North Africa Region”. J Natl Compr Canc Netw. 2010; 8 Suppl 3:S5-7.
46. Abulkhair O, Saghir N, Sedky L, Saadedin A, Elzahwary H, Saddiqui N, Al Saleh M, Geara F, Birido N, Al Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S, Kandil A, Khatib S, El-Mistiri M, Salem D, Sayd el SH, Jaloudi M, **Jahanzeb M**, Gradishar WI; MENA Breast Cancer Regional Guidelines Committee. “Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North African Region. J Natl Compr Canc Netw. 2010 Jul; 8 Suppl 3:S8-S15.
47. Jazieh AR, Azim HA, McClure J, **Jahanzeb M**, “The Process of NCCN Guidelines Adaptation to the Middle East and North African Region” J Natl Compr Canc Netw. 2010 Jul; 8 Suppl 3:S5-7.
48. Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, Javaid M, Khader J, Khodadad K, Omar W, Saadeddin A, Sabe HA, Shadmehr MB, El Sherif A, Uddin N, **Jahanzeb M**, Ettinger D.; MENA Lung Cancer Regional Guidelines Committee, “Modification and Implementation of NCCN Guidelines on Non-Small Lung Cancer in the Middle East and North Africa Region”. J National Comprehensive cancer Network. 2010; 8 Suppl 3:S16-
49. Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman J, Howell P, **Jahanzeb M**, et al, “NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: “Recommendations for Stakeholders” Journal of the National Comprehensive Cancer Network, September 2010, Volume 8

Supplement 7.

50. Jazieh A, Azim H, McClure J, **Jahanzeb M** "The Abu Dhabi Declaration: Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region" Journal of the National Comprehensive Cancer Network, 2010 Jul: Volume 8 Supplement 3.
51. Mahtani R, **Jahanzeb M** "Bisphosphonates as anticancer therapy for early breast cancer" Clinical Breast Cancer. 2010 Oct 1; 10(5):359-66.
52. Ettinger D, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, **Jahanzeb M**, et al. "Non-small cell lung cancer." Journal of the National Comprehensive Cancer Network, 2010 Jul; 8(7):740-801.
53. **Jahanzeb M**, et al. "Bisphosphonates in lung cancer: more than a palliative therapy?" Seminars in Oncology. 2010 Jun; 37 Suppl 1:S45-52.
54. Sachdev JC, Ahmed S, Mirza MM, Farooq A, Kronish L, **Jahanzeb M** "Does race affect outcomes in triple negative breast cancer?" Breast Cancer. 2010 May 7; 4:23-33.
55. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney R, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, **Jahanzeb M**, et al, "NCCN Clinical Practice Guidelines in Oncology, Non- Small Cell Lung Cancer" National Comprehensive Cancer Network 2010.
56. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, **Jahanzeb M**, et al, "NCCN Clinical Practice Guidelines in Oncology, Breast Cancer." National Comprehensive Cancer Network 2010.
57. **Jahanzeb, M**, "Continuing trastuzumab beyond progression" Journal of Clinical Oncology. 2009 Apr 20; 27(12):1935-7.
58. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, **Jahanzeb M**, et al, "Breast Cancer Treatment Guidelines." J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92.
59. Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Hutchinson S, **Jahanzeb M**, et al, "Venous Thromboembolic Disease. NCCN. Clinical practice guidelines in oncology." J Natl Compr Canc Netw. 2008 Sept; 6(8): 716-53.
60. Carlson R, Moench S, Hurria A, Balducci L, Burstein H, Goldstein L, Gradishar W, Hughes K, **Jahanzeb M**, "NCCN Task Force Report: Breast Cancer in the Older Woman", JNCCN, July 2008, Vol 6 No 4, p 1-27.
61. Ettinger D, Akerley W, Bepler G, Chang A, Cheney R, Chirieac L, D'Amico T, Demmy T, Feigenberg S, Figlin R, Govindan R, Grannis Jr. F, Jahan T, **Jahanzeb M**, "Non-Small Cell Lung Cancer" JNCCN, March 2008, Vol 6 No 3, p 228-229, 251-269.
62. Gralow J, Rugo H, Gradishar W, O'Shaughnessy J, **Jahanzeb M**, et.al, "Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable", Clinical BreastCancer, Vol 8, No 1, Feb 2008, p 33-37.
63. Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., ... & Francis, C.

W. (2007). "American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer". *Journal of clinical oncology*, 25(34), 5490-5505..

64. Hirsh V, Desjardins P, Needles B, Rigas J, **Jahanzeb M**, et.al., "Oral Versus Intravenous Administration of Vinorelbine as a Single Agent for the First-Line Treatment of Metastatic Non-Small Cell Lung Carcinoma (NSCLX): A Randomized Phase II Trial" , *Am J Clin Oncol*. 2007 Jun; 30(3):245-51.
65. Limentani SA, Brufsky AM, Erban JK, **Jahanzeb M**, et al, "Phase II Study of Neoadjuvant Docetaxel/Vinorelbine and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women with HER2-Overexpressing Locally Advanced Breast Cancer", *Journal of Clinical Oncology*, Vol 25 No 10, April 2007
66. Carlson R, Burstein H, Edge S, Goldstein L, Hayes D, **Jahanzeb M**, et.al., "Invasive Breast Cancer", *JNCCN* March 2007, Vol. 5 No. 3, p 246-312
67. Limentani, SA, Brufsky, AM, Erban, JK, **Jahanzeb, M**, et.al., "Phase II Study of Neoadjuvant Docetaxel/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women With Stage IIB and III Breast Cancer", *Clinical Breast Cancer*, Vol 6, No 6, Feb 2006:511-517
68. Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldaber SZ, Grover TS, Haire W, Hassoun H, **Jahanzeb M**, et.al., "Venous Thromboembolic Disease. Clinical Practice Guidelines in Oncology", *J Natl Compr Cancer Network*, 2006 Oct 4 (9): 838-69
69. Ettinger D, **Jahanzeb M**, et.al., (NCCN Non-Small Cell Lung Cancer Panel Members), "Non-Small Cell Lung Cancer: Clinical Practice Guidelines in Oncology", *JNCCN*, Vol 4, No. 6, July 2006, p. 548.
70. Carlson R, Moench S, Hammond ME, Perez E, Burstein H, Allred C, Vogel C, Goldstein L, Somlo G, Gradishar W, Hudis C, **Jahanzeb M**, et al, "HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations", *JNCCN*, Vol 4, Supp 3, July 2006
71. Herbst R, Prager D, Hermann R, et.al. (Investigator – **Jahanzeb M**), "TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined with Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small Cell Lung Cancer", *J Clin Onc*, Sept. 2005, Vol. 23 No. 25, p 5892-5899
72. Gradishar WJ, Wedam SB, **Jahanzeb M**, et.al., "Neoadjuvant Docetaxel Followed by Adjuvant Doxorubicin and Cyclophosphamide in Patients with Stage III Breast Cancer", *Ann Oncol*. 2005; May 19, p2541
73. Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, **Jahanzeb M**, et.al., "Breast Cancer", *Journal National Comprehensive Cancer Network*. 2005 May; 3(3):238-89.
74. Neuss, M, Desch, C, McNiff, K, Eisenberg, P, Gesme, D, Jacobson, J, **Jahanzeb, M**, et.al. "A Process for Measuring the Quality of Cancer Care: The Quality Oncology Practice Initiative (QOPI)", *Journal of Clinical Oncology*, 2005 Sept 1; 23(25):6233-9.
75. Muggia, FM, Carmichael, J, Winer, E, Jahanzeb, M., et.al., "Efficacy and Safety of Liposomal Anthracyclines in Phase I/II Clinical Trials", *Seminars in Oncology*, Dec 2004, Vol 31, No 6, suppl 13. 53-90
76. **Jahanzeb M**, Sarna, G, Hirsch, R, Radice, P, Koletsky, A, et.al, "Docetaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Carcinoma: A Phase II Study, Anticancer



Research, 2004; 24: 1239-1242.

77. Herbst R, Giaccone G, Schiller J, et.al., (Investigator – **Jahanzeb M**), “Gefitinib in Combination with Paclitaxel and Carboplatin in Advanced Non-Small Cell Lung Cancer: A Phase III Trial – INTACT 2”, J of Clinical Oncology, Mar 2004, Vol. 22, No. 5, p 785-794.
78. International Adjuvant Lung Cancer Trial (IALT) Collaborative Group: “Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer”, (Investigator – **Jahanzeb M**) the New England Journal of Medicine, Vol. 350, No. 4, January 22, 2004; 351-360.
79. Kris M, Natale R, Herbst R, et.al., (Investigator – **Jahanzeb M**), “Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer”, JAMA, Oct 22/29, 2003, Vol 290, No. 16, p 2149-2158
80. **Jahanzeb, M**: “Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice”, Clinical Breast Cancer, Vol. 4, No. 1, April 2003; 28-38
81. Semba C, Deitcher S, et al. (**Investigator - Jahanzeb M**) “Treatment of Occluded Central Venous Catheters with Alteplase: Results in 1,064 Patients”, J Vasc Interv Radiol 2002; 13:1199-1205
82. **Jahanzeb M**, Mortimer J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir T, Kronish L: “Weekly Herceptin with Navelbine in Chemonaive Patients with HER2 Positive Metastatic Breast Cancer: A Phase II Multicenter Trial, Oncologist 2002;7 (5): 410-17
83. Deitcher S, Fesen M, et.al., (Investigator – **Jahanzeb M**) “Safety and Efficacy of Alteplase for Restoring Function in Occluded Central Venous Catheters: Results of the Cardiovascular Thrombolytic to Open Occluded Lines Trail”, J of Clinical Oncology, Vol 20, Issue 1 (January), 2002 p 317-324
84. Slamon DJ, Leyland-Jones B, Shak S, et.al., “Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2”, New England Journal of Medicine, March 15, 2001, vol 344, no 11
85. Scheurle, D, **Jahanzeb M**, Aronsohn, R, Watzek, L, and Narayanan, R. “HER-2/neu Expression in Archival Non-Small Cell Lung Carcinomas Using FDA-Approved HercepTest”, Anticancer Research 2000 May-June; 20(3B): 2091-2096
86. Scheurle, D, DeYoung, MP, Binninger, D, Page, H, **Jahanzeb M**, Narayanan, R, “Cancer Gene Discovery Using Digital Differential Display, Cancer Research 60, 4037-4043, August 2000
87. McCarthy, M, Thompson A, Rivers, S, **Jahanzeb M**: “The Benefits of Support Group Participation to Lung Cancer Survivors”, Clinical Lung Cancer, Vol.1, No.2, 110-117, Nov. 1999
88. **Jahanzeb M**, Frankel C, Elkersh M., Koletsky A, Radice P, and Vogel C: “Rationale of Studying Doxil in Metastatic Breast Cancer”. Oncology (suppl) 11:45-53, Oct, 1997
89. Graham MV, **Jahanzeb M**, Dresler JD, Cooper J, Emami B and Mortimer J: “Results of a Trial with Topotecan Dose Escalation and Concurrent Thoracic Radiation Therapy for Locally Advanced, Inoperable Non-Small Cell Lung Cancer”, Int J Rad Oncol Biol Phys. 1996 Dec 1; vol 36, no. 5: 1215-1220
90. **Jahanzeb M**, Virgo KS, McKirgan LW and Johnson FE,: “Evaluation of Outcome by Race in Veterans with Early-Stage Non-Small Cell Lung Cancer”. Oncol Rep 4: 183-186,1997

91. Vokes EE, Rosenberg R, **Jahanzeb M**, Craig J, Gralla R, Belani C, Jones S, Purvis J and Hohnaker J: "Multicenter Study of Oral Navelbine in Previously Untreated Stage IV Non-Small Cell Lung Cancer (NSCLC)". *J Clinical Oncology* 1995; 13:637-644.
92. Vokes EE, Rosenberg R, **Jahanzeb M**, Craig J, Gralla R, Belani C, Jones S, Bigley J and Hohnaker J: "Oral Vinorelbine (Navelbine) in the Treatment of Advanced Non-small Cell Lung Cancer: A Preliminary Report" *Seminars in Oncology* 1994; 21 ( 5), suppl. 10: 35-41.

## Reviews

1. Ernani V, Steuer CE, **Jahanzeb M**, "The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer" *Annual Review Med. Annu Rev Med.* 2017 Jan 14;68:153-168
2. JC. Sachdev, MD, **M Jahanzeb**, "Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective" *Clin Breast Cancer.* 2016 Apr;16(2):73-81. Review
3. Aapro M, Andre F, Blackwell K, Calvo E, **Jahanzeb M**, Papazisis K, Porta C, Pritchard K, Ravaud A, "Adverse Event Management in Patients With Advanced Cancer Receiving Oral Everolimus: Focus on Breast Cancer" *Annals of Oncology* 25:763-773, 2014
4. Sachdev J, **Jahanzeb M**, "Blockade of the HER family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer". *Clinical Breast Cancer*, Vol. 12, No 1, 19-29
5. Mahtani R, Khan R, **Jahanzeb M**, "The Potential Application of Zoledronic Acid as Anticancer Therapy Patients with Non-Small Cell Lung Cancer" *Clin Lung Cancer.* 2011 Jan; 12 (1):26-32.
6. Mahtani R, **Jahanzeb M**, "Bisphosphonates as Anticancer Therapy for Early Breast Cancer". *Clinical Breast Cancer*, 2010 Oct 1; 10(5):359-66.
7. **Jahanzeb M**, et al. "Bisphosphonates in lung cancer: more than a palliative therapy?" *Seminars in Oncology.* 2010 June; 37 Suppl 1:S45-52.
8. Schreiber A, Sachdev J, **Jahanzeb M**, "Anastozole versus Exemestane in patients with postmenopausal breast cancer and visceral metastases" *Clinical Medicine Reviews in Oncology* 2010:2 79-87
9. Sachdev J, **Jahanzeb M**, "Evolution of Bevacizumab-Based Therapy in the Management of Breast Cancer", *Clinical Breast Cancer*, October 2008, Vol 8, No 5, p 402-410
10. Allen J, **Jahanzeb M**, "Extensive-Stage Small-Cell Lung Cancer: Evolution of Systemic Therapy and Future Directions", *Clinical Lung Cancer*, September 2008, Vol 9, No 5, p 262-270
11. **Jahanzeb M**, "Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer", *Clinical Breast Cancer*, August 2008, Vol 8, No 4, p 324-333
12. Allen J, **Jahanzeb M**, "Neoadjuvant Chemotherapy in Stage III Non-Small Cell Lung Cancer", *JNCCN*, March 2008, Vol 6 No 3, p 285-292
13. **Jahanzeb M**, "Clinical Review: Trastuzumab: the foundation of care for HER2-positive breast cancer." *AmJ Hem/Onc.* 2007; 6 (suppl 12):1-8.
14. **Jahanzeb M**, "Reducing Breast Cancer Recurrence after Tamoxifen in Postmenopausal Women with Hormone-Sensitive Breast Cancer", *Clinical Therapeutics*, *Clinical Therapeutics*, Vol 29, No 8, Aug 2007, p

1535-1547.

15. **Jahanzeb M**, "Trastuzumab: The Foundation of Care for HER2-positive Breast Cancer", *Am J Hem Oncol*, 2007;6 (suppl 12):1-8.
16. **Jahanzeb M**, Leyland-Jones B, "Management of a Patient with HER2-Overexpressing Infiltrating Ductal Carcinoma with Ductal Carcinoma In Situ", *Oncology Consultations*, Vol 3, No 9, July 2006.
17. **Jahanzeb M**, "Management of deep vein thrombosis in cancer patients", *J Natl Compr Canc Netw*. 2005 Nov; 3 Suppl 1:S50-3.
18. **Jahanzeb M**, Ihde DC: "Role of Adjuvant Therapy in Patients with Surgically Resected Non-Small Cell Lung Cancer" *Cancer Control* 1994 Oct;1(5):467-473.

### **Editorials / Monographs / Book Chapters / Case Reports**

1. **Jahanzeb M**, Warsch S, "Patient with typical carcinoid initially diagnosed as high-grade neuroendocrine carcinoma" *Lung Cancer Manag*.VOL.6, NO.2
2. **Jahanzeb M**, "Continuing Trastuzumab Beyond Progression", 2009 *Journal of Clinical Oncology*, Vol. 27, No 12 (April 20), 2009; pp.1935-1937
3. Raez L, Silva O, **Jahanzeb M**, "Lung Cancer: A Practical Guide", 2008 Elsevier Limited, p. 111-123.
4. **Jahanzeb M**, Sachdev J, "HER2-Positive Early-Stage Breast Cancer: Decision-Making and Practical Management", *Clinical Advances in Breast Cancer*, January 2008, Vol 1, No. 1.
5. Sachdev J, **Jahanzeb M**, "Advances in the Treatment of Breast Cancer", *The Memphis Medical Society Quarterly*, Fall 2007, Vol 10 No 3.
6. Sachdev J, **Jahanzeb M**, "A Patient with Bilateral Breast Cancer Treated with Neoadjuvant and Adjuvant Trastuzumab", *Case Studies in Breast Cancer*, Feb 2007, Vol. 5, No. 4.
7. **Jahanzeb M**, "Help Your Health Care Team Help You", *Caring4Cancer*, Vol. 1, Issue 4, Spring 2007
8. **Jahanzeb M**, "Sexuality and Cancer", *Caring4Cancer*, Vol.1, Issue 4, Spring 2007
9. **Jahanzeb M**, Galleshaw J, "How to Choose Therapy" *Caring4Cancer*, Issue 1, Vol 1, p 4, Spring 2006.
10. **Jahanzeb M**, Vogel C, "Adjuvant Chemotherapeutic Treatment of Node-Positive, Hormone-Negative Breast Cancer", *Oncology Consultations*, Vol. 3, No. 3, Feb 2006.
11. Rosenthal, M, **Jahanzeb M**, "After Diagnosis of Non-Small Cell Lung Cancer, The Real Workup Begins", *Hem/Onc Today*, Vol 6, No.6, June 2005 p. 27.
12. **Jahanzeb M**, "An Overview of Anti-HER2 Therapy in Combination with Chemotherapy in Metastatic Breast Cancer", *Biological Therapy of Breast Cancer*, Vol. 5, No. 3, Dec. 2004
13. **Jahanzeb M**, et.al., "Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology", *Journal of*

National Comprehensive Cancer Network, Vol. 2, Number 2, March 2004 (134).

14. Aslam R, **Jahanzeb M**, "A Patient With HER2 Positive Metastatic Breast Carcinoma Treated with Trastuzumab Based Therapy", Physicians' Education Resource, Aug. 2004, Vol 3 No 11.
15. **Jahanzeb M**, et.al., NCCN Lung Cancer Treatment Guidelines for Patients, Version II; JNCCN, March/April 2004; Vol 2 No 2.
16. **Jahanzeb M**: "Treatment of HER2-Overexpressing Metastatic Breast Cancer with Chemotherapy and Anti-HER2 Monoclonal Antibody", Human Epidermal Growth Factor Receptors in Oncology, Feb., 2004, Vol 1, No. 2: 6-8.
17. **Jahanzeb M**: "Advances with Trastuzumab/Chemotherapy in Metastatic Breast Cancer: Tidbits from Texas (the 2002 San Antonio Breast Cancer Symposium)", Cancer Abstracts and Summaries, April 2003, Vol.4., No.9.
18. Chantler ML, and **Jahanzeb M**, "Breast Cancer", The Washington Manual of Oncology, Lippincott Williams & Wilkins, 2002, 112-142.
19. **Jahanzeb M**, Sarna G, Hirsch R. "A Multicenter Phase II Study of Docetaxel and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Carcinoma" Cancer Conference Highlights, August, 2000
20. **Jahanzeb M**, "New Combinations Using Vinorelbine in the Management of Lung Cancer" Cancer Conference Highlights, 8th World Conference on Lung Cancer, February 1998
21. **Jahanzeb M**, "Navelbine (Vinorelbine) for the Elderly Breast Cancer Patient" Navelbine: Emerging Data in the Treatment of Solid Tumors, Monograph, February, 1998
22. **Jahanzeb M** and Ihde DC: "Chemotherapy of Lung Cancer" in Perry MC (ed) The Chemotherapy Source Book 2nd ed. Philadelphia, Williams & Wilkins 1995, 1103-1123
23. **Jahanzeb M** and Ihde DC: "Role of Adjuvant Chemotherapy in Surgically Resected Non-Small Cell Lung Cancer" Cancer Control 1994; 1 (5): 467-473.

#### **Partial Contributor / Expert Reviewer**

1. **Jahanzeb M**, Yardley D, "Focus on Cytotoxic Therapy", Recent Progress in Metastatic Breast Cancer, Physicians' Education Resource, July 2013, pp1-12
2. **Jahanzeb M**, "Breast Cancer: A Primer"
3. **Jahanzeb M**, "Non-Small Cell Lung Cancer: Clinical Practice Guidelines in Oncology", Journal National Comprehensive Cancer Network, Mar 2008, Vol 6 No 3 p 228.
4. **Jahanzeb M**, "Management of Deep Vein Thrombosis in Cancer Patients", Journal National Comprehensive Cancer Network, 2005 Nov; 3(Suppl 1):S50-S53.
5. **Jahanzeb M**, "Potential use of Humanized Antibodies in the Treatment of Malignant

- Breast Cancer”, *Anticancer Therapy*, Vol. 6 No. 7, July 2006, pp 1065-1074.
6. **Jahanzeb M**, “Sexuality and Cancer”, *Caring4Cancer*, Vol 1, Issue 4, Spring 2007
  7. **Jahanzeb M**, “The New Targeted Therapies: What You Should Know”, *Caring4Cancer*, Vol 1, Issue 4, Spring 2007
  8. **Jahanzeb M**, “Managing Side Effects of Cancer Treatments”, *Caring4Cancer*, Vol 1, Issue 4, Spring 2007

## Abstracts

1. M Pierobon, N.J. Robert, D.W. Northfelt, **M Jahanzeb**, S Wong, K. A. Hodge, E Baldelli, J Aldrich, D.W. Craig, L.A. Liotta, S Avramovic, J Wojtusiak, F Alemi, J. D. Wulfkuhle, A Bellos, R. I. Gallagher, David Arguello, Amber Conrad, Ariane Kemkes, David M. Loesch, Linda Vocila, Bryant Dunetz, John D. Carpten, Emanuel F. Petricoin, Stephen P. Anthony “Multi-omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial” Accepted 25 August 2021, *Molecular Oncology*.
2. Kaufman PA, Hurvitz SA, O’Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, **Jahanzeb M**. “Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry”. *Breast Cancer Res Treat*. 2021 Feb 28. doi: 10.1007/s10549-021-06103-z. Epub ahead of print. PMID: 33641083.
3. Mohammadi O, Haines K, **Jahanzeb M**. “Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction”. *Cancer Treat Res Commun*. 2021;26:100291. doi: 10.1016/j.ctarc.2020.100291. Epub 2020 Dec 19. PMID: 33388727.
4. Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, **Jahanzeb M**, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. “Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial”. *J Thorac Oncol*. 2020 Dec;15(12):1907-1918. doi: 10.1016/j.jtho.2020.09.001. Epub 2020 Sep 9. PMID: 32916310.
5. MA R G Campelo, Y Zhu, H M Lin, M Perol, **M Jahanzeb**, S Popat, P Zhang, E Goodman, D. R Camidge, “Health-related quality of life (HRQoL) results from ALTA-1L” European Society for Medical Oncology (ESMO) Poster September 2020
6. Campelo, M. R. G., Lin, H. M., Zhu, Y., Pérol, M., **Jahanzeb, M.**, Popat, S., ... & Camidge, D. R. (2021). Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naïve ALK+ non-small cell lung cancer (ALTA-1L). *Lung Cancer*, 155, 68-77
7. Lin HM, Wu Y, Gorritz M, McGuinness C, Huang 2, Chen CC, **Jahanzeb M**, “Treatment Duration and Adherence in ALK+ Non-Small Cell Lung Cancer Patients Treated with Brigatinib Following Prior ALK TKI Therapy in the US” ESMO Poster April 2020

8. Q. J. Khan, A O'Dea, A Bardia, K Kalinsky, K.B Wisinski, R. O'Regan, Y Yuan, C X. Ma, **M Jahanzeb**, M.S. Trivedi, L Spring, I Makhoul, J L. Wagner, O Winblad, AL Amin, S Blau, GJ Crane, M Elia, M Hard, P Sharma; "Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial)" *Journal of Clinical Oncology* 38, no. 15\_suppl (May 20, 2020) 505-505Abstract #307255, Submitted ASCO 2020
9. T Quill, K.D Miller, R O'Regan, T.A Traina, R Andrie, K.L. Obholz, **M Jahanzeb**, "Treatment patterns for metastatic hormone receptor-positive breast cancer: Comparing expert and community practice" Abstract: P4-14-07. SABCS19-P4-14-07 Published February 2020
10. Sachdev JC, Sandoval AC, **Jahanzeb M**, "Update on Precision Medicine in Breast Cancer" *Cancer Treat Res.* 2019;178:45-80
11. Park, W., Mezquita, L., Okabe, N., Chae, Y. K., Kwon, D., **MJahanzeb**, ... & Lopes, G. (2020). "Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer". *British journal of cancer*, 122(3), 340-347
12. N Abdelhafiez, M.M Alshami, M.O Al-Kaiyat, T Pasha, N Mutairi, T Gilmore, **M Jahanzeb**, A R Jazieh "Improving quality of cancer care: Lessons learned from the journey towards QOPI Certification" *J Clin Oncol* 37, 2019 (suppl 27; abstr 263) 2019 ASCO Quality Care Symposium
13. R G Campelo, H M Lin, M Perol, **M Jahanzeb**, S Popat, P Zhang, D. R Camidge, "Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC)" *J Clin Oncol* 37, 2019 (suppl; abstr 9084) 20th World Conference on Lung Cancer (WCLC) 2019
14. X Pan, M M Lin, Y Yin, P Hou, P Baumann, **M Jahanzeb**, "Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK1) non-small cell lung cancer (NSCLC) in the United States" *Annals of Oncology*, Volume 30, Issue Supplement\_2, April 2019, mdz063.037
15. J Mortimer, J Di Palma, K Schmid, Y Ye, **M Jahanzeb**, "Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial" *Breast Cancer Res* 21, 32 (2019) doi:10.1186/s13058-019-1112-5
16. **M Jahanzeb**, H M Lin, X Pan, Y Yin, P Hou, B Nordstrom, A Desai, M A. Socinski, "Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC)" ESMO 2018
17. H M Lin, X Pan, Y Yin, P Hou, B Nordstrom, A Desai, M A. Socinski, **M Jahanzeb**, "Real-World Treatment Patterns of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC)" ESMO 2018
18. H M Lin, X Pan, P Hou, H Huang, A Desai, **M Jahanzeb**; "Economic Burden of Brain Metastases in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Receiving Second-Line ALK Inhibitors" Submitted, September 2018

19. **M Jahanzeb**, S Grubbs, W Birch, T Gilmore, A Roach, D Pyle, C Hendricks, “Can Measuring Quality lead to Improvement? Evidence from International Participants of ASCO’s Quality Oncology Practice Initiative (QOPI®) During 2015-2017” Poster 1587P, ESMO 2018
20. KL Reckamp, P Gilman, B Halmos, **M Jahanzeb**, J McCann, H Paripati, L Seneviratne, J Wallace, B Rueter, A Esler, E Dowling, M Koczywas, “Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: preliminary results” Poster ESMO 2018
21. SA Hurvitz, J O’Shaughnessy, G Mason, DA Yardley, **M Jahanzeb**, A Brufsky, HS. Rugo, SM Swain, PA Kaufman, D Tripathy, L Chu, H Li, V Antao, M Cobleigh, “Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERs” Submitted, April 2018
22. W Park, L Mezquita, N Okabe, D Kwon, D Saravia, YK Chae, A Desai, D Planchard, C Caramella, R Mudad, **M Jahanzeb**, H Suzuki, B Besse, G Lopes, “Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: independent international validation of the iSEND model”, Poster presentation at ASCO 2018
23. M Pierobon, NJ Robert, DW Northfelt, **M Jahanzeb**, S Wong, K. A Hodge, J Aldrich, DW Craig, LA Liotta, JD Wulfkuhle, RI Gallagher, D Arguello, A Conrad, AC Kemkes, DM Loesch, L Vocila, B Dunetz, JD Carpten, E Petricoin III, SP Anthony, “Multi-omic profiling of metastatic lesions to guide treatment selection: the Side Out 2 trial experience” Submitted ASCO 2018
24. D Saravia, N Okabe, W Park, D Kwon, L Mezquita, Y K Chae, R Mudad, **M Jahanzeb**, B Besse, H Suzuki, G Lopes, “Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors” 2018 ASCO Annual Meeting
25. **M Jahanzeb**, HM Lin, P Hou, H Huang, A Desai, “Real-World Utilization of Brigatinib in Patients with Non- small Cell Lung Cancer (NSCLC)” Submitted 2018
26. I Mayer, A O’Neill, CL Arteaga, X.J Yang, L Wagner, D Cella, NJ Meropol , TJ Saphner , RE Swaney, K Hoelzer, W Gradishar, VG Abramson, PK Sundaram , SZ Jilani, EA Perez, NU Lin, **M Jahanzeb**, GW. Sledge “ECOG-ACRIN Cancer Research Group E1105: A randomized phase III placebo-controlled trial of chemotherapy/ trastuzumab ± bevacizumab for HER2+ metastatic breast cancer” Submitted, CCR-18-0635, 2018-02-23 17:14:23
27. M. Pierobon, K.A Hodge, E Baldelli, S Anthony, N J. Robert, D W. Northfelt, **M Jahanzeb**, L Vocila, L.A. Liotta, B Dunetz, E F. Petricoin, “PD-L1 expression differs across cancer metastatic sites from breast tumors” Poster 3129, Submitted AACR Annual Meeting 2018
28. **Jahanzeb M**, Tripathy D, Hurvitz S.A, O’Shaughnessy J, Mason G, Yardley D.A, Brufsky A, Rugo H.S, Cobleigh M, Swain SM, Chu L, Antao V, Yoo B, Kaufman P.A, “First-Line Treatment Patterns by Age for Patients With HER2-Positive Metastatic Breast Cancer (MBC) in the SystHERs Registry” ESMO Poster, September 2017, 275P
29. Kaufman PA, Hurvitz S.A, O’Shaughnessy J, Mason G, Yardley D.A, Brufsky A, Rugo H.S, Cobleigh M,

- Swain S.M, Tripathy D, Chu L, Antao V, Yoo B, **Jahanzeb M**, “Baseline Characteristics and First-Line Treatment of Patients With HER2-Positive Metastatic Breast Cancer (MBC) from the SystHERs Registry” Submitted ESMO 2017
30. Mason G, Mayer M, Swain MS, Kaufman AP, Tripathy D, Hurvitz AS, O’Shaughnessy J, Yardley AD, Brufsky A, Rugo SH, Cobleigh M, Chu L, Antao V, Morris A, Yoo B, **Jahanzeb M**, “Experience and Impact of Alopecia in Patients with HER2-Positive Metastatic Breast Cancer (MBC) in the SystHERs Registry”, 2017 ASCO Quality Care Symposium, J Clin Oncol 35, 2017 (suppl 8S; abstract 239)
  31. Balfe. L, Warsch. S, **Jahanzeb M**, “Patient with typical carcinoid initially diagnosed as high-grade neuroendocrine carcinoma” Poster presentation: PS01.38, J Thorac Oncol. 2016 Nov;11(11S):S292-S293
  32. Pierobon M, Wong S, Reeder A, Anthony SP, Robert N, Northfelt DW, **Jahanzeb M**, Vocila L, Wulfkuhle J, Dunetz B, Jessica Aldrich, Sara Byron, David Craig, Liotta L, Carpten JD, Petricoin EF, “A Multi-Omic Analysis to Explore the Impact of “Actionable” Genomic Alterations on Protein Pathway Activation: Clinical Implication for Precision Medicine in Metastatic Breast Cancer” Poster: P1-07-09. SABCS 2016
  33. B Zhang, W Lloyd, **M Jahanzeb**, M J. Hassett, “Use of patient-reported outcome measures in Quality Oncology Practice Initiative registered practices: Results of a national survey” J Clin Oncol 34, 2016 (suppl; abstr e18236)
  34. M Pierobon, C Ramos, S Wong, A. K. Reeder, J Aldrich, S Byron, S. P. Anthony, N Robert, D. W. Northfelt, **M Jahanzeb**, L Vocila, J Wulfkuhle, G Gambara, B Dunetz, N Hoke, T Dong, D Craig, L. A.Liotta, J.O’Shaughnessy, J.D. Carpten, E.F. Petricoin, “Enrichment of PIK3/AKT/MTOR pathway activation in hepatic metastases from breast cancer” SABCS 2016
  35. Cobleigh M, Yardley D, Brufsky A, Rugo H, Swain S, Kaufman P, Tripathy D, Mayer M, Hurvitz S, O’Shaughnessy J, Mason G, Chu L, Antao V, Beattie M, Yoo B, **Jahanzeb M**. “Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR-HER2+ disease from the SystHERs registry”. Poster P5-08-08, SABCS 2016
  36. D.Saravia, B.Laderian, W. Park, A.Desai, F.Vargas, R.Elias BA, S.Warsch, R.Mudad, C.Ikpeazu, L.Balfe, **M.Jahanzeb** “Complete Blood Count (CBC) Parameters as Predictors for Response and Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab” IASLC 2016 P3.02c-081, S1327
  37. B. Laderian, D.Saravia, A.Laderian, A.Ishkanian, **M Jahanzeb**, “ Comparison of Gender, Race Distribution, and Survival in the 1990s to 2010s in Lung Cancer Patients at a Single Institution” IASLC July 2016, P1.01-043
  38. Cobleigh. M, Yardley. B, Brufsky. A, Rugo,H, Swain. S, Kaufman. P, Tripathy. D, Mayer. M, Hurvitz. S, O’Shaughnessy.J, Mason. G, Chu.L, Antao.V, Beattie.Y, **Jahanzeb M**, “ Baseline Characteristics, treatment patterns, and outcomes in patients with hormone receptor (HR)+ vs HR-HER2+disease from the SystHERs Registry”. SABCS 2016, P5-08-08



39. Pierobon M, Wong S, Reeder A, Anthony S.P, Robert N, Northfelt D.W, **Jahanzeb M**, Vocila L, Wulfkuhle J, Dunetz B, Jessica Aldrich, Sara Byron, David Craig, Liotta L, Carpten J.D, Petricoin E.F, “A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: clinical implication for precision medicine in metastatic breast cancer” SABCS 2016, P1-07-09
40. **M. Jahanzeb**, D.Tripathy, H.Rugo, S.Swain, P.Kaufman, M.Mayer, S.Hurvitz, J.O’Shaughnessy, G.Mason, D.Yardley, A.Brufsky, L. Chu, V.Antao, M.Beattie, B.Yoo, M.Cobleigh, “Treatment patterns and clinical outcomes in patients (pts) with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry” SABCS 2016, P5-08-27
41. J. Mortimer, J.D. Palma, **M. Jahanzeb**, K.Schmid, Y.Yee, “Characterization of neratinib-associated diarrhea in patients with early-stage HER2-positive breast cancer: analyses from the phase III ExteNET trial” SABCS 2016 Abstract,Poster P4-21-10
42. Robert N.J., Anthony S.P., Arguello D. , Jameson G.S. , Northfelt D.W. , **Jahanzeb M.** , Petricoin E. , Pierobon M. , Dunetz B. , Liotta L.A. , Loesch D.M., “Predictive value of Topoisomerase 1 by Immunohistochemistry (Top1 IHC) in patients with metastatic breast cancer receiving Irinotecan-Based Therapy.” 2016 ASCO Quality Care Symposium, J Clin Oncol 34, 2016 (suppl; abstr 1037)
43. G. B. Rocque, D. Blayney, **M. Jahanzeb**, et.,al., “Choosing Wisely in oncology: Are we ready for value- based care?” ASCO Quality Symposium February 2016, J Clin Oncol 34, 2016 (suppl 7S; abstr 275)
44. B. Zhang, **M. Jahanzeb**, et.al., “Use of patient-reported outcome measures in Quality Oncology Practice Initiative registered practices: Results of a national survey.” J Clin Oncol 34, 2016 (suppl; abstr e18236)
45. T A. Quill, PhD<sup>1</sup>; **M Jahanzeb**, MD<sup>2</sup>; K L. Obholz, PhD<sup>1</sup>; E Brady, PhD, CHCP<sup>1</sup>; A Howson, MA, PhD, CHCP<sup>3</sup>; M Rasulina, PhD, MBA, MPH<sup>4</sup>; CWillis<sup>5</sup>; Sara Hurvitz, MD<sup>6</sup>. “Impact of Therapeutic Complexity on Practice Patterns for MBC in the United States: Results of a 2-Phase National Study”. SABCS 2015 poster for Abstract P5-09-02
46. Pierobon M, Anthony SP, Reeder A, Nicholas Robert, D. Northfelt, **Jahanzeb M**, Vocila L, Wulfkuhle J, Dunetz B, Liotta L, Petricoin E. F. Pathway activation mapping metastatic breast cancer identifies potential organ-specific signatures: implications for patient stratification to targeted treatment”. SABCS 2015 poster for abstract 1-07-23
47. S Hurvitz, J O’Shaughnessy, G Mason, D Yardley, **M Jahanzeb**, A Brufsky, H Rugo, S Swain, P Kaufman, D Tripathy, M Mayer, L Chu, B Yoo, M S. Beattie, M Cobleigh. “Central Nervous System Metastases at Diagnosis in Patients with HER2-Positive MBC: Baseline Characteristics, HER2-Targeted Treatments and Clinical Outcomes From the SystHERs Registry”. SABCS 2015 poster for abstract P6-17-01
48. G M. Frampton, S M. Ali, M Rosenzweig, J W. Goldman, C B. Lee, J Weiss, J A. Bufill, RSalgia, **M. Jahanzeb**, K Konduri, P M. Forde, D Morosini, J S. Ross, Sai-Hong Ignatius Ou, R Yelensky, V A. Miller, P J. Stephens. “Comprehensive genomic profiling (CGP) of advanced cancers identifies MET

exon 14 alterations that confer sensitivity to MET inhibitors” ASCO 2015 (Abstract #11007) J Oncol, 2015

49. D Tripathy<sup>1</sup>, A Brufsky<sup>2</sup>, M Cobleigh<sup>3</sup>, **M Jahanzeb**<sup>4</sup>, P Kaufman<sup>5</sup>, G Mason<sup>6</sup>, M Mayer<sup>7</sup>, J O’Shaughnessy<sup>8</sup>, H S. Rugo<sup>9</sup>, S M. Swain<sup>10</sup>, D A. Yardley<sup>11</sup>, M Beattie<sup>12</sup>, B Yoo<sup>12</sup>, S Hurvitz<sup>13</sup> Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: early results from the Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry Study. SABCS 2015 (Poster P3-07-14)
50. S Hurvitz, **Jahanzeb M**, P Kaufman, G Mason, M Mayer, H Rugo, D Tripathy, S Ogale, A Masaquel, B Yoo, M Beattie, M Cobleigh, “Patient reported outcomes (PROs) from the systemic therapies for HER2- positive metastatic breast cancer (MBC) registry study (SystHERs): eliciting the patient experience. Accepted 2014. (Abstract 286)
51. Pierobon M, Anthony SP, Reeder KA, Robert NJ, Northfelt DW, **Jahanzeb M**, Vocila L, Wulfkuhle JD, Dunetz B, Liotta LA, Petricoin EF. Pathway activation mapping of metastatic breast cancer identifies potential organ-specific signatures: Implications for patient stratification to targeted treatment. (Abstract 1019)
52. L Leon, MP Kosty, **Jahanzeb M**, Spigel D, A Wozniak, Brahmer J, Kumar P, S Fish, Flick D. E, S Hazard J, Lynch, Jr. T, Effectiveness and Safety of Bevacizumab Exposure Beyond Disease Progressive in Patients With Non-Small Cell Lung Cancer: Analyses of the ARIES Observational Cohort Study. American Journal of Epidemiology. (Abstract 200)
53. Tripathy D<sup>1</sup>, Rugo HS, Kaufman PA, Swain S, O’Shaughnessy J, **Jahanzeb M**, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S., The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer”, BMC Cancer. 2014 May 2
54. Tripathy D, Brufsky A, Cobleigh M, **Jahanzeb M**, Kaufman P, Mason G, Mayer M, O’Shaughnessy J, Rugo S. H, Swain. M S, Yardley A. D, Beattie M, Yoo B, Hurvitz S, “Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: early results from the Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry Study”, SABCS 2014: Abstract
55. Hurvitz S, **Jahanzeb M**, P Kaufman, G Mason, M Mayer, H S. Rugo, D Tripathy, S Ogale, A Masaquel, B Yoo, M Beattie, M A. Cobleigh Patient-Reported Outcomes (PROs) from the Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry Study (SystHERs): Eliciting the Patient Experience. Oct. 2014 (Abstract #137187)
56. Aapro M<sup>1</sup>, Andre F, Blackwell K, Calvo E, **Jahanzeb M**, Papazisis K, Porta C, Pritchard K, Ravaud A., “Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.” Ann Oncol. 2014
57. Maltzman JD, Fatato P, Hoffman K, Dougherty K, O’Shannessy D, Somers EB, Cobo M, Felip E, **Jahanzeb M**; Morphotek, Exton, PA; “Phase 2 Double-Blind, Placebo-Controlled Doublet in Subjects with Previously Untreated Folate Receptor Alpha (FRA) Expressing Non Small Cell Lung Cancer (NSCLC)”. Poster presentation IASLC 2013

58. Snider JN, Sachdev JC, Allen JW, Schwartzberg LS, Young RR, Javed AY, Yunus F, Verrier CS, **Jahanzeb M**; "High pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) + carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple negative breast cancer (TNBC)". Proceedings of ASCO 2013 Abst # 1068
59. KL Obholz, KL Blackwell, S Glück, **Jahanzeb M**, KD Miller, NJ Robert, AD Bowser, J Mortimer, and RW Carlson, Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC) Cancer Res December 15, 2013 73; *Abstract* P1-12-01 (Poster presentation SABCS 2013)
60. Snider JN, Allen JW, Young R, Schwartzberg L, Javed Y, **Jahanzeb M**, Sachdev JC, "Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer" SABCS December 15, 2012; Volume 72, Issue 24, Supplement 3 (Posters)
61. Ettinger D, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, **Jahanzeb M**, et. al, "Non-small cell lung cancer." J Natl Compr Canc Netw. 2012 Oct 1;10(10):1236-71.
62. Snider, J Young R, Schwartzberg, L, **Jahanzeb M**, and Sachdev J Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer. PASC0 2012 Abst # TPS1137
63. Lynch TJ, **Jahanzeb M**, Spigel D, Wozniak AJ, Leon L, Fish S, Flick ED, Dalal D, Kosfy MP, "Cumulative Exposure to Bevacizumab (BV) after Disease Progression (PD) Correlates with Survival in Non-Small Cell Lung Cancer (NSCLC)": a time-dependent analysis of the ARIES observation cohort study. Journal/Congress: ESMO 2012. Accepted for Poster Presentation
64. Snider JN, Young RR, Schwartzberg LS, Allen, JW Javed, YA, **Jahanzeb M**, Sachdev JC; "Neoadjuvant Bevacizumab with Weekly Nab-Paclitaxel + Carboplatin followed by Doxorubicin + Cyclophosphamide (AC) for Triple Negative Breast Cancer". Proceedings of American Society of Clinical Oncology, Submitted 2012.
65. Mayer I A, O'Neill A M, Arteaga C L, Swaby R F, Alpaugh R K, Yang X J, Wagner L I, Meropol N J, Saphner T J, , Perez EA, Lin N U, **Jahanzeb M**, Sledge GW; "A Randomized Phase III Double-Blinded Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER2/neu-overexpressing Metastatic Breast Cancer (HER2+ MBC): A Trial of the Eastern Cooperative Oncology Group (E1105). Proceedings of American Society of Clinical Oncology. Submitted 2012.
66. Wozniak A, **Jahanzeb M**, Lynch T, "Cumulative Exposure to Bevacizumab (BV) After Induction Therapy (tx) Correlates with Increased Survival in Patients (pts) with Non-small Cell Lung Cancer (NSCLC)", Stockholm Congress, September 2011, ECCO/ESMO Poster Presentation, Poster # 079
67. Brahmer J, **Jahanzeb M**, Priya K, Robles R, Wozniak A, Lynch T, "Use of Bevacizumab (BV) After Induction Therapy is Associated with Survival Benefit in Patients (pts) with Non-small Cell Lung

Cancer (NSCLC) in the ARIES Observational Cohort Study (OCS)", Stockholm Congress, September 2011, ECCO/ESMO Poster Presentation, Poster # 009.

68. Kosty M, **Jahanzeb M**, Garst J, Spigel D, Leon L, Wendlberger S, Schnurr J, Photowala H, "Clinical Outcomes for Bevacizumab (BV)-treated Elderly Patients with Non-small Cell Lung Cancer (NSCLC): Results from the ARIES Observational Cohort Study (OCS)", Stockholm Congress, September 2011, ECCO/ESMO Poster Presentation, Poster # 062.
69. Sachdev JC, Kronish LE, West S, Schwartzberg L, **Jahanzeb M**, "Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer" ASCO 2010 abstract# TPS100 December 15, 2012; Volume 72, Issue 24, Supplement 3
70. Wozniak A, Garst J, **Jahanzeb M**, Kosty MP, Vidaver R, Beatty S, Teng SL, Flick ED, Sing A, Lynch T for the ARIES Investigators "Preliminary clinical outcomes (CO) for advanced non-small cell lung cancer (NSCLC) patients (pts) from ARIES, a bevacizumab (BV) treatment observational cohort study (OCS)" ASCO 2010 abstract# 7618
71. Brahmer J, Spigel D, Garst JL, **Jahanzeb M**, et al "Preliminary effectiveness outcomes by tumor histology in advanced non-small-cell lung cancer (NSCLC) patients(pts): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS), ESMO 2010
72. Kosty M, Kumar P, Wozniak A, **Jahanzeb M**, Chung C, Wang L, Sing A, Lynch T, "Development of Cavitation While on Bevacizumab (BV) Therapy in Patients (Pts) with Non-Small Cell Lung Cancer (NSCLC): Results from ARIES – a Bevacizumab (BV) Treatment Observational Cohort Study (OCS)", submitted – December 2008
73. Sachdev J, Kronish L, Cohen N, Havlin K, Levine E, **Jahanzeb M**, "A multicenter phase II trial of carboplatin, vinorelbine and trastuzumab in previously untreated patients with HER-2 positive metastatic breast cancer", submitted to Breast Cancer Symposium
74. Lynch T, **Jahanzeb M**, et.al, "Clinical Outcomes for Non-Small Cell Lung Cancer (NSCLC) from the ARIES Study: a Bevacizumab (BV) Treatment Observational Cohort Study (OCS), Abstract # 239P (Poster Presentation) ESMO 2008.
75. McFarlane J, Liman A, **Jahanzeb M**. "Contribution of positive renal vein margin to relapse risk in renal cell cancer". Submitted to ASCO 2008
76. Azmi S, Sachdev J, Kronish L, **Jahanzeb M**, Smeltzer M, "Hypersensitivity of Cetuximab: Is there an Association with Race, Region or both?" ASCO 2008
77. Paba C, Sachdev J, Kronish L, **Jahanzeb M**, Waheed S. "Empiric dose reduction of Pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy". ASCO 2008
78. Franz, G, Kronish L, Osarogiagbon R, Thompson L, **Jahanzeb M**, "Patterns of PET/CT scan use in patients with advanced Non Small Cell Lung Cancer (NSCLC)". ASCO 2008.
79. Schreiber, A, **Jahanzeb M**, Kronish L, "Serial measurements of quality measures using the quality

oncology practice initiative (QOPI) by oncology trainees (fellows) at a single institution". ASCO 2008.

80. **Jahanzeb M.** "Reducing the Risk for Breast Cancer Recurrence after Completion of Tamoxifen Treatment in Postmenopausal Women". *Clinical Therapeutics*, vol. 29 number 8, pgs 1535 – 1547. August 2007.
81. Sachdev J, **Jahanzeb M**, A multicenter phase II trial of carboplatin, vinorelbine, and trastuzumab in previously untreated patients with HER2 positive metastatic breast cancer. *SABCS*, Dec. 2007.
82. Waheed S, **Jahanzeb M**, Empiric dose reduction of pegfilgrastin in breast cancer patients receiving cytotoxic chemotherapy. *SABCS*, Dec. 2007.
83. **Jahanzeb M**, Limentani SA, et.al.: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support, Selected for poster presentation at American Society of Clinical Oncology Annual Meeting, 2005 (Abst #591)
84. Desch CE, Eisenberg D, Gesme D, Jacobson J, **Jahanzeb M**, et.al.: A practice-based, voluntary program for promoting excellence in cancer care: A Pilot study of feasibility, cost and preliminary results, American Society of Clinical Oncology Annual Meeting, 2004 (Abst #6029)
85. Limentani SA, Brufsky AM, Erban JK, **Jahanzeb M**, Lewis D: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor supplements, San Antonio Breast Cancer Symposium, December, 2003 (Abst #251)
86. Limentani SA, Brufsky AM, Erban JK, **Jahanzeb M**, Lewis D: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support, San Antonio Breast Cancer Symposium, December, 2003 (Abst #240)
87. Swain, S.M., **Jahanzeb M**, Erban, J.K., Limentani, S.A., Hardikar, S., Tsai, D.T., Olsen, S.R., Gradishar, W.J., National Cancer Institute, Bethesda, MD: Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide for stage III breast cancer: Clinical response and long-term survival, American Society of Clinical Oncology, June, 2003 (Abst #143)
88. Limentani, S.A., Brufsky, A.M., John, E., **Jahanzeb M**, Lewis, D., Carolinas Hem-Onc Associates and the Blumenthal Cancer Center, Charlotte, NC: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support, American Society of Clinical Oncology, June, 2003 (Abst #131)
89. Dragnev, K.H., Clamon, G., Raez, L. **Jahanzeb M**, et.al., Docetaxel and cisplatin as induction therapy for stage IIIA (N2) non-small cell lung cancer (NSCLC), American Society of Clinical Oncology, June, 2003 (Abst #2652)
90. Peyton, J.D., Flax, S., **Jahanzeb M**,: Low utility of bone marrow biopsy and aspirate for ruling out malignancy as a cause for FUO in HIV patients, American Society of Clinical Oncology, June, 2003 (Abst #3580)
91. Limentani, SA, Brufsky, AM, Erban, J, **Jahanzeb M**, Lewis, D., Carolinas Hem-Onc Association and the

Blumenthal Cancer Center, Charlotte, NC, University of Pittsburgh Cancer Institute, Magee-Women's Hospital, Pittsburgh, PA, Tufts-New England Medical Center, Boston, MA, University of Tennessee College of Medicine, Memphis, TN: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support, San Antonio Breast Cancer Symposium, 2002.

92. Limentani, SA, Brufsky, AM, Erban, J, **Jahanzeb M**, Lewis, D, Carolinas Hem-Onc Association and the Blumenthal Cancer Center, Charlotte, NC, University of Pittsburgh Cancer Institute, Magee-Women's Hospital, Pittsburgh, PA, Tufts-New England Medical Center, Boston, MA, University of Tennessee College of Medicine, Memphis, TN: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support, San Antonio Breast Cancer Symposium, 2002 (Abst #162)
93. Natale R, Skarin A, Maddox A, Hammond L, Thomas R, Gandara D, Gerstein H, Panella T, Cole J, **Jahanzeb M**, Kash J, Hamm J, Langer C, Saleh M, Stella P, Heyes A, Helms L, Ochs J, Wolf M, Kay A: Improvement in Symptoms and Quality of Life (QOL) for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ZD 1839 ('IRESSA') in Ideal 2, American Society of Clinical Oncology, May, 2002 (Abst #1167)
94. Limentani, SA, **Jahanzeb M**, O'Leary P, Lewis D, Kronish, L: Neoadjuvant Treatment of Women With Breast Cancer Utilizing Docetaxel and Vinorelbine With Growth Factor Support, Proceedings of ASCO, 2002 (abst #1939)
95. **Jahanzeb M**, Mortimer, J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir T, Kronish L: Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer. *The Oncologist* 2002, 7:410-417.
96. Treat J, Huang C, Damanjov N, **Jahanzeb M**, Edelman M, Koehler M: ZD0473 Phase II Monotherapy Trial in Second-Line Non-Small Cell Lung Cancer, European Journal of Cancer, Vol 37. Suppl. 6, October 2001 (Abst #209)
97. **Jahanzeb M**, Mortimer J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir, T Kronish L: A Phase II Multicenter Trial of Weekly Herceptin with Navelbine in Chemonaive Patients with HER2 Positive Metastatic Breast Cancer, European Cancer Conference (ECCO), Lisbon, Oct 2001, Poster presentation
98. **Jahanzeb M**, Mortimer, J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir T, Kronish L: Multicenter Phase II Trial of Weekly Vinorelbine plus Herceptin in Chemonaive Patients with Her-2/neu Positive Metastatic Breast Carcinoma, Proceedings of American Society
99. **Jahanzeb M**, Sarna G, Hirsch R, Radice R, Koletsky A, Martinez M, Kruglyak E, Wolin E, Comacho E, Kronish L, And Byrne, C: Carboplatin (C) and docetaxel (D) in Previously Untreated Advanced Non-Small Cell Lung Carcinoma (NSCLC): A Multicenter Phase II Trial, International Association for the Study of Lung Cancer (IASLC) 9th World Conference on Lung Cancer, Sept 2000 (oral presentation)
100. **Jahanzeb M**, Sarna G, Hirsch R, Radice P, Koletsky A, Martinez M, Kruglyak E, Wolin E, Comacho E, Pearce P, Byrne C, and Frankel C: A Multicenter Phase II Trial of Carboplatin (C) and Docetaxel (D) in

Previously Untreated Advanced Non-Small Cell Lung Carcinoma (NSCLC), Proceedings of American Society of Clinical Oncology, May 2000, (Abst #2011)

101. Scheurle D, **Jahanzeb M**, Aronsohn R, Watzek L, and Narayanan R: HERs/neu Expression in Archival Non-Small Cell Lung Carinomas (NSCLC) Using FDA Approved Hercep test and Clinical Correlation, Proceedings of American Society of Clinical Oncology, May, 2000 (Abst 2012)
102. **Jahanzeb M**, Greenhawt M, Koletsky A, Frankel C, Pearce P, Byrne C: A Phase I Trial of Gemcitabine and Vinorelbine in Relatively Elderly Patients with Refractory Solid Tumors, Poster Presentation, U S Gemzar Investigators Meeting, New Orleans, March, 1999
103. **Jahanzeb M**, Hirsch R, Marrs N, Sharpington T: Phase I Study of Doxil in Combination with Escalating Doses of Navelbine for the Treatment of Patients with Advanced Malignancies., Proceedings of American Society of Clinical Oncology, May 1999 (Abst #827)
104. Hirsch R, **Jahanzeb M**, Marrs N., Sharpington, T: Phase I Study of Doxil in Combination with Escalating Doses of Taxotere for the Treatment of Patients with Advanced Malignancies., Proceedings of American Society of Clinical Oncology, May 1999 (Abst #820)
105. Radice P, Koletsky A, **Jahanzeb M**, Gomez E, Kruglyak E, Hirsch R, Cecchi G, Martinez M, Irwin D, Lemon R, Tracy M, Pearce P, Byrne C, Frankel C: Weekly Peglyated Liposomal Doxorubicin (PEG-LD) is Extremely Well Tolerated as Second Line Chemotherapy, Proceedings of American Society of Clinical Oncology, May 1999 (Abst #2004)
106. Koletsky A, **Jahanzeb M**, Radice P, Berliner A, Gomez E, Kruglyak E, Hirsch R, Cecchi G, Martinez M, Irwin D, Lemon R, Tracy M, Byrne C, Frankel C: Peglyated Liposomal Doxorubicin (PEG-LD) as Second Line Treatment of Advanced Non-Small Cell Carcinoma (NSCLC) After Platinum Based Therapy: A Randomized Phase II Trial, Proceedings of American Society of Clinical Oncology, May, 1999 (Abst #1976)
107. Greenhawt M, **Jahanzeb M**, Koletsky A, Frankel C, Pearce P, Bryne C: A Phase I Trial of Vinorelbine and Gemcitabine in Relatively Elderly Patients with Refractory Solid Tumors, Proceedings of American Society of Clinical Oncology, May 1999 (Abst #897A)
108. **Jahanzeb M**, Koletsky A, Greenhawt M, Frankel C, Byrne C: A Phase I Trial of Gemcitabine and Vinorelbine Employing Planned Half Doses on Day 8 in Patients with Refractory Solid Tumors, Poster Presentation, Gemzar Investigators Meeting, Memphis, TN, March, 1998
109. Koletsky A, **Jahanzeb M**, Radice P, Gomez E, Kruglyak E, Hirsch R, Cecchi G, Martinez M, Irwin D, Lemon R, Tracy M, Frankel C, Byrne C: A Randomized Phase II Trial of Pegylated Liposomal Doxorubicin (PEG-LD) as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients with Prior Exposure to Platinum Based Therapy, Proceedings of American Society of Clinical Oncology, May, 1998 (Abstract #1888)
110. **Jahanzeb M**, Frankel C, Elkersh M, Koletsky A, Radice P, and Vogel C: Activity and Favorable Toxicity of Stealth Liposomal Doxorubicin (Doxil) in a Population of Heavily Pretreated Patients with Solid Tumors.UICC Oral Presentation, First International meeting of Advances in the Knowledge of

Cancer Management, June 28 to July 1, 1997, Vienna Austria (Abst #160)

111. **Jahanzeb M**, Vogel C, Elkirsh M, Koletsky A, Radice P, and Frankel C: Stealth Liposomal Doxorubicin (Doxil) Causes a Mild and Delayed Leukopenia Compared to Standard Doxorubicin in Patients with Solid Tumors. Proceedings of American Society of Clinical Oncology, May 1997 (Abst # 843)
112. **Jahanzeb M**, Virgo KS, McKirgan LW and Johnson FE: Evaluation Of Outcome by Race In Veterans with Early-Stage Non-Small Cell Lung Cancer (NSCLC) (selected for poster presentation at the 1995 annual meeting of ASCO) (Abst #442)
113. Vokes EE, Rosenberg R, **Jahanzeb M**, Craig J, Gralla R, Belani C, Jones S, Purvis J and Hohneker J: Multicenter Study of Oral Navelbine in Previously Untreated Stage IV Non-Small Cell Lung Cancer (NSCLC). Proceedings of 7th World Lung Cancer Conference, June 1994 (Abst # 465)
114. Graham MV, **Jahanzeb M**, Dresler C, Cooper J, Emami B and Mortimer J: Preliminary results of a Phase I study of Topotecan plus thoracic radiotherapy for locally advanced Non-Small Cell Lung Cancer Proceedings of American Society of Clinical Oncology, May, 1994 (Abstract # 1132)
115. Vokes EE, Rosenberg R, **Jahanzeb M**, Craig J, Gralla R, Belani C, Jones S, Purvis J and Hohneker J: Multicenter Study of Oral Navelbine in Previously Untreated Stage IV Non-Small Cell Lung Cancer (NSCLC). Proceedings of American Society of Clinical Oncology, May, 1993 (Abstract # 1120)
116. **Jahanzeb M**, Zutter M, Loeb V and Mortimer J: Castleman's Disease: Recent Experience at Washington University. Proceedings of American Society of Clinical Oncology, May, 1992 (Abstract 154)